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Summary 
Heart failure is a common disorder, which is increasing in prevalence worldwide. It carries a 
significant burden in terms of both morbidity and mortality, and in terms of both economic 
and social cost. Recent advances in pharmacological and device therapy have lead to a 
reduction in the morbidity and mortality associated with heart failure with reduced left 
ventricular systolic function. No such therapeutic strategies have been forthcoming for 
patients with heart failure and preserved left ventricular systolic function (HF -PSF), resulting 
in static mortality rates, and, in the context of our ageing popUlation, an escalating problem. 
At the time of starting this work, the syndrome of heart failure with preserved systolic 
function was a neglected area in clinical cardiovascular research. The aim of this study was to 
improve our understanding of this condition by investigating the prevalence of HF-PSF in a 
cohort of patients admitted to hospital with heart failure, examining their clinical 
characteristics and determining their prognosis. 
Until recently, there have been relatively few data concerning the prevalence of HF-PSF. 
However, the indications are that it is a common condition and this is corroborated by my 
findings, that around half of all patients admitted with heart failure have preserved left 
ventricular systolic function. 
By comparing the detailed clinical characteristics of patients with HF -PSF to those of patients 
with reduced systolic function, this study has provided a number of important insights into 
this common syndrome. Patients with preserved systolic function heart failure tend to be 
older, and are more likely to have a history of hypertension. These are findings have now 
become well established in the HF-PSF literature. 
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In relation to comorbidity, I specifically examined the prevalence of chronic obstructive 
pulmonary disease (COPD) in the subset of my study patients with HF-PSF, with a view to 
determining if they may have been misdiagnosed. On the contrary, while few patients had 
both a normal BNP and abnormal PFTs, a significant number of those patients with HF-PSF 
who had previously received a clinical diagnosis of COPD, actually had nOlmal spirometry 
but an elevated BNP. This rather suggests that they may have been misdiagnosed with COPD, 
when in fact, they were suffering from HF-PSF. The importance of the interplay between 
COPD and HF is increasingly recognised, and these results serve to underline the need for 
further study in this area. 
In addition to the idea that HF-PSF was merely misdiagnosis, until recently conventional 
expectations were that HF-PSF would produce a mild version of the clinical syndrome. 
However, in this study I found that patients with HF-PSF did indeed display markers of 
severe and complicated heart failure. The majority were classified as Killip IIA or greater on 
admission to hospital, and the majority had moderate renal dysfunction. 
This suggestion that HF-PSF is not a benign condition is borne out by the mortality data from 
this study. All-cause mortality in the HF-PSF group, although lower than that for heart failure 
with reduced systolic function, was significant, with a case fatality rate of 37% after three 
years. This high m0l1ality rate underscores the need for effective treatments for patients with 
HF-PSF. 
Before we can develop such treatments, we need to understand the aetiology of the condition. 
Comparatively little is known about the aetiology of heart failure in the context of preserved, 
as opposed to reduced systolic function. Left ventricular diastolic dysfunction has received 
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much attention as a potential mechanism, whereby reduced L V compliance impairs left 
ventricular filling and therefore reduces stroke volume. However, in a practical clinical 
context, there has been much debate regarding the assessment of diastolic function, for which 
there is no concensus method. In this study, I compared a number of different 
echocardiographic criteria and found a wide variation in the estimated prevalence of diastolic 
dysfunction. 
Natriuretic peptides have recently revolutionised the diagnosis and risk stratification of 
patients with heart failure and reduced systolic function. BNP and its precursor, NT pro BNP 
have also been found to have prognostic significance in patients with HF-PSF. In this study I 
determined normal ranges of natriuretic peptides from an age-matched local population and 
applied these to my cohort. BNP and NT -pro BNP were elevated in both types of heart 
failure, and although absolute levels were higher in patients with reduced systolic function, a 
significant majority of the HF-PSF group had elevated natriuretic peptide levels. This 
constitutes biochemical evidence of left ventricular compromise in these patients, despite the 
fact that systolic function is preserved. 
Aminoterminal propeptide of type III procollagen (PIIINP) is a novel marker of myocardial 
fibrosis, a process which has been implicated in left ventricular remodelling, and may 
therefore be important in the aetiology of heart failure with either reduced or preserved 
systolic function. In my examination of PIIINP levels in this cohort of patients, the majority 
of patients with HF-PSF also had an elevated PIIINP, supporting a possible causative role for 
myocardial fibrosis in the development ofHF-PSF. 
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In summary, this thesis describes the detailed characterisation of the syndrome of heart failure 
with preserved left ventricular systolic function, through the examination of the clinical, 
biochemical and echocardiographic indices and long term follow-up of a cohort of patients 
hospitalised for heart failure. I have shown that this is a common condition which results in 
significant mortality. The findings of this work are consistent not only with the hypothesis 
that heart failure with preserved systolic function is a well-defined clinical entity in its own 
right, but also that it is a major public health issue both now and for years to come. 
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CHAPTER ONE 
INTRODUCTION 
27 
1.01 The burden of heart failure 
Heart failure (HF) is now fully recognised as a major public health problem1;2. It has been 
estimated that there are nearly 23 million people with HF worldwide1• HF is an escalating 
public health problem, particularly in industrialised countries, due to the ageing population. 
In the UK, the overall incidence of HF has been estimated to be 3-20 cases per 1,000 
population, rising to more than 100 cases per 1,000 in those aged 65 years and 0lder3. HF 
produces significant mortality and morbidity, in the recent Sudden Cardiac Death in Heart 
Failure Trial (SCD HeFT), patients in the placebo arm were on best medical therapy, and the 
mortality was 36.1% at 5 years or 7.2% per year4. These combined mean that management 
of heart failure is a considerable financial burden to the National Health Service (NHS). This 
cost is relatively easy to assess in terms of the number of hospital admissions, which are 
increasing, with 20-30% of HF patients being hospitalised3. In the UK, almost 2% of the 
entire NHS budget is spent on caring for patients with HF3. Estimates of HF spending from 
the US are of the order of 15-40 billion dollars per annum5;6. Significant healthcare spending 
is only a part of the problem posed by the high prevalence ofHF. Much of the long-term care 
afforded to patients disabled by HF is provided by family and extended family members. It is 
clear that the burden of HF borne by society as a whole is extensive, and has far reaching 
consequences. 
1.02 Heart Failure with preserved left ventricular systolic function 
Until recently the medical profession have focused on diagnosis and treatment of HF caused 
by reduced left ventricular systolic function (HF-RSF). The concept ofHF with preserved left 
ventricular systolic function (HF-PSF) was initially developed in the 1970's7, following the 
clinical observation that a number of patients had a heart failure syndrome but without 
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I-
I 
depressed left ventricular (L V) function. Over the past decade there has been a growing 
interest in HF-PSF8-12. 
1.02.1 Prevalence of heart failure with preserved systolic function 
Epidemiological studies estimate the proportion of patients with clinical HF who have 
preserved LV systolic function to be 40%-71% (with a mean of 56%). However, there was 
wide variation with respect to sample size, and the age range of individuals studied 13 . This 
may go some way to explaining the wide variation in recorded prevalence. These studies also 
used different criteria to define HF in general and HF-PSF in particular. The definitions of 
HF in these studies varied from utilising the diagnosis of a single physician, to using 
epidemiological questionnaires (e.g. Framingham score). The echocardiographic tools 
employed to assess LV function varied from qualitative assessment of left ventricular ejection 
fraction (L VEF), to quantitative measurements such as fractional shortening (FS), wall motion 
score or LVEF (ie. by Simpson's rule). There were also differences in the thresholds used for 
dividing "reduced" from "preserved" systolic function. For example, the most commonly 
used method was FS. This method measures systolic function at the base of the heart and can 
be normal in patients with apical hypokinesis, in whom the L VEF would be expected to be 
reduced. The Copenhagen14 and Vasteras15 studies highlight how very different proportions 
of patients with HF-PSF may be calculated depending on whether a left ventricular wall 
motion index (LVWMI) of>1.5 or >1.7 is used as a cut-point. To further illustrate this point, 
in the Cardiovascular Health Study (CHS), 80% of patients had an LVEF >0.45, but only 55% 
had an LVEF >0.55 16. What these studies highlight is that there is currently no accepted 
binary division between preserved and reduced systolic function. What this leaves us with is 
an uncertain "grey area" where, depending on the investigator these patients could be 
classified as having either reduced or preserved systolic function l3 . 
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The above findings are supported by observations from large-scale studies such as the 
Improvement Programme in Evaluation and Management of Heart failure (IMPROVEMENT-
HF) studyJ 7, which was undertaken in primary care in 15 member countries of the European 
Society of Cardiology, and also the Italian Network on Congestive Heart Failure (IN-CHF) 
study, conducted in out-patients in 133 out of 192 Italian cardiology centres18• 
1.02.2 Incidence of heart failure with preserved systolic function 
There are two prospective studies which aim to identify the relative incidence of reduced and 
preserved systolic function within the HF populationI9;20. In the Olmsted study, 216 patients 
with new HF were identified over a 12 month period. Of these, 137 (63%) had had a recent 
echocardiographic assessment of LV function recorded as LVEF. HF-PSF was defined as 
L VEF 2: 50%, and a further subdivision was made according to the presence or absence of 
valvular heart disease (isolated PSF). Fifty-nine (43%) had HF-PSF, and five of these had 
significant valve disease, leaving fifty-four (39%) with a diagnosis of HF with isolated PSF. 
In the Bromley Heart Failure study, all local primary care physicians were asked to refer new 
cases of HF to a specialised clinic and all patients who had a hospital admission for HF were 
also included. Over a 14 month period, 332 new cases ofHF were identified, and 310 (93%) 
had an echocardiogram. By echocardiographic criteria, 16% had HF-PSF, and 84% had HF-
RSF J3 . Again, we see a wide variation in estimated incidence ofHF-PSF. 
1.02.3 Preserved systolic function in patients hospitalised for heart failure 
Since 2000 there have been a limited number of studies published on hospitalised cohorts of 
patients with HF-PSF (Table 1.1). These heterogeneous studies range from a small single-
centre study with a majority of African-American patients, to a large sample of Medicare 
beneficiaries in the USA, to a countrywide epidemiological survey from France. Full 
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information on the assessment of LV function is lacking in many of these studies. However, 
the proportion of patients with PSF was lower than in the population studies, ranging from 
24%-55% (mean 41 %). This is consistent with evidence, which will be discussed later in this 
Chapter, that patients with HF-PSF have less severe symptoms and are therefore less likely to 
require in-patient treatment. The patients in these studies were less likely to have a prior 
history of hospitalisation for HF. As seen in the population studies, a greater proportion of 
patients with HF-PSF were female. Masoudi et at confirmed that female gender was an 
independent predictor of PSF in patients with HF21. The recent Euro Heart Failure survey of 
over 11,000 hospital discharges from 115 hospitals in 24 European countries supports these 
findings22. Only 28% of women with HF had an LVEF of <0.40, compared to 51 % of men. 
Patients with HF-PSF were also older, though the relationship between age and PSF appears 
to be less strong than that between PSF and female gender21. Berry et at recently published 
results from over 500 emergency admissions with heart failure based on the discharge letter 
and prescription. Of these, 29% had HF-PSF (L VEF >0.40) and 62% of these were female 
compared to 45% of the HF-RSF group23. 
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Table 1.1 
first authorl 
country 
Philbin (USA-
MISCHF 
Registry/6 
Malki (USA-
Detroit)27 
Dauterman 
(USA-
California)28 
Ahmed (USA-
Alabama)29 
Cohen-Solal 
(France)30 
Varela-Roman 
(Spain)31 
Tsutsui 
(Japan)32 
Thomas (USA-
ChiCC!gQ)33 
Masoudi (USA-
Medicare)34 
Smith (USA-
Connecticut)35 
Gustafsson 
(Denmark) 36 
Varadarajan 
(USA-
California)37 
t 
P/R 
MISCHF 
RNVG 
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Prevalence of heart failure with preserved left ventricular systolic function: hospitalisation cohort studies 13. 
Year of n=* design criteria for preserved LV preservedl 
publication systolic function total (%) 
2000 1291 MISCHF registry, DRG 127, echo/RNVG/other 31211291(24) 
(2906) LV function assessment within 6 months of LVEF ~50% 
discharQe, numeric LVEF available 
2002 187 prospective, clinical & radiologic pulmonary echo LVEF ~ 50% 57/187(30) 
(?) cong_estion, echo. within 6 months 
2002 782 retrospective chart review, Medicare ~ 65 yrs, echo/RNVG/other 2381438(54) 
(1720) CXR cardiomegalylpulmonary oedema, LVEF ~40% 
LV function measurement, No CII to ACE-I or qualitative LV assessment 
2002 438 Medicare ~ 65 years, clinical score, L VEF >40% or qualitative LV 430/782(55) 
(1091) LV function measurement assessment 
2000 739 prospective, national epidemiological survey, echocardiographiclRNVGI 200/438(46) 
(1058) Framingham criteria clinical diagnosis other LVEF, echo L VEF > 40% 
2002 229 prospective, Framingham criteria, echo LVEF ~ 50% 66/229(29) 
(301) LV function assessment within 2 weeks 
2001 172 retrospective chart review, Framingham criteria, echo LVEF >50% 61/172(35) 
_(23~ deaths excluded, Echo L VEF 
2002 225 prospective, consecutive admissions over 4 qualitative echo L VEF ~ 45% 104/225(46) 
(282) months, Framingham criteria 
2003 19,710 Medicare (~65 years) sample April 1998-March L VEF ~50% or qualitatively 6,700/19,710 
(33,814) 1999 normal LV systolic function, (35) 
past history of CHF or 
radiographic evidence 
2003 413 prospective, consecutive admissions, 1996- echo/RNVG/other 2001413 (48) 
1998, NHANES criteria LVEF ~40% 
2003 5491 randomised controlled trial, admissions with echo WMI > 1.6 (approximates 2218/5240 
CHF 1993-1996 to LVEF > 48%) (42) 
2003 2,258 retrospective chart review, 1990-1999, echo LVEF ~ 55% 963/2258 (43) 
echocardiogram 
.. 
number With LVEF measurement (total number In cohort); ? It IS unclear whether whole cohort had a LVEF measurement 
years non-white 
non-caucasian -It 75% overall 
Preserved/reduced LV systolic function AA African/American 
Management to Improve Survival in Congestive Heart Failure LVEF left ventricular ejection fraction 
USA 
ESC 
DRG 
LV 
radionuclide ventriculogram CXR chest X-ray 
female mean AA% 
% (P/R) age** (P/R) 
(P/R) 
70150 75174 4/3t 
63/46 69/65 60179 
69149 - 15/14*** 
69149 - 14/19 
51129 76171 -
64133 67/66 -
51/33 69/68 -
56135 59/54 * 
79/49 80178 9110 
63/35 73170 21/25t 
49/33 73/71 -
3/97 70171 11/10 
United States of America 
European Society of Cardiology 
diagnosis related group 
left ventricular 
1.02.4 Clinical characteristics of patients with HF-PSF 
A comparison of the demographic characteristics of HF patients with reduced and preserved 
systolic function will provide important insights into HF-PSF. Only three of the prevalence 
studies discussed earlier, specifically cite the separate figures for men and women. 
Consistently across these studies the proportion of women with HF-PSF exceeds that of men. 
Consistent with this, in a case control study from Framingham 73% of the 33 women and 33% 
of the 40 men had HF-PSF8. 
Few studies have consistently reported the frequency of characteristic symptoms of HF such 
as dyspnoea at rest or on exertion, orthopnoea or paroxysmal nocturnal dyspnoea (PND), or 
signs such as an elevated jugular venous pressure (JVP), pedal oedema and pulmonary 
crepitations on auscultation. The two studies which have done this, have shown that signs and 
symptoms were similar in patients with HF-PSF compared to those with HF-RSF. The 
exception to this was the presence of a 3 rd heart sound which was more common in HF-
RSF24;25. Philbin et al26 and Varela-Roman et az27 found that patients with HF-PSF were less 
likely to be in a high New York Heart Association (NYHA) class. This finding was 
confirmed in the IN-CHF study18. Smith et al2S recently reported that severe dyspnoea was 
less common in patients with HF-PSF. Philbin et al26 measured quality of life (QoL), using 
the Ladder of Life scoring system. The mean score was 6.5 for HF-RSF and 6.4 for HF-PSF 
and these results were almost identical to those from Jaarsma et al29 who used the same QoL 
questionnaire. Other studies, using both a general QoL questionnaire and a disease-specific 
questionnaire such as the Minnesota Living with Heart Failure Questionnaire, have shown 
that QoL is lowest in those with HF-RSF but that QoL is lower with either types of HF than 
that which would be expected in the general population30• 
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In four studies reporting length of hospital stay in the two types of HF, there was little 
difference. In one study, the duration of stay was 11 days in both groups3l. Other studies 
have reported, for HF-PSF and HF-RSF, in-patient stays of 7.5 versus 7.9 days26, 6.1 versus 
7.0 days32, and 5.2 versus 5.9 days24. In more detailed analyses, however, both Philbin et aZ 
and Malki et aZ found that length of stay did increase with worsening L V systolic 
function24;26. 
1.02.5 Concomitant medical pathology in HF -PSF 
Much of the information regarding concomitant cardiac problems comes from hospitalisation 
cohort studies. Myocardial infarction (MI) or any evidence of previous coronary heart disease 
(CHD) is less commonly found in those with HF-PSF. However, evidence of CHD in HF-
PSF is more common than in age and gender-matched controls8. Other evidence of 
atherosclerotic disease, such as peripheral arterial disease or cerebrovascular disease (CVD) 
was also less common in HF-PSF, compared with HF-RSF. These findings were 
corroborated by the IN-CHF study17. Masoudi et aZ demonstrated that CHD independently 
predicted patients less likely to have PSF in patients hospitalised with HF2l. 
Conversely, a history of hypertension was more common in patients with HF_PSF33;3\ a 
finding again supported by the IN-CHF study18. Masoudi et aZ also found that a history of 
hypertension was an independent predictor of PSF in patients hospitalised with HF21. In 
association with this finding, left ventricular hypertrophy (L VH) was more commonly found 
in HF_PSF26 with the exception of the study by Thomas et aZ25. 
The incidence of atrial fibrillation (AF), was more common in HF-PSF, occurring in one-
quarter to one-third of patients. In the IN-CHF study, 16% of the HF-RSF patients had AF 
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compared with 25% of the HF-PSF patients (defmed as LVEF >45%)18. Masoudi et at 
demonstrated that AF was an independent predictor of PSF in patients hospitalised with HF21. 
The question of whether AF is a primary cause or secondary problem in HF-PSF remains 
unanswered 13 • 
It has been previously speculated that diabetes mellitus (DM) is more common in HF-PSF. 
DM has been found to be more common in both types of HF compared with the general 
population. However, this co-morbidity has not been found to be more frequent in patients 
with PSF, with the exception of the Strong Heart Studl5• It should be noted however, that 
Redfield et at found that DM was a risk factor for the presence of diastolic dysfunction36. 
Chronic pulmonary disease was more common in patients with PSF, raising a concern of 
misdiagnosis37. 
To date, there has been no clear evidence that there is a significant difference in renal 
function, as measured by serum creatinine or by creatinine clearance, between the two types 
of heart failure. In a recent study, Benoy et at confirmed that the renal function was impaired 
but comparable between the two types of HF. As serum creatinine concentration can be an 
inaccurate measure of renal function, especially in the elderly this study confirmed the 
comparable renal function using estimated glomerular filtration (eGFRi3. 
1.02.6 Medical Treatment 
Studies to date have documented a wide variation in the medications taken by HF patients 
with RSF and PSF. Angiotensin converting enzyme inhibitors (ACE-I) and digoxin were 
used less frequently in patients with PSF38. Beta-blocker (~B) use was higher in the PSF 
group, although these studies were generally before the benefits of ~B in HF-RSF were 
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accepted. Findings from the IMPROVEMENT-HF17 and IN_CHF18 registries were consistent 
with the above. Calcium channel blocker (CCB) use was also higher in the PSF group, 
perhaps reflecting the view that these agents may be useful in this subset of patients and 
harmful in those with HF-RSF39. In the IN-CHF registry, 23% of patients with an LVEF 
>45% were taking a CCB compared to 8% of those with HF_RSF18. 
1.02.7 Economic considerations 
There are few formal cost studies dealing with the specific problem of HF-PSF. However, 
some crude estimates of cost can be inferred from the rate of hospitalisation, which accounts 
for most of the overall cost of HF to health care systems. This is cost is primarily driven by 
the length of stay. As discussed above, approximately 40% of patients hospitalised with HF 
have PSF and the length of stay in hospital is very similar to those with HF-RSF. Therefore, 
approximately 40% of the overall cost of HF is probably accounted for by patients with HF-
PSF. Some support for this conclusion comes from Philbin et ai, who calculated the mean 
hospital charge for both types ofHF to be approximately $8,60026• 
1.02.8 Morbidity and mortality 
If we use figures for mortality and repeat hospital admissions to estimate prognosis, then 
studies indicate that the prognosis for patients with HF-PSF is poor. In the Helsinki Ageing 
Study, four-year mortality in individuals free of HF was 30%. In those with HF of any type 
the mortality rate was 46%, in those with HF-PSF the mortality rate was 43% and in those 
with HF-RSF the mortality rate was 54%40. In the Cardiovascular Health Study (CHS), the 
6.4-year mortality rate in subjects without HF was 16% compared to 45% in those with HF. 
Mortality rate was 87 per 1000 patient years in subjects with HF-PSF, 115 in those with HF 
and borderline systolic function, and 154 in subjects with HF and reduced systolic function41 . 
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These figures are similar to the overall five-year mortality rate of 65% in the Olmsted County 
incidence studyl9. In this study, the age and gender-adjusted mortality rates in those with HF 
were higher than those without HF, but there was no significant difference between patients 
with PSF and those with RSF. Patients with HF-RSF in the Framingham study with had an 
annual mortality rate of 18.9% compared with 4.1 % in age and gender-matched controls (over 
6.2yrs). In patients with HF-PSF the annual mortality was 8.7% compared to 3% in matched 
controls. In an adjusted analysis, patients with both types of HF had four times the risk of 
death compared with age and gender-matched controls. The median survival in patients with 
reduced systolic function was 4.3 years, and in those with HF-PSF it was 7.1 years8. Redfield 
et al recently demonstrated the importance of diastolic dysfunction with regard to prognosis 
within this population and the authors concluded that mortality increases with increasing 
diastolic dysfunction36• Hospital cohort studies show that patients with HF-PSF have a better 
survival at all time points from admission. However, patients with HF-PSF still have a high 
mortality following admission to hospital, with rates of 40-50% after four to five years of 
follow-up, and the annual death rate is similar to that in the Framingham study8. Gustafsson 
et al also demonstrated that survival decreases with worsening systolic function in a graded 
wa/2. The IN-CHF registry has reported I-year mortality data for out-patients with HF. For 
those with LVEF <35% the I-year mOliality was 18.9%, where LVEF was greater than 45% 
I -year mortality was 8.9% and for those with an LVEF between 35% and 45% I-year 
mortality was 11.5 %18. 
In terms of hospital readmissions, the Olmsted County incidence study showed that for those 
with HF -RSF, over a five year period 10% were never hospitalised, 41 % were hospitalised 
once, and 49% were hospitalised twice or more. These proportions for patients with PSF 
were 24%, 51 %, and 25% respectively. Thus patients with RSF had more hospital 
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admissions19. The CHS also reported the risk of non-fatal MI and stroke41 . In subjects 
without HF these were 10.9 and 12.5 per 1,000 patient-years at risk respectively. These rates 
increased to 23.3 and 27.5 in patients with HF-PSF, 37.7 and 50.7 in those with HF and 
borderline systolic function but dropped to 19.4 and 45.2 in subjects with HF-RSF. There is 
no obvious explanation for the latter finding. In hospital cohort studies, overall the rates of 
readmission for HF-PSF are very high, 15 - 25% of patients are readmitted with an 
exacerbation of HF within six months and one-third within a year. Approximately 45-60% 
are readmitted within one year for any causel3 . It is clear that with both types of heart failure 
there is a poor prognosis. This is highlighted in the findings of Philbin et a126, who showed 
that the six-month rate of death or readmission was 50% in patients with HF-PSF and 52% in 
patients with HF-RSF. 
1.03 Pathophysiology of heart failure with preserved systolic function 
It is now accepted that HF with preserved, as opposed to reduced systolic function is a 
separate clinical entity. What is more controversial is the nature of the underlying 
pathological change. For the majority of patients, this is presumed to be diastolic 
dysfunction 43;44. 
1.03.1 Left ventricular diastolic function 
Normal LV diastolic function may be clinically defined as the capacity of the left ventricle to 
receive a filling volume which will result in an adequate stroke volume at low pressures45 • 
There are two main pathophysiological processes which produce diastolic dysfunction. These 
are impaired LV relaxation and increased LV stiffness9;46. Zile et al assessed the diastolic 
properties of the LV in 47 patients who had HF-PSF. All had impaired relaxation and 
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increased left ventricular chamber stiffness when compared to a control group. The authors 
concluded that the signs and symptoms of HF in patients with preserved systolic function are 
caused by abnormalities in diastolic function. It is thought that these abnormalities in 
diastolic function make patients susceptible to sodium retention, neurohormonal activation, 
increased venous tone or increased arterial stiffness, all of which can result in pulmonary 
oedema. Also, increased LV stiffness means that the ventricle is unable to accept venous 
return adequately, without high diastolic filling pressures. High filling pressures result in 
decreased lung compliance, which increases the work of breathing and contributes to 
breathlessness 43. 
Patients with HF-PSF are often found to have impaired exercise tolerance. This is also 
thought to be due to increased L V stiffness. In addition to the effect on filling pressures 
described above, the stiff ventricle operates on a flat portion of the Frank-Starling curve. 
Consequently, these patients have little or no increase in stroke volume on exercise. Overall, 
during exercise, the stiff ventricle is unable to fill properly or to increase its stroke volume 
and therefore the cardiac output does not increase, producing symptoms on exercise 43. There 
are limitations to the non-invasive assessment of the pathophysiology of HF-PSF, however, 
the work done to date suggests that impaired diastolic function causes the signs and symptoms 
of HF. This is an area where more work is required, and tools such as cardiac MRI may 
provide more specific information in the future. 
1.03.2 Echocardiography and diastolic dysfunction 
Spectral Doppler echocardiography, particularly of the mitral inflow, is widely used for the 
non-invasive assessment of diastolic filling of the left ventricle47 . The normal mitral inflow is 
biphasic (Figure 1.1). 
39 
Figure 1.1 Mitral inflow pattern 
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The mitral inflow velocity trace reflects the relative driving force across the mitral valve. 
When pulsed wave Doppler is sampled from the level of the tips of the mitral valve leaflets, 
the measured peak velocity is indicative of the relative instantaneous change in pressure 
between the left atrium (LA) and the LV after the opening of the mitral valve. 
The E velocity is the peak early filling velocity, and is influenced by the LA pressure at mitral 
valve opening, LA compliance, the pressure gradient between the LA and LV, and the rate of 
ventricular relaxation47. The rate of decrease of velocity following the E peak is measured as 
the deceleration time (DT). The initial slope is extrapolated to baseline, and the DT is the 
interval between the peak E velocity and the intersection of the slope with the baseline. The 
DT depends on the rate of increase in LV pressure in early diastole, after it has reached its 
nadir, and is a measure of the effective chamber compliance of the LV47. The A velocity 
measures mitral inflow during atrial contraction. As LA contraction usually occurs after 
relaxation is completed, the peak velocity depends on L V chamber compliance as well as the 
volume and contractility of the LA. Normal mitral inflow velocities vary with loading 
conditions, age and heart rate. In a normal middle-aged subject the E velocity is larger than 
the A velocity, and the DT is approximately 200 +1- 40ms. 
Diastolic function has been categorised into: 
1) Normal 
2) Mild dysfunction - Impaired relaxation without evidence of increased filling 
pressures 
3) Moderate dysfunction - Impaired relaxation associated with elevated filling 
pressures or pseudonormal filling 
4) Severe dysfunction - Reduction in compliance or restriction of the LV 
41 
Pseudonormal filling is as a normal resting mitral inflow pattern, but EI A ratio reversal on 
Valsalva manoeuvre. 
Impaired LV relaxation produces specific changes in the mitral inflow Doppler trace. As 
there is slower reduction in the rate of decrease of the L V pressure, and the duration of 
relaxation is prolonged into mid or late diastole. This results in a lower initial driving force 
across the mitral valve producing a low peak E velocity. The prolonged duration of 
ventricular relaxation results in prolongation of the DT. There is a subsequent increase in 
mitral inflow during atrial contraction, because of higher atrial preload, resulting in a higher 
peak A velocity. To summarise impaired LV relaxation is indicated by a low peak E velocity, 
a high peak A velocity and a prolonged DT on spectral Doppler of mitral inflow47 • 
As the diastolic dysfunction progresses, the peak A velocity increases and becomes greater 
than the peak E velocity, termed E/A reversal. When LV restriction is also present there is 
EI A reversal and a shortened deceleration time (Figure 1.2). 
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Figure 1.2 
2 
J.5 
~ 
'i 1 
~ 
(IS 
43 
Mitral inflow criteria for classification of diastolic function (adapted from Redfield et af6) 
Nonnal Diastolic 
Function 
O.75<E/A<1.5 
DT>140 ms 
E 
Mild Diastolic 
Dysfunction 
Impaired Relaxation 
E/A::;O.75 
15 
05 
15 
05 
Moderate Diastolic 
Dysfunction* 
Pseudononnal 
O.75<E/A<1.5 
DT>140 DlS 
2 
15 
05 
Severe Diastolic 
Dysfunction 
Fixed Restrictive 
E/A>1.5 
DT<140 ms 
1.03.3 Natriuretic Peptides 
In the early 1980s de Bold et al observed that extracts of atrial tissue infused into rats caused 
a massive diuresis. From this work came the isolation of atrial natriuretic peptide (ANP), the 
first in the family of natriuretic peptides48. A decade later the second member of the family 
was described, B-type natriuretic peptide (BNP). Since the 1980's four different natriuretic 
peptides have been described: ANP, BNP, C-type natriuretic peptide (CNP) and D-type 
natriuretic peptide (DNP). They all contain a characteristic 17 amino-acid ring structure, 
formed by an disulfide bridge between two cysteine residues49. The amino- and carboxy-
terminal tail varies between the different peptides: ANP has a 28 amino acid polypeptide, 
BNP a 32 amino acid polypeptide, CNP a 53 amino acid polypeptide and DNP a 38 amino 
acid polypeptide 50. They all exist as pro-hormones with relatively high molecular weight, 
which are cleaved to active moieties before release into the circulation5!. 
The ANP and BNP precursor peptide genes are located in tandem on the distal short arm of 
chromosome 152. The CNP precursor peptide gene is localized on chromosome 252. The gene 
encoding the DNP precursor peptide has not as yet been c1oned53. 
The precursor protein of ANP (pro-ANP) is a 126 amino-acid molecule. It is proteolytically 
cleaved to a 98 amino acid fragment and a 28-carboxy-terminal fragment, which constitutes 
biologically active ANp54. In the normal human adult heart, the atria are the main source of 
ANp50. 
BNP will be discussed in detail later in this chapter. 
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CNP is expressed primarily in the central nervous system and in vascular tissues, but unlike 
ANP and BNP is nearly non-existent in cardiac tissue55 , Despite this, CNP does play an 
important role in cardiovascular physiology, as it is a potent vasodilator, as well as being an 
inhibitor of smooth muscle proliferation and endothelial migration56, 
DNP is a 38 amino acid peptide and is the most recently discovered of the natriuretic peptides, 
Originally isolated from the venom of the green mamba snake (Dendroaspis Angusticeps)57, 
Currently there are little data regarding DNP in humans, Some authors suggest that DNP is a 
primitive cardiac natriuretic peptide and is an evolutionary precursor of ANP and BNpS3 ;58, 
There are three known natriuretic peptide receptors (NPR): NPR-A, NPR-B and NPR-C, 
These mediate the physiological effects of the natriuretic peptides, Each receptor contains a 
single transmembrane domain and an extracellular binding domain59, NPR-A and NPR-B are 
structurally similar with 44% homology in the ligand-binding extracellular domain60, ANP 
and BNP bind preferentially to NPR-A which then dimerizes and uses the chloride ion to hold 
itself in the "open" position, The receptor is linked to a guanosine 3',5'-(cyclic)phosphate (c-
GMP)-dependent intracellular signalling cascade, which mediates most of its biological 
activities61 , Mice lacking functional NPR-A exhibit hypertension, cardiac hypertrophy and 
dilatation and premature sudden death62, It has been demonstrated that BNP has a ten-fold 
lower affinity for NPR-A compared with ANp63 , This has led to speculation that an 
additional BNP-specific cGMP coupled receptor may playa role in its functioning64, Both 
NPR-A and NPR-B are found in adrenal glands and kidney but NPR-A is most abundant in 
large blood vessels, whereas NPR-B is most abundant in the pituitary gland51 , NPR-B has a 
low affinity for ANP and BNP but is activated by CNp61;64, 
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In contrast to NPR-A and B, NPR-C uses a G-protein coupling system for intracellular 
signalling to mediate its physiological effects61 . NPR-C is found in vascular endothelium, 
smooth muscle, cardiac muscle, adrenal and kidney65. As demonstrated in NPR-C knockout 
mice, its function is to clear ANP, BNP and CNP66. These molecules are internalised in a 
receptor vesicle and enzymatically degraded, following which the receptor returns to the cell 
surface5o. This receptor binds all three natriuretic peptides, having the highest affinity for 
ANP, followed by CNP then BNp67. This accounts for the longer half-life of BNP compared 
with ANP in humans6!. 
There are two mechanisms of clearance of natriuretic peptides. As described above, NPR-C -
mediated endocytosis followed by lysososomal degradation. Natriuretic peptides are also 
degraded by neutral enodpeptidase49. The relative importance of each mechanism is not yet 
clear. Renal pathways playa lesser part in clearance of CNP56. Some investigators believe 
that lysosomal degradation is the main process, while others believe that the increase in 
natriuretic peptides in heart failure saturates receptors, and the enzymatic degradation process 
takes ovel8. 
Regulation of natriuretic peptide release at a cellular level is controlled predominantly by the 
degree of stretch of the atria and ventricles. Increased wall stretch can act directly or via local 
paracrine factors such as endothelin-1 69, nitric oxide56, and angiotensin II 70 to increase 
natriuretic peptide levels. Other stimuli include tachycardia7! and glucocorticoids72, both of 
which contribute to induction of cardiac BNP mRNA in overt heart failure56. The trigger for 
ANP release is primarily raised atrial transmural pressure. It has been demonstrated that ANP 
gene induction occurs days after the increase in atrial pressure73 . This relatively slow 
induction of ANP allows for its storage in granules and periodic release 74. 
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Experimental data suggests that ANP is released in heart failure regardless of severity and 
occurs even in compensated heIDt failure when hypertrophy is present but L Vend diastolic 
pressure (L VEDP) is normafs. The trigger for BNP release is a combination of pressure and 
volume overload. This is illustrated by the correlation seen between LV chamber size76, 
LVEDp77, and plasma BNP concentration. BNP gene activation is seen within hours of 
increased chamber pressure, BNP is not stored in granules, but instead released in bursts 78. In 
contrast with ANP, BNP is only induced in heart failure when the L VEDP is elevated7s • 
Natriuretic peptides act on the kidney at the level of the glomerulus and collecting ducts to 
stimulate natriuresis and diuresis. At the glomerulus they cause afferent arteriolar dilation 
with efferent arteriolar vasoconstriction which consequently increases the glomerular 
filtration rate (GFR)79. In the collecting duct, their effect is to decrease sodium reabsorbtion, 
thereby increasing sodium excretion8o• Both ANP and BNP inhibit the secretion of renin, 
angiotensin II and aldosterone81 . Experimental studies have shown that BNP acts a 
cardiomyocyte-derived anti-fibrotic factor, and therefore may be a local regulator of 
ventricular remodelling61 • Both ANP and BNP have inhibitory effects on the sympathetic 
nervous systemso. 
Table 1.2 summarises the main characteristics of the natriuretic peptides discussed above. 
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Table 1.2 Characteristics of the natriuretic peptides (Adapted from Vanderheyden et aZ58) 
ANP BNP CNP DNP 
BNP NT-proBNP 
Components Ct-ANP(28 AA) BNP(32AA) Nt fragment (1-76) CNP-22 
NT -proBNP (1-108) CNP-53 
Hormonally Nt-ANPt (98 AA) Endocrine / NT -proBNP (1-108) CNP-53 paracrine 
active Endocrine / paracrine 
paracnne 
Genesis Cleavage from Cleavage form Release from ventricular myocytes Cleavage from pro-CNP 
pro-ANP pro-BNP 
Half-life 20 min 120 min 
Clearance Neutral Neutral Renal clearance Neutral endopeptidase unk 
mechanism endopeptidase endopeptidase 
Clearance receptor NPR-C 
Clearance Clearance 
receptor NPR-C receptor NPR-C 
Approved unk 100 pg/ml Age <75 years: 125 pglml - -
cutoff for 
CHF 
diagnosis 
Tissue Cardiac atria and Brain Brain Brain, ovary, uterus Testis Snake venom 
distribution ventricles Cardiac Cardiac ventricles epidydimis 
ventricles Myocardial fibrosis 
Myocardial 
fibrosis 
Ct = carboxy-terminal . Nt = ammo-terminal AA = ammo aCId Unk = unknown 
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BNP, and more recently NT -proBNP have been recognised to be of particular importance in 
heart failure. As described above, the predominant source of BNP in humans is the ventricular 
myocardium 78;82. BNP is released in bursts as a 108 amino acid prohormone which is then 
cleaved to form biologically active BNP, a 32 amino acid molecule and the 76 amino acid 
molecule, NT -proBNP. Figure 1.3 summaries this process. 
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Figure 1.3 Structure and formation of BNP and NT -proBNP (adapted from Hall et aL83) 
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Circulating BNP has the characteristic natriuretic peptide ring structure with an amino-
terminal tail of nine amino acids, and a carboxy- tail of six amino acids51 . 
In normal subjects, the plasma concentrations of BNP and NT -BNP are similar. The half-life 
of BNP and NT -proBNP in blood are approximately 22 minutes and 120 minutes 
respectively. This suggests that they could be used to reflect pulmonary capillary wedge 
pressure changes every two and 12 hours respectively84. In patients with LV systolic 
dysfunction both BNP and NT-proBNP are elevated, however, increases in NT-proBNP are 
two-to ten-fold greater than increases in BNP. The explanation for this is unknown. Both 
BNP and NT -proBNP can be measured by radioimmunoassay (RI). The combination of its 
longer half-life and greater increases in heart failure, may make NT -proBNP a better marker 
of heart failure 8S • 
The accuracy of the natriuretic peptides as markers of cardiac function, is influenced by renal 
function, gender and age. There is a correlation between BNP and estimated GFR, such that 
BNP rises as GFR falls (r = -0.20). This implies that a higher value for the upper limit of 
normal is required when using BNP in the diagnosis of HF if GFR is reduced. However, BNP 
does maintain a high level of diagnostic utility despite this86. NT-proBNP has a stronger 
correlation with with GFR than BNP (r = -0.60) and is influenced by the normal age-related 
decline in renal function. For example, an eGFR less than 60ml/minl 1. 73m2, which is 
common in elderly patients, may make the detection ofHF using NT-proBNP less accurate87. 
In this context, some authors have suggested that NT -proBNP specifically reflects cardio-
renal rather than cardiac function85• 
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Redfield et al demonstrated than in normal subjects with no known cardiovascular disease or 
detectable structural heart disease, plasma BNP concentrations were higher in females and 
correlated positively with increasing age. The authors suggest that the increased BNP found 
in females may be due to oestrogen status, as BNP levels were higher in women on hormone 
replacement therapy preparations. Interestingly, it has also been speculated that diastolic 
dysfunction and ventricular stiffening is more common in women88-90. 
The mechanism of the increase in BNP with age is not known, however, the LV does stiffen 
with age, which would be expected to stimulate BNP production88• Regardless of mechanism, 
Redfield et al demonstrated than the effect of age and gender on BNP was independent of 
atrial volume, LV dimension and LV mass. They concluded that both gender and age should 
be taken into account when interpreting BNP concentrations on a diagnostic basis9o. 
The New York Heart Association (NYHA) functional classification system for heart failure 
correlates well with symptoms and mortality. BNP levels also cOlTelate with NYHA class. 
For some time it has been accepted that BNP levels are elevated in patients with heart failure 
due to impaired LV systolic function91 -93 • BNP is also raised in those with asymptomatic LV 
systolic dysfunction92-94 • More recently NT -proBNP has been shown to be elevated in 
patients with heart failure, post-MI LV systolic dysfunction and asymptomatic LV 
dysfunction95-97• 
Breathlessness is a common problem in patients presenting to casualty. Differentiating 
between respiratory and cardiovascular causes of breathlessness is often problematic. Davis 
et al reported the usefulness of BNP in distinguishing between HF and chronic obstructive 
pulmonary disease in this setting. BNP concentrations of greater than 22pg/ml predicted the 
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presence of HF with a sensitivity of 93 % and a specificity of 90%98. Subsequent studies have 
confirmed the ability of BNP to accurately predict the presence of HF in a breathless patient 
(area under the ROC being 0.97)99. The role of BNP in identifying dyspnoea due to HF was 
specifically addressed in the Breathing Not Properly Multinational Study. This was a 
multicentre prospective study of 1586 patients presenting with acute dyspnoea. BNP was 
measured in the Accident and Emergency Department. BNP levels were significantly higher 
in those with HF (either HF-RSF or HF_PSF)lOO. 
The most important feature of BNP as a diagnostic tool in HF, is its high negative predictive 
value (NPV). Cowie et at demonstrated a negative predictive value of 97%, indicating a role 
for BNP as a "rule out" test101 • 
It has also been suggested that BNP could be used to guide treatment in HF. Patients who are 
admitted with fluid overload, are found to have a high BNP (a so-called "wet BNP"), and this 
level falls as they are rendered euvolaemic (or "dry BNP"). This could be used as a guide for 
timing discharge from hospital. Patients in whom the BNP remains high despite euvolaemia 
often have a poor prognosis88. Both BNP and NT-proBNP concentrations have been 
positively correlated with worse prognosis. Omland et at were the first to report that an 
elevated plasma BNP concentration taken on day three post-MI, was an independent predictor 
of cardiovascular death102• 
Subsequent studies have corroborated this finding. Richards et at demonstrated that BNP and 
NT -proBNP are the most sensitive predictors of poor outcome and have the highest NPV for 
mortality post MI when compared with other natriuretic peptides95 • Others have confirmed 
the association of elevated NT-proBNP and a poor outcome post-MI, both in terms of death 
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and subsequent L V systolic dysfunction96• Tsutamoto et at have shown that BNP is superior 
to ANP in determining prognosis and that BNP is an independent predictor of mortalityl03. 
Richards et at showed that NT -proBNP is similarly effective at predicting adverse outcome in 
patients with ischaemic LV systolic dysfunction, without prior MI104. Even in unselected 
population studies, it has been shown that an elevated BNP concentration is an independent 
predictor of four year all-cause mortality. It has also been shown to be a useful prognostic 
marker in the elderly105. Recently, Gardner et at demonstrated that NT -proBNP concentration 
is an independent predictor of both mortality alone or a combined endpoint of death or urgent 
transplantation in patients with advanced heart failure referred for consideration of cardiac 
transplantation106. Berger et at have also demonstrated that elevated BNP concentrations are 
a predictor of sudden cardiac death in heart failure 107• 
Most of the work on natriuretic peptides has been done in patients with heart failure and 
reduced LV systolic function. Less is known about natriuretic peptide levels in patients with 
heart failure and preserved systolic function. The introduction to Chapter five outlines the 
evidence to date. 
1.03.4 Aminoterminal propeptide of type III pro collagen (PIIINP) as a marker of 
myocardial collagen turnover in heart failure 
The myocardial extracellular matix (ECM) is the connective tissue skeleton of the heart and 
plays a key role in cardiac function. It is a fibrillar network which determines the structure, 
tensile strength and stiffness of the tissue. It is therefore a major determinant of diastolic 
function. In myocardium, the main types of collagen are I and III. The extracellular matrix is 
known to be dynamic. The controlling mechanisms are complex, but are principally mediated 
by matrix metalloproteinaeses (MMPs), which are involved in the degradation of the ECM 
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and are thought to be a key component of myocardial matrix remodelling108• The MMPs are a 
family of functionally related zinc-containing endoproteinases. Myocardial MMPs are 
produced by fibroblast-like cells and cardiomyocytes109. There are four main groups: 
collagenases, gelatinases, stromelysins, and membrane-type. The first group includes MMP-l 
(interstitial collagenase), MMP-8 (neutrophil collagenase) and MMP-13 (collagenase-3), all 
of which cleave fibrillar collagens (type I, II and III). These collagen form fibrils which are 
tightly opposed and highly cross-linked, and are thus extremely resistant to cleavage by most 
proteinases. Recent evidence has suggested that the substrate-based classification of MMPs is 
not useful, as there is cross-linkage in action between the four groups. For example, 
gelantinases are thought to play an important role in cleavage of interstitial collagens as well 
as gelatins, and therefore play a more important role in ECM remodelling than was first 
appreciatedllO-ll2. The regulation of ECM degradation by MMPs is achieved through 
regulation of MMP expression, and by specific endogenous MMP inhibitors called tissue 
inhibitors of metalloproteinases (TIMPs). MMP inhibition by TIMPs occurs following 
binding at the zinc binding site of the active MMP. There are other naturally occurring 
inhibitors of MMPs such as alpha-macroglobulin which is a large (750kDa) protein produced 
by the liver108. 
Individual myocyte function is preserved during the ageing process, however, myocytes are 
replaced by ECM, in particular by collagen deposition, and this contributes to the ventricular 
dilatation and reduction in LV function seen with ageingll3;1l4. 
Cardiac fibrosis is defined as an increase in the concentration of matrix collagens in the 
interstitium, but also involves a change in the type of collagen found1l5;1l6, its 
organisationll7;1l8, cross_linkage1l9;120, and denaturationl17;1l8. Cardiac fibrosis III 
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hypertrophied hearts develops in two distinct phases121 • Firstly, there is a reactive 
accumulation of connective tissue in the interstial space due to de novo synthesis of collagen. 
This fibrogenesis occurs without loss of parenchyma. Secondly, there is a adaptive process 
where parenchymal cells are lost and replaced by fibrotic tissue. The accumulation of 
collagen fibrils in the interstitial space has been attributed, at least in part, to growth factors 
produced in response to mechanical load. Stimulators of local collagen biosynthesis include 
agents such as platelet-derived growth factor (PDGF), transforming growth factor-B (TGF-B), 
angiotensin II, aldosterone and endothelin 122; 123. 
Type III collagen is a major constituent of developing granulation tissue124-126. The 
aminoterminal propeptide of type III pro collagen (PIIINP) is an extension peptide of the type 
III procollagen, which is cleaved off during the conversion from type III procollagen to type 
III collagen127. As a consequence, PIIINP reflects enhanced collagen turnover and therefore, 
myocardial fibrosis1 28;129. There is accumulating evidence that serum PIIINP and MMP 
concentrations can be used as markers of myocardial remodelling. This comes mainly from 
studies on patients following MI or with dilated cardiomyopathy (DCM). Elevated serum 
PIIINP is associated with L V dilatation and depressed ejection fraction, as well as with a 
restrictive L V filling pattern. Elevated PIIINP concentrations in these clinical settings are 
also associated with a worse prognosis 129-133 . 
Only a few studies have examined the relationship of PIIINP to diastolic function using 
echocardiography. Poulsen et al studied the relationship between PIIINP and LV function in 
patients presenting with a first acute MI. The authors concluded that the PIIINP 
concentrations measured in the sub-acute phase of MI related, in the long-term, to detrimental 
changes in L V systolic function. Those with higher PIIINP concentrations were more likely 
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to have a restrictive LV filling pattern, which is associated with increased LVEDP. This 
could either be due to increased myocardial stiffness or increased L V volume. In this 
particular group, the restrictive L V filling pattern is more likely to be due to increased LV 
volumes 129. This relationship was also observed recently by Rossi et all3i , who examined 
out-patients with dilated cardiomyopathy. To date, serum PUINP concentrations have not 
been described in patients with HF-PSF. 
1.03.5 Renin and aldosterone 
The renin-angiotensin-aldosterone system (RAAS) is one of the main physiological systems 
involved in mediating the pathology of heart failure. HF causes over-activation of the RAAS 
and aldosterone excess. Aldosterone increases renal reabsorption of sodium ions in exchange 
for potassium and hydrogen ions. This in tum leads to sodium retention and expansion of the 
extracellular volume, with eventual impairment of haemodynamic responses and a fall in 
cardiac output. A cycle is then established, whereby the resultant reduction in renal perfusion 
causes further activation of the RAAS, leading to further compromise of cardiac function, 
along with secondary hyperaldosteronism and hypokalaemia. 
The first work to explore the role of aldosterone as a cause of cardiac fibrosis was by Karl 
Weber in 1988. This has lead to the key concept, that aldosterone can cause cardiac fibrosis, 
independent of its effect on blood pressure or on the development of ventricular hypertrophy. 
Plasma aldosterone and renin concentrations have not been described in patients with HF-
PSF. 
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1.04 Aims of study 
It is clear from the above discussion that HF-PSF is an important cause of morbidity and 
mortality, but that this complex clinical entity is, as yet, poorly understood. Establishing 
exactly what constitutes HF-PSF requires comprehensive study of such patients and their 
outcomes. At the time of starting this study, the majority of data regarding clinical 
characteristics and long- term adjusted mortality rates were derived from out-patient 
populations, and there was limited prospective data from hospitalised cohorts. Another major 
limitation of the published work at that time, was that there was little focus on elucidating the 
relevant pathophysiological processes in HF-PSF. No study had prospectively investigated 
both indices of diastolic function and natriuretic peptides in the same cohort of patients with 
HF-PSF. No studies had documented PIIINP or renin and aldosterone levels in such patients. 
This study aims to define a COhOli of patients hospitalised for heart failure, to characterise 
them using clinical, echocardiographic and biochemical variables and to compare the 
characteristics of patients with reduced and preserved systolic function. This study also aims 
to determine mortality rates and independent predictors of mortality in both groups of heart 
failure patients. 
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2.01 Patient population 
All patients were recruited from the Western Infirmary which is a community hospital for 
north-west Glasgow, with a catchment area of approximately 250,000. Patients are admitted 
to the hospital either by self referral to the Accident and Emergency Department or directly 
from their General Practitioner for review by the medical receiving team. All patients 
admitted to the Medical Admissions Unit are assessed by a senior member of the medical 
receiving team. A provisional diagnosis and treatment plan is initiated by the senior medical 
physician, and then reviewed by the medical consultant at 12 hourly intervals. The working 
diagnosis and continuing management plan are implemented following this review. 
All patients admitted to the Medical Admissions Unit were screened for clinical evidence of 
heart failure such as shortness of breath, basal lung crepitations, peripheral oedema or 
treatment with intravenous diuretics on admission. Patients fulfilling any of these clinical 
features were approached to enter the study. Patients who agreed to enter the study signed a 
written consent form and were given written confirmation pertaining to the study as agreed 
with the North Glasgow Ethics Committee (see appendix 1). Patients who were clinically too 
ill to formally consent or those with documented dementia were not approached to enter the 
study. If, at this initial meeting, it was felt that the patient had an element of cognitive 
impairment then the patient was not asked to enter the study. 
Patients who met the inclusion criteria and who consented to enter the study were then 
assessed for clinical evidence of heart failure using the three heart failure scoring systems: the 
Boston score13\ the NHANES score135 and the Framingham score136 (see appendix 2). For 
the purposes of this study a patient was deemed to have heart failure if they scored positively 
in anyone of these scoring systems. 
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All three of the heart failure scoring systems use a combination of physical and radiographic 
assessment, along with objective measures of ventricular performance and an estimate of 
exercise capacity. Each of these variables has limitations when used independently 137. 
Consequently, combinations of these have been developed as scoring systems and have been 
used in epidemiological studies and clinical trials. Both the Framingham and NHANES 
scores were developed for use in large epidemiological studies and the Boston score was 
validated to assess the degree of HF in cardiovascular medication trials. 
It has previously been established that the Boston heart failure score has a sensitivity of 
0.50138 and a specificity of 0.78 to detect a left ventricular ejection fraction :S 40% and a 
sensitivity of 0.90 for identifYing a pulmonary wedge pressure of 12mmHg or more in 
patients undergoing non-emergency right heart catheterisation139. The Boston score 
comprises three sections: clinical symptoms, clinical signs and chest radiograph (CXR) 
appearances. A maximum score of 4 can be obtained from each section to give a total score 
out of 12. Scores of less than 5 suggest that HF is not present, a score of between 5 and 8 
indicate possible HF and a score of 8 or more suggests definite heart failure. 
The Framingham HF score has both a sensitivity and specificity of 0.63 for the detection of a 
left ventricular ejection fraction:S 40%138. This score is divided into major and minor criteria. 
HF is defined as present when either two major criteria or one major and two minor criteria 
are met. 
The NHANES score is based on the same principles as the other two scores and includes 
clinical, symptomatic and CXR criteria. A score of greater than 3 is suggestive of heart 
failure. In a study comparing six heart failure scores including NHANES the authors found 
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that all the scores were similar in terms of their capability to detect HF. All the scores had a 
high sensitivity for the detection of definite heart failure and a lower sensitivity for detection 
of possible heart failure l4o . 
It is important to note that these HF scoring systems have all been validated in assessing HF 
with reduced ejection fraction. Their sensitivity and specificity to detect HF with preserved 
EF is unknown. 
For this study, the clinical assessment comprised: a detailed cardiovascular and medical 
history with systematic documentation of the presence or absence of symptoms of HF, a 
clinical examination for signs of HF, a record of the patients cardiorespiratory parameters as 
well as electrocardiogram (ECG) and CXR findings from admission (see Appendix 3). 
Specific information was recorded from the ECG of each patient including heart rate and 
rhythm, and the presence or absence of: atrioventricular block; bundle branch block; mean 
QRS axis deviation; ventricular hypertrophy; ST segment deviation; T-wave inversion; 
pathological Q-waves and QT interval prolongation (see Appendix 4). All patients had a 
CXR on admission. 
It is well established that both ECG and CXR play an imp0l1ant role in the diagnosis of heart 
failure. This is outlined in the European Society of Cardiology Task Force for the diagnosis 
and treatment of chronic heart failure diagnostic algorithm (Figure 2.1)141. These HF 
guidelines were the most up to date at the time of sta11ing the study in 2002. Since then they 
have been updated142. 
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ECG abnormalities are common in patients with heart failure. The negative predictive value 
of a normal ECG to exclude left ventricular systolic dysfunction (L VSD) is greater than 
90%143-146. Likewise, the presence of either anterior Q-waves or left bundle branch block 
(LBBB) in patients with ischaemic heart disease are good predictors of decreased LV ejection 
fractionl47 . The presence ofECG signs of atrial stretch or left ventricular hypertrophy can be 
associated with both systolic and diastolic dysfunction but have a relatively low predictive 
value. For the purposes of this study, left ventricular hypertrophy by ECG was based on 
either the Sokolow and Lyon criteria (S VI + R Vs or V6 > 35 mm) or the Cornell criteria (S 
V3 + R avL > 28mm [men] and S V3 + R avL > 20 mm [females]). The ECG is also 
particularly important for the detection of arrhythmias which may contribute to or exacerbate 
heart failure. The diagnostic power ofECG abnormalities is markedly increased when used in 
combination with clinical signs and symptoms of heart failure l41 . 
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Figure 2.1 Algorithm for the diagnosis of heart failure159 
Heart failure suspected because of 
symptoms and signs 
I 
Assess presence of 
cardiac disease by ECG, 
X-Ray or Natriuretic 
peptides (where 
available) 
~ 
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... 
Imaging by 
echocardiography 
(nuclear angiography or 
MRI were available) 
l 
Test Abnormal 
1 
Assess aetiology, degree, 
precipitating factors and 
type of cardiac 
dysfunction 
r ---cho~~e-th;r~;y----l 
Normal 
Heart failure unlikely 
Normal 
Heart failure unlikely 
Additional diagnostic tests 
where appropriate (e.g. 
coronary angiography 
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Those patients in whom the initial clinical assessment revealed evidence of heart failure then 
underwent objective assessment of heart failure severity. This was achieved using the New 
York Heart Association (NYHA) and Killip classification system for HF. Patients were asked 
at the time of admission about their symptoms in the weeks prior to admission. These 
symptoms were given an NYHA class (Table 2.1). The severity of heart failure at 
presentation based on clinical examination findings was given a Killip score (Table 2.2)142. 
Table 2.1 NYHA classification of heart failure 
--"" 
NYHAClass Definition 
I No limitation. Ordinary physical activity does not cause undue 
fatigue, dyspnoea or palpitations 
I 
II Slight limitation of physical activity. Comfortable at rest but ordinary I 
activity results in fatigue, dyspnoea or palpitations 
I 
III Marked limitation of physical activity. Comfortable at rest but less 
than ordinary activity results in symptoms 
IV Unable to carry out any physical activity without discomfort. 
Symptoms of heart failure are present at rest and made worse by any 
type of activity 
----_ ... - _ ... __ ... _ .. _ ... _ ... - -- ... - ... - --
-
Table 2.2 Killip classification of heart failure 
Killip classification Description 
I No heart failure 
lIa Heart failure. Basal lung crepitations 
lib Heart failure. Basal to mid zone lung crepitatons 
III Frank Heart failure. Lung crepitations throughout lung fields 
IV Cardiogenic shock 
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2.02 Blood sampling and biochemical analyses 
The European Society of Cardiology Task Force also recommends various laboratory 
investigations as part of the evaluation of heart failure: serum haemoglobin (Hb), white cell 
count (WCC), platelets, electrolytes, creatinine, glucose, hepatic enzymes and urinalysis 
should be carried out. They also recommend that additional tests are considered, including C-
reactive protein (CRP), thyroid function (TFT) , serum uric acid, and cardiac enzymes or 
troponin to exclude myocardial infarction141 . 
Anaemia may exacerbate existing heart failure or may develop as a result of heart failure. 
Regardless of aetiology the presence of anaemia in heart failure is associated with a worse 
prognosis148-150. For the purposes of this study the World Health organisation (WHO) criteria 
for anaemia were used. These define anaemia as Hb < 12g/dL in both males and females l5l . 
A raised haematocrit suggests the possibility of other pathologies for breathlessness such as 
respiratory disease. 
In the context of heart failure, an elevated serum creatinine is usually caused by either 
primary renal disease, as a result of reduced cardiac output or by drug treatment. The 
relationship between heart failure and renal dysfunction is complex, primary renal failure 
often results in fluid overload, producing clinical signs very similar to those found in heart 
failure. Also, heart failure and renal dysfunction often coincide because of common 
underlying diseases such as diabetes and hypertension, or because increasing age is associated 
with both heart failure and a reduction in GFR. Heart failure associated with a low cardiac 
output can cause renal dysfunction by producing chronic renal hypoperfusion. In addition, 
many of the agents available for the treatment of heart failure can have deleterious effects on 
renal function. ACE-inhibitors, angiotensin receptor blockers, aldosterone antagonists and 
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diuretics all have the potential to impair renal function, particularly when used in 
combination, as is often necessary for optimal heart failure treatment. As an absolute serum 
creatinine is not a comparative marker of renal function between individuals, in this study 
renal function was assessed using estimated glomerular filtration rate (eGFR). This was 
calculated using the Modified Diet in Renal Disease (MDRD) formula152;153, a validated 
measure of renal function. The value for eGFR is calculated as follows: 
eGFR (mLiminl1.73m2) = 186 x (plasma creatinine) -1.154 x (ageyO.203 x 0.742 if female. 
Renal function as measured by eGFR was then categorised using the National Kidney 
Foundation classification153• Renal function was classed as normal if the eGFR was 2: 90 
mLiminl1.73m2. Impairment of renal function was defined as mild (eGFR 60 - < 90 
mLiminl1.73m2), moderate (eGFR 2: 30 :s 60 mLimini 1. 73m2) or severe (eGFR < 
30mLlminl1.73m2)154. 
Liver function may become deranged in HF as a consequence of hypoperfusion. Urine 
analysis can be useful to detect proteinuria and glycosuria indicating the possibility of 
underlying renal dysfunction or diabetes which may complicate heart failure. Thyrotoxicosis 
causing rapid atrial fibrillation can present as heart failure, especially in the elderly. 
Hypothyroidism can also present as heart failure. Hyponatraemia and renal dysfunction in the 
context of heart failure indicate a poor prognosis141 . 
In this study all patients had blood samples taken at the time of admission for routine 
haematological and biochemical analyses including full blood count (FBC), coagulation 
screen (COAG), urea and electrolytes (U&E), glucose, thyroid function (TFT), liver function 
(LFT) and Troponin I. The routine blood samples were taken and analysed in the hospital 
biochemistry and haematology laboratories on the day of venesection. Troponin I was 
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measured using an ADVIA Centaur analyser (Bayer Diagnostics), which employs a 
chemiluminescent assay. A positive troponin was taken to be one greater than or equal to 
0.2flg/L. 
In addition, four further study-specific blood samples were taken within 24 hours of 
admission. These were taken to provide serum to measure BNP, NT -proBNP, PIIINP, 
aldosterone and renin. All serum samples were taken from the anticubital fossa with the 
patient in the supine position for a minimum of 10 minutes prior to venesection. While each 
patient was being entered into the study the blood samples were stored in the ward fridge. 
All study-specific blood samples were then taken directly to the research laboratory in the 
Western Infirmary and spun directly at 4°C in a centrifuge for 15 minutes at 3000 rpm. The 
supernatant was removed and put into separate freezer containers labelled with the patient 
subject number and stored in the freezer at -20T until the assays were analyzed in batches of 
approximately 100 samples. 
Plasma BNP was measured using the Shionoria immunoradiometric kit (Schering CIS, West 
Sussex, England). It has a within-assay and between-assay confidence variable (CV) of3.7% 
and 7.5% respectively. The normal range for BNP quoted from the radioimmunoassay kit in 
subjects aged 55-74 years is 3.2 - 91pg/ml. Work carried out on a local healthy population 
identified the 95th percentile at 61.3pg/ml for those aged 55-69 years and 67.6pg/ml for those 
aged 70 years and over. For the purposes of this study, an elevated BNP value was taken to 
be one greater than the 95th percentile for the relevant age group155. 
The Roche Elecsys proBNP (Roche Diagnositics, East Sussex, England) Immunoassay was 
used to analyse NT-BNP (proBNP). Roche claim equivalence with the Biosite Triage BNP 
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test. The Elecsys method used was an electrochemiluminescent immunoassay on an Elecsys 
2010 autoanalyser. This has a within-assay and between-assay CV of 2.7 and 3.2% 
respectively. The measuring range ofthe assay is 5 - 35,000 pglml. The analytical sensitivity 
of the assay is 5pglml. The diagnostic information quotes the cut-off for patients younger 
than 75 years to be 125 pglml and 450pg/ml for those 75 years and older. From work 
conducted on a healthy population, the following 95th percentile figures were established as 
normal ranges dichotomised for age and sex (Table 2.3)156. An elevated NT-proBNP was 
taken to be a value greater than the 95th percentile for each age and sex category. 
Table 2.3 
Age (years) 
Female 
Male 
95 th percentile according to age and sex of NT -proBNP for a healthy 
population 
NT -proBNP concentration pglml 
:S 64 65-69 70-74 ? 75 
213.4 314.2 338.5 355.3 
122.6 112.6 236 295.7 
A commercially available kit, UniQ PUINP radioimmunoassay (Quidel (UK) Ltd, licensed 
from Orion Diagnostic) was used for PUINP analysis. This has a within- and between-assay 
precision of 7% and 6.5% respectively. Table 2.4 details the reference intervals supplied by 
the manufacturer. 
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Table 2.4 Serum PIIINP reference intervals 
Adults 
Number of subjects 232 
Mean 3.7 ug/L 
, 
Reference Interval 2.3 - 6.4 ug/L 
0.90 Confidence interval for lower reference limit 1.9 - 2.6 ug/L I 
I 
0.90 Confidence interval for upper reference limit 5.5 - 6.7 ug/L ! 
I 
~- ... - .... - ... - .... - ... -~ .. -- ..... - ... - .... - ._.- .. _- ..... - -- ... - .... - ... - - ... - I 
Normal ranges from the literature using the same immunoradiometric assay at the time of 
setting up the study, estimate the upper limit of normal to be 4.5fLg/L. For the purposes of this 
study an elevated PIIINP was taken to be a value greater than 4.5fLg/L129;131;132;157. 
Aldosterone was measured using a commercially available Coat-A-Count assay (Euro/DPC, 
Ltd, Gwynedd, Wales)158. This is a solid-phase radioimmunoassay designed for the 
quantitative measurement of aldosterone levels in unextracted serum. A minimum of 200uL 
of sample is required. The assay is based upon aldosterone-specific antibody immobilised to 
the wall of a polypropylene tube. 125I-labelled aldosterone competes for antibody sites with 
aldosterone in the patients sample for a fixed time. The tube is decanted to separate bound 
from free aldosterone, and the radio labelled aldosterone is then counted in a gamma counter. 
The amount of aldosterone present is then determined from a calibration curve. The within-
assay and between-assay CV are up to 5.4 and 15.7% respectively. An elevated aldosterone 
concentration was again defined as greater than the 95th percentile of a local healthy 
population. Consequently, for purposes of this study an elevated aldosterone concentration 
was taken to be one greater than 20ng/dL. 
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Plasma renin concentrations were measured using an in-house assay with a CV of < 3.S%. 
The expected normal range is S_SOuU/mllS9. For the purposes of this study an elevated 
plasma renin concentration was taken to be a value greater than SOuU/mL 
The radioimmunoassays above were completed by Dr Ian Morton who was blinded to clinical 
details, including LV systolic function. The results were recorded on a Microsoft Excel 
spreadsheet separate from any other clinical details or patient identifiers. 
2.03 Echocardiography 
The use of echocardiography as an objective measure of cardiac dysfunction is necessary for 
the diagnosis of heart failure l41 . All patients had a departmental echocardiogram usually 
within 48 hours of admission. Often this was an investigation which was clinically indicated 
as part of their admission to hospital and was therefore outwith the study protocoL In these 
instances a copy of the echocardiogram report was obtained. Otherwise an echocardiogram 
was requested as part of the study protocol. These echocardiograms were conducted by a 
single operator, who is a British Society of Echocardiography trained senior cardiac 
technician within the cardiology department. The echo machine used was an Acuson Sequoia 
C2S6, which is the machine used for all such studies within the Western Infirmary. For the 
examination patients were positioned in the left lateral decubitus position. 
The primary function of this echo was to make an assessment of left ventricular systolic 
function (L VSF) and to establish any structural abnormalities such as valvular heart disease 
(VHD) or wall motion abnormalities. A qualititative assessment of overall L VSF (preserved 
or reduced function) was made. Such qualitative assessment has previously been shown to 
correlate closely with formal echocardiographic and radionuclide measurement of left 
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ventricular ejection fraction I 60-162. It is however, known that using this method 
standardisation among different observers is difficult to obtainl63 . Therefore, in this study, a 
single experienced operator and a single reporter conducted all echocardiographic 
examinations. Those with reduced L VSF were further classified into borderline, mild, mild-
moderate, moderate, moderate-severe and severe left ventricular dysfunction. Only patients 
with normal left ventricular systolic function were classed as having preserved LVSF. Figure 
2.2 is an illustration of the echo cardiographic appearances of the two types ofHF. 
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Figure 2.2 Diagramatic echo image of: 
A) LV systolic dysfunction 
Dilated thin walled 
Left ventricle 
B) Preserved systolic function with left ventricular hypertrophy 
Thickened restrictive 
left ventricle 
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In addition to assessment of L VSF further recordings were taken where images allowed. In 
the parasternal long axis view (in cm): left atrial diameter, right ventricular diameter, LV 
internal diameter in systole (L VIDS) and diastole (L VIDD), inter-ventricular septum diameter 
in systole (IVSDS) and diastole (IVSDD), LV posterior wall in systole (L VPWS) and diastole 
(L VPWD). In the apical four-chamber view: mitral inflow maximum velocity (m/s), mitral 
valve pressure-half time (m/s) , aortic valve outflow maximum velocity (m/s) , aOltic valve 
gradient (mmHg), and estimated peak pulmonary mtery pressure (mmHg). 
For this study, significant valvular incompetence was defmed as mitral or aortic regurgitation 
classified as more than mild. Aortic stenosis was defined as significant when the aortic 
gradient was greater than 50mmHg. Significant mitral stenosis was defined as a mitral valve 
pressure-halftime greater than 100m/s. 
Using the heart failure classification scores the patients were divided into two groups: those in 
whom heart failure was present (HF-positive) and those in whom heart failure was not present 
(HF-negative). The HF-positive group were fulther subdivided using a combination of ECG 
and echo cardiography: 
1. Reduced systolic function (+1- significant valve disease) - HF-RSF 
2. Preserved systolic function (HF-PSF) 
• HF-PSF + significant valvular heart disease (VHD) + atrial fibrillation 
(AF) 
• HF-PSF + significant valve disease (no AF) 
• HF-PSF + AF (no valve disease) 
• 'Isolated' HF-PSF (no valve disease I no AF) 
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Patients in the HF-RSF and HF-PSF group with significant valve disease or AF had no further 
investigations requested as part of the study unless they were clinically indicated. All of those 
patients were given cardiology clinic appointments if clinically indicated and not already been 
arranged as part of their discharge plan. 
2.04 Ecbocardiograpby and Doppler indices of diastolic dsysfunction 
Patients with isolated HF-PSF (HF-IPSF) returned for follow-up and Doppler 
echocardiography within 1 month of discharge. This echocardiogram was performed again by 
a single operator, who is a British Society of Echocardiography trained senior cardiac 
technician. These examinations were carried out on an Accuson 128XP machine normally 
used for out-patient echocardiography. 
During this echo cardiogram the same standard measurements described above were repeated. 
In addition, pulsed wave Doppler was performed across the mitral valve in the apical four-
chamber view, to measure the mitral E-wave, mitral A-wave, mitral EfA ratio, isovolumettic 
relaxation time (IVRT) and deceleration time (DT) [Figure 2.3]. 
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Figure 2.3 Bipbasic mitral inflow pattern and indices of diastolic function 
MITRAL INFLOW (Biphasic pattern) I, 
2 
Early Diastolic Filling 
E 
~CfJ 
~i: Atrial Systole 
o TIME-_ 
Vel = Velocity 
IVRT = Interventricular relaxation time 
DT = Deceleration time 
Where possible, on completion of the echo cardiogram patients were asked to perform a 
Valsalva manoeuvre by blowing against a fixed syringe. Measurements of the E-wave, A-
wave and EI A ratios were repeated during the Valsalva. It has been demonstrated that 
measurements taken during Valsalva can be used to differentiate pseudonormal diastolic 
function from normal. Patients with pseudonOimal diastolic function will show reversal of a 
nOimal resting mitral valve inflow pattern during Valsalva164• 
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Seven criteria for diastolic dysfunction were identified using a Medline search. Doppler data 
from patients in this study with HF-IPSF were used and compared against all 7 criteria. 
; 
Details of each criteria are described below. 
1) Krishnaswamy criteria165: Diastolic dysfunction was grouped by three categories 
i) pseudonormal pattem, ii) impaired relaxation and iii) restrictive pattem. 
Impaired relaxation EI A < 1 + DT > 240msec in patients < 55yrs 
E/A < 0.8 + DT > 240msec in patients 2: 55yrs 
Restrictive pattem E/A > 1.5 + DT < 150msec 
I: 
Pseudonormal EI A > 1 + DT > 240msec with confirming evidence of either: 
Pulmonary vein diastolic flow 
AbnOlmalIVRT 
Left atrial enlargement 
Left ventricular hypertrophy 
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2) Lubien criteria166: Diastolic dysfunction was classified into 3 criteria 
Impaired Relaxation EfA ratio < 1 or DT > 240ms in patients < 55yrs 
EfA ratio < 0.8 + DT > 240ms in patients ~ 55yrs 
Pseudonormal EfA ratio of 1 -1.5 + DT > 240ms 
Confirmation included: PVdfPVs> 1.5 or IVRT < 90msec 
or 
Reversal ofEfA ratio (to < 1.0) by Valsalva 
Restrictive pattern DT < 160ms + ~ 1 or the following: 
Left atrial size> 5cm 
EfA> 1.5 
IVRT< 70ms 
PVdfPVs>1.5 
Pulmonary A-wave reversal duration exceeding forward 
mitral A-wave duration 
3) Redfield criteria36 : Diastolic function was categorised according to the progression of 
diastolic dysfunction 
i) Normal 
ii) Mild (impaired relaxation) EfA:S 0.75 
iii) Moderate (pseudonormal) 0.75 < EfA < 1.5 + DT > 140ms 
iv) Severe (restrictive filling) Ef A> 1.5 + DT < 140ms 
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4) Cohen criteria167: 
i) Impaired relaxation E/A ratio < 1, DT > 220ms, IVRT > lOOms 
ii) Pseudonormalisation E/ A ratio> 1 < 2, 
iii) Restrictive filling: 
DT> ISO < 220ms, 
IVRT> 60 < lOOms 
E/A ratio> 2, DT < lS0ms, IVRT < 60ms 
S) European Working Group criteria168 : 
i) Signs and symptoms of congestive heart failure 
and 
ii) Normal or mildly reduced left ventricular systolic function 
and 
iii) Evidence of abnormal left ventricular relaxation 
IVRT «30yr) > 92ms, IVRT (30-S0yr) >100ms, IVRT (> SOyr) > 10Sms 
and/ or 
iv) Slow early left ventricular filling 
E/A « SOyr) < 1.0 and DT « SOyr) > 220ms 
or 
E/A (> SOyr) < O.S and DT (> SOyr) > 280ms 
6) Chen criteria169: i) Abnormal relaxation E/A < 0.7S 
ii) Restrictive pattern E/ A > 1.S and / or DT < 160 ms 
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7) Zile criteria 170: 
i) Abnormal diastolic function EI A ratio < 1.0 or> 1.5 
DT < 160 or> 280ms 
IVRT < 60 or> 105 ms 
LV mass was estimated from the M-mode measurements of the LV in diastole. The 
American Society of Echocardiography recommends that a correction factor was used when 
calculating LV mass from diastolic measurements therefore the following formula for LV 
mass usedl64: 
LV mass (g) = 0.8 x (1.04 x ((LVIDD + IVSDD + LVPWD)3 - LVIDD3) + 0.6g 
Where possible, all patients with HF-PSF underwent pulmonary function testing (PFT). The 
primary aim was to identify patients with significant pulmonary disease which may account 
for their symptoms. Pulmonary disease is a frequent cause of admission to hospital and often 
the symptoms and signs can mimic those of heart failure. Likewise, patients with pulmonary 
disease often have co-morbidity, including heart failure and this must not be overlooked 171. 
The measurements taken included: forced expiratory volume in one second (FEV 1), forced 
vital capacity (FVC), FEV 1IFVC ratio, and vital capacity (VC). The PFTs were reported by a 
respiratory physician blinded to clinical details. For the study, PFTs were recorded as being 
normal or abnormal. 
For the purposes of the study the patients with HF-PSF were reviewed on one occasion 
following discharge and further follow-up or investigations were arranged as was clinically 
indicated. 
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2.05 Quality of Life 
Quality of Life (QoL) was measured in all patients using the Cantril Ladder of Life scoring 
system. This instrument has been used in various cardiovascular studies and is considered to 
be a valid measure of "global well-being" 172; 173. Figure 2.4 illustrates the Ladder of Life 
scoring system. Patients were given envelopes containing the scoring system and asked to 
score how they had been feeling in the weeks prior to admission. The envelopes were then 
sealed and returned. 
Figure 2.4 Cantrils Ladder of Life 
10 10 = Best possible life for you 
9 
8 
7 
6 
5 
4 
3 
2 
1 
0 o = worst possible life for you 
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2.06 Follow-up 
Once reclUitment was complete the patient identifiers were sent to the Information and 
Statistics Division (ISD) in Edinburgh for flagging in order to obtain mortality follow up data. 
ISD linked my database by probability matching, to information held by the General 
Registrar's Office for Scotland on in-hospital and out-of hospital deaths. 
2.07 Statistical analyses 
All study data were entered into an Access database (2000) created specifically for the study. 
Minitab (version 13) statistical package was used for all basic statistical analyses and SPSS 
(version 12) was used for mortality analyses. 
Survival time was calculated from date of screening (earliest date 1 st November 2002) until 
death or censoring at 1 st March 2006. ClUde case fatality was calculated for follow-up using 
the actuarial life table method. Fatality was calculated separately for helli failure groups. This 
method accounts for the date of death and the different follow-up periods for each individual. 
Kaplan-Meier survival curves were constlUcted to illustrate the survival experience of the 
individuals according to heart failure group. Curves were compared using the log rank test. 
This involves calculating the observed and expected number of deaths in both groups at 
separate time intervals and summing these. The Kaplan-Meier survival method was used to 
determine median survival. This could only be calculated in the groups in which 50% of the 
individuals had suffered the event of interest i.e. all-cause death. 
Cox regression analysis was used to determine factors associated with all-cause mortality. 
The model adjusted for the following variables: smoking, age, eGFR, Hb, HR, AF, DM, 
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hypercholesterolemia, PAD, COPD, IHD, CVD, HF group (PSF vs. RSF), NYHA class III, 
NYHA class IV, bundle branch block, SBP, DBP, BNP and sex (male vs. female). 
The model was built by entering the variables that were available from this study that had 
previously been shown to predict all cause mortality in the CHARM cohort174• As no 
significant departure from linear trend was found, age, eGFR, Hb, HR, SBP, DBP and BNP 
were modelled as continuous variables. For each variable entered into a model, the lowest 
class was set at unity. For NYHA class, class I and class II were combined for reasons of 
power (there were very few with class I heart failure). After fitting the final model, the 
assumptions were checked. The assumptions underlying a Cox propOltional hazards model 
are: 
1. Proportional hazards, the ratio of hazard functions for two individuals with different 
covariates does not vary with time. 
2. Linearity, the relationship between the covariates and the hazard function should be linear 
in the log space. 
3. Survival times should be independent, as should survival times and censoring times and 
the censoring should not be affected by the covariates. 
These were checked by looking at log minus log plots for each categorical covariate in the 
model, which should demonstrate parallel lines if the hazards are proportional. In addition 
visual inspection of the Kaplan Meier curve confirmed that the proportional hazards 
assumption was met. All mortality analyses were carried using SPSS statistical package. 
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CHAPTER THREE 
CLINICAL CHARACTERISTICS OF PATIENTS WITH 
HEART FAILURE AND PRESERVED SYSTOLIC 
FUNCTION 
84 
3.01 Introduction 
At the time of starting this study only 2 previous authors had reported any of the clinical 
characteristics of patients with HF_PSF24;25. This Chapter aims to describe in detail the 
clinical characteristics of a cohort of patients with HF -PSF and to make comparisons with 
HF-RSF. 
3.02 Results 
3.02.1 Study population 
Recruitment for the study took place over a 21 month period from November 2002 to July 
2004. During this period, 5476 acute medical admissions were screened for clinical evidence 
of heart failure (HF). Details of recruitment to the study are described in Chapter 2. Of the 
5476 patients screened, 324 patients were eligible and agreed to enter the study. 
Of the 324 patients recruited, 307 had clinical evidence ofHF, defined as a positive score on 
at least one of the three HF scores (HF +ve). 17 patients were considered to have no clinical 
evidence of HF (HF -ve), as they did not score positively on any of the HF scoring systems. 
Ofthe 307 patients with clinical evidence ofHF, 296 had an echocardiogram. In the 11 cases 
where an echocardiogram was not available, this was either because the patient was too 
unwell to attend the echocardiography department or because the patient died prior to their 
echocardiogram being carried out. Of the 296 patients who had clinical evidence of HF and 
an echocardiogram, 149 had reduced LV systolic function (HF-RSF) and 147 had preserved 
systolic function (HF-PSF). This chapter will describe and compare the clinical 
characteristics of these two groups of patients with HF (Figure 3.1). 
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Figure 3.1 Patient groups 
5476 patients screened 
324 eligible 17 HF negative 
307 HF positive 
f---------.. ~[-l~o~c~ --I 
296 HF positive + echo 
149 RSF 147 PSF 
3.02.2 Demographics 
The two groups of patients had similar demographic characteristics (See Table 3.1). Their 
mean ages were similar, as was the proportion of patients aged 75 years or over in each group. 
The only significant difference between the two groups was that there was a higher proportion 
of female patients in the HF-PSF group (66% vs. 46%, p < 0.000l). The majority of patients 
in each group were Caucasian. 
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Table 3.1 Demographic characteristics of patients with HF-RSF and HF-PSF 
HF-RSF HF-PSF p value 
(n = 149) (n = 147) 
Age (years) mean (SD) 76 (10) 75 (10) 0.593 
n(%) 
~ 75years 91 (61) 84 (57) 0.491 
Female 69 (46) 97 (66) <0.0001 
Caucasian 146 (98) 146 (99) 0.318 
3.02.3 Signs and symptoms of heart failure 
Table 3.2 shows the symptoms and signs of HF present on admission in each group. These 
data were collected prior to the echocardiogram being performed. 
An assessment of the severity of HF before admission was made using the NHY A 
classification. The severity of HF on admission was assessed using the Killip classification 
(both described in Chapter 2). With respect to pre-admission functional limitation, a higher 
proportion of patients in the HF-RSF group had at least moderately severe HF (NYHA class 
III/IV). However, the proportion of patients with at least moderately severe HF on admission 
(Killip class ~ IIA) was not significantly different between the two groups (p = 0.223). In 
both groups, more than two-thirds of patients were in Killip class IIA or higher at the time of 
admission. Tables 3.3 and 3.4 show the individual NYHA and Killip classification scores for 
both types of HF. 
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The symptoms of HF reported by patients in the two groups were generally similar, whether 
or not systolic dysfunction was present. However, a higher proportion of the group with HF-
RSF, reported PND and orthopnoea, though the difference from those with HF-PSF was not 
statistically significant (p=0.064 and p=0.062 respectively). Otherwise, similar proportions 
reported reduced exercise tolerance, ankle swelling, general fatigue and leg fatigue. Weight 
loss was reported too infrequently to perform statistical analysis. 
In terms of distinguishing clinical signs, a higher propOltion of patients with HF-RSF group 
had an elevated jugular venous pressure (NP) (60% vs. 43% in the group with HF-PSF). 
Otherwise, a similar proportion of patients in each group with had crepitations, sacral oedema, 
peripheral oedema and wheeze. The mean respiratory rate (RR) was elevated in both types of 
HF, with no significant difference between the groups. The presence of a third heart sound 
(S3), hepatomegaly or ascites occurred in too few patients to perform statistical analysis 
though each appeared to be slightly more common in the patients with HF-RSF. 
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Table 3.2 Comparison of signs and symptoms of heart failure in HF-RSF I HF-PSF 
RSF PSF p value 
(n) % (n = 149) (n = 147) 
HF Classifications 
NYHA class III/IV 90 (60) 64 (44) 0.003 
Killip class 2: IIA 124 (83) 115 (78) 0.223 
Clinical data 
RR breaths pm, mean (SD) 21 (7.8) 21 (7.7) 0.370 
HR bpm, mean (SD) 92 (26) 89 (25) 0.305 
Signs 
Raised lVP 90 (60) 63 (43) 0.002 
3f oHS 6 (4) 2 (1) N/A 
Crepitations 126 (85) 119 (81) 0.410 
General wheeze 38 (26) 44 (30) 0.394 
Sacral oedema 12 (8) 5 (3) 0.083 
Peripheral oedema 86 (58) 84 (57) 0.920 
Ascites 3 (2) 1 (0.6) N/A 
Hepatomegaly 4 (3) 2 (1) N/A 
Symptoms 
Orthopnoea 89 (60) 72 (49) 0.062 
PND 62 (42) 46 (31) 0.064 
Reduced ex tolerance 130 (87) 134 (91) 0.277 
Reported ankle swelling 98 (66) 97 (66) 0.969 
General fatigue 115 (77) 111 (76) 0.735 
Leg fatigue 67 (45) 63 (43) 0.715 
Weight loss 7 (5) 3 (2) N/A 
NYHA = New York Heart Association, RR = respiratory rate, pm = per minute, HR = heart rate, bpm = beats per 
minute, JVP = jugular venous pressure, HS = heart sound, PND = paroxysmal nocturnal dyspnoea, ex tolerance 
= exercise tolerance. 
P value N/A = where the size of the group was too small to accurately perform statistical analysis. 
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Table 3.3 NYHA scores 
NYHA score 0 (%) HF-RSF (0 = 149) HF-PSF (0 = 147) 
I 1 0 
II 57 (38) 83 (56) 
III 47 (32) 37 (25) 
IV 44 (30) 27 (18) 
_____ L---
Table 3.4 Killip Scores 
Killip score 0 (%) HF-RSF (0 = 149) HF-PSF (0 = 147) 
I 1 0 
II 23 (15) 32 (22) 
IIa 65 (44) 68 (46) 
lIb 19 (13) 24 (16) 
III 41 (28) 23 (16) 
IV 0 0 
3.02.4 Heart Failure scores 
Each subject was screened for clinical evidence of HF using the three scoring systems 
described in Chapter 2. There was a small number of patients who scored positively for only 
one HF score and negatively in the other two. The table below shows their distributions 
according to HF scores (Table 3.5). 
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Table 3.5 Distribution of isolated positive HF scores 
Heart Failure score HF-RSF (n = 149) HF-PSF (n = 147) 
Boston 3 4 
NHANES 2 7 
Framingham 0 0 
I, 
These patients accounted for only 3% of those with HF-RSF. The proportion was slightly 
higher in the HF-PSF group, but still accounted for only 7% of patients. These cases were 
split between the Boston and NHANES scoring systems. As described in Chapter 2, the 
Boston score is divided into possible and definite heart failure. All four patients who scored 
positively for the Boston score but negatively for the others, were classified as probable heart 
failure. All four patients also had other potential causes for their symptoms, such as chronic 
obstructive pulmonary disease, atrial fibrillation or valvular heart disease. Seven patients 
with HF-PSF scored positively for HF with the NHANES instrument and negatively with the 
other scoring systems. Of these, only two had no other clinical explanation for their 
presenting symptoms. The other five patients were either smokers, had atrial 
fibrillation/flutter or were clinically obese. In both groups, no patient scored positively with 
the Framingham system without also scoring positively in at least one other scoring system. 
Table 3.6 summarises the distribution of patients scoring positively for one, two or all three 
HF scores. A significantly higher proportion of patients with HF-RSF scored positively for all 
three HF scores than in the HF-PSF group (p<O.OOl). However, nearly four-fifths of the 
patients with HF-PSF showed concordantly positive results. 
91 
Table 3.6 Summary of HF scores 
No. positive HF Scores HF-RSF HF-PSF p value 
n(%) (n = 149) (n = 147) 
1 5 (3) 11 (7) N/A 
• 
2 9 (6) 25 (17) N/A , 
3 135 (91) 111 (76) <0.0001 ! 
p values NI A = where the size of the group was too small to accurately perform statistical analYSIS. 
3.02.5 Co-morbidity 
With respect to co-morbidity, there were four main differences between the two groups (Table 
3.7). Firstly, a significantly higher proportion of patients with HF-RSF had valvular heart 
disease, compared to those with HF-PSF (45% vs. 24%, p<O.OOOl). Secondly, within the HF-
RSF group there was a higher proportion of patients with a prior history of peripheral arterial 
disease (PAD) (12% vs. 5%, p=0.02). Thirdly, there was a higher proportion of patients with 
a prior history of hypertension in the HF-PSF group compared with the HF-RSF group (56% 
vs. 38%, p=O.OOl). Finally, nearly half of the patients with HF-RSF (47%) had a prior 
diagnosis ofHF, compared to 16% of those with HF-PSF (p<0.0001). Of note, there were no 
significant differences between the two groups in terms of prevalence of other relevant co-
morbidities, particularly ischaemic heart disease (IHD) and diabetes mellitus (DM). Atrial 
fibrillation (AF) was also present in similar proportions in both groups. 
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Table 3.7 Co-morbidity in HF-RSF and HF-PSF 
n(%) HF-RSF HF-PSF P value 
(n=149) (n=147) 
Ischaemic heart disease* 86 (58) 78 (53) 0.42 
Cerebrovascular disease* * 28 (19) 29 (20) 0.84 
Peripheral arterial disease 18 (12) 7 (5) 0.02 
Diabetes mellitus 32 (21) 26 (18) 0.41 
Hypertension 56 (38) 83 (56) 0.001 
Hypercholesterolaemia 45 (30) 38 (26) 0.40 
Atrial Fibrillation 44 (30) 42 (29) 0.86 
Valve Disease 67 (45) 36 (24) <0.0001 
Prior diagnosis of HF* * * 70 (47) 23 (16) <0.0001 
Current smoker 29 (19) 34 (23) 0.41 
Ex-smoker 54 (36) 52 (35) 0.88 
*Ischaemic heart disease was defmed as a history of angina, previous myocardial infarction or previous CABG 
**Cerebrovascular disease was defmed as a history of previous cerebrovascular accident, transient ischaemic 
attack or previous carotid endarterectomy. 
***HF=Heart Failure 
Chronic obstructive pulmonary disease (COPD) was considered to be present when there was 
a documented diagnosis in the medical records, or if the patient was prescribed inhalers, long 
term oxygen therapy (L TOT) or regular nebulised bronchodilators or if there was evidence of 
COPD on pulmonary function testing (PFT). COPD was common in both types of HF but 
was more common in those with HF-PSF (p=0.022). This is discussed fully in Chapter 8. 
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3.02.6 Admission clinical data 
Clinical findings on admission were very similar between the two groups of patients with HF 
(Table 3.8). 
Table 3.8 Admission clinical data 
Mean (SD)* HF-RSF HF-PSF P value 
(n = 149) (n = 147) 
SBP (mmHg) 141 (32.9) 145 (29.5) 0.195 
DBP (mmHg) 78 (19.4) 78 (17.6) 0.969 
HR(bpm) 92 (26) 78 (17.6) 0.969 
RR(bpm) 21 (7.8) 21 (7.7) 0.370 
Urea 11.8 (9.7) 8.6 (5) <0.0001 
Creatinine ((lmol/L) 136 (54) 114 (52) 0.001 
eGFR (ml/minlmL) 47 (17.6) 54 (16.8) 0.001 , 
Hb (g/dL) 12.41 (2) 12.51 (2) 0.662 I 
BMI (kg/m2) 28 (5.4) 29 (5.8) 0.285 
I 
Anaemia n (%) 59 (40) 53 (36) 0.529 
I 
Troponin +ve, n (%) 61 (41) 30 (20) <0.0001 
I 
* except anaemia and troponin 
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, RR = respiratory rate, eGFR = 
estimated glomerular filtration rate mL/minl1.73m2 [186 x (Plasma creatinine) ·1.154 x (agey°.203 x 0.742 if 
female], Troponin +ve = positive troponin, BMI = body mass index, Anaemia = WHO classification of anaemia 
(Hb<12 g/dL for males and females) 
Renal function was worse in the group with HF-RSF, when using either serum creatinine (136 
!JmollL ± 54) or eGFR (47 mllminlm2 ± 52) as the measure (p = 0.001 in both cases). In both 
groups, the mean eGFR equated to "moderate" renal dysfunction according to the National 
Kidney Foundation classification of kidney disease (described in Chapter 2)154. In both 
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groups, two-thirds or more of patients had at least moderate renal dysfunction (eGFR < 
60mLlminlm2). Plasma urea concentrations were also significantly higher in HF-RSF 
compared to those with HF-PSF (p < 0.0001) [Table 3.9]. 
Table 3.9 Comparison of range of eGFR in HF-RSF and HF-PSF 
eGFR mL/min/m2 HF-RSF HF-PSF 
I 
(n=149) (n=147) 
n(%) 
~90 0(0) 3 (2) 
I 
60-89 37 (25) 47 (32) 
I 
30-59 87 (58) 90 (61) 
0-29 25 (17) 7 (5) 
<60 112 (75) 97 (66) 
eGFR = estimated glomerular filtration rate 
One significant difference in the admission clinical data between the two groups was the 
higher proportion of patients with HF-RSF who had a raised troponin (41% vs. 20% in the 
group with HF-PSF, p<O.OOOl). 
Values for routine haematological investigations carried out on admission are presented in 
Table 3.10. The findings were very similar in both groups. The mean platelet count was 
higher in patients with HF -PSF group, compared to those with HF -RSF though the mean 
value in both groups was within the normal range. A similar proportion of patients in each 
group were anaemic (see Table 3.8). 
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Table 3.10 Routine haematology 
Mean (SD) HF-RSF (n = 149) HF-PSF (n = 147) P value 
Hb (g/dL) 12.41 (2) 12.51 (2) 0.66 
I 
MCV (ft) 92 (10) 91 (6.9) 0.76 
WCC x10Y (cells/L) 9.1 (3.3) 9.5 (3.2) 0.31 
Lymphocytes x10Y (cellslL) 1.37 (1.1) 1.3 (0.9) 0.83 
Neutrophils x10Y (cellslL) 6.9 (2.7) 7.2 (3.1) 0.32 
Platelets x 1 O~ (cells/L) 252 (90) 276 (107) 0.04 
- - -- -
Hb = haemoglobin, Mev = mean mean cell volume, wee = white cell count 
Table 3.11 shows the results of the routine biochemical investigations carried out in the two 
groups. Renal function, as measured by median serum urea and creatinine concentration, was 
worse in the patients with HF-RSF (p < 0.0001). That group also had a significantly higher 
median random serum glucose concentration (p = 0.023) and a higher median level of serum 
bilirubin (p = 0.045), AST (p = 0.046) and GGT (p = 0.011), compared to the group with HF-
PSF. There was also a trend towards a higher median serum CRP concentration in the group 
with HF-RSF, though the difference was not statistically significant. Conversely, mean 
cholesterol level was significantly lower in the group with HF-RSF (4.2 mmoIlL), compared 
to the group with HF-PSF (4.8 mmol/L, p = 0.011), as was the median serum albumin, 39 giL 
in HF-RSF compared to 40 giL in those with HF-PSF (p=0.024). 
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Table 3.11 Routine biochemistry 
Median (IQR) HF-RSF (n = 149) HF-PSF (n =147) p value 
Sodium (mmollL) 140 (137-142) 140 (138-142) 0.19 
Potassium (mmollL) 4.3 (3.9-4.7) 4.2 (3.9-4.5) 0.06 
Urea (mmollL) 9.5 (6.6-13.1) 7.5 (5.5-10.1) <0.0001 
Creatinine (flmollL) 124 (102-155) 104 (89-120) <0.0001 
Cholesterol (mmoI/L) 4.2 (3.5-5.1) 4.8 (3.7-5.6) 0.01 
Glucose (mmoI/L) 6.7 (5.5-9.0) 6.0 (5.5-7.6) 0.02 
*Random glucose> 21 (14%) 11 (7%) 0.05 
llmmollL n (%) 
Bilirubin (flmoI/L) 14 (11-22) 13 (10-18) 0.05 
ALP (ulL) 196 (150-259) 197 (159-246) 0.79 
AST (ulL) 26 (20-40) 25 (19-34) 0.05 
GGT (ulL) 40 (22-72) 31 (18-55) 0.01 
Albumin (giL) 39 (36-41) 40 (38-42) 0.02 
CRP (mglL) 19 (8-60) 13 (6-42) 0.08 
* median (lQR) except n (%) random glucose> 11 mmol/L 
ALP = alkaline phosphatase, AST = aspartate aminotransferase, GGT = gamma glutamyl transpeptidase, CRP = 
C-reactive protein 
For logistical reasons it was not possible to calculate body mass index (BMI) for all patients, 
however, with the available data there was no significant difference in mean BMI between the 
two groups. In both groups the mean BMI was at the upper limit of the range defmed by the 
WHO as "overweight" (BMI 25_29.9)175;176. 
3.02.7 Cardiovascular medications 
Table 3.12 compares the cardiovascular medications being taken by each group on admission. 
These were very similar in the two groups, with the exception of ACE-I. A higher proportion 
of patients with HF-RSF were taking an ACE-I compared to those in the group with HF-PSF 
(45% and 31 % respectively). 
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Table 3.12 Admission cardiovascular medications 
Medication HF-RSF 
n(%) (n = 149) 
Antiplatelet 90 (60) 
Diuretics 106 (71) 
Spironolactone 12 (8) 
ACE-I 67 (45) 
ARB 12 (8) 
B Blocker 54 (36) 
Digoxin 22 (15) 
Vasodilators 51 (34) 
Statin 60 (40) 
ACE-I = Angiotensin converting enzyme inhibitor 
ARB = Angiotensin receptor blocker 
HF-PSF 
(n = 147) 
78 (53) 
98 (67) 
3 (2) 
46 (31) 
8 (5) 
48 (33) 
20 (14) 
62 (42) 
50 (34) 
Vasodilators = Calcium channel blocker, nitrates, and nicorandil 
P value 
0.225 
0.455 
N/A 
0.016 
0.378 
0.543 
0.793 
0.144 
0.284 
P value N/ A = where the size of the group was too small to accurately perform statistical analysis. 
3.02.8 Electrocardiographic findings 
Table 3.13 illustrates that a significantly higher proportion of patients with HF-RSF (79%) 
had an abnormal ECG at the time of presentation compared to patients with HF-PSF (63%) 
[p=0.002]. However, it should be noted that nearly two-thirds of patients with HF-PSF also 
had an abnormal ECG. A significantly higher proportion of patients with HF-RSF had left 
bundle branch block (LBBB) (29%), left axis deviation (LAD) (21%) or left ventricular 
hypertrophy (LVH) (25%) compared to those with HF-PSF: 12% (p<0.000l), 12% (p=0.046) 
and 14% (p = 0.16), respectively. 
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Table 3.13 ECG findings 
ECG features n (%) HF-RSF (n=149) HF-PSF (n=147) p value ! 
I 
SR 94 (63) 101 (69) 0.25 
i 
AF 44 (30) 42 (29) 0.25 I 
LBBB 40 (27) 13 (9) <0.0001 I 
RBBB 8 (5) 3 (2) N/A 
LVH 35 (23) 18 (12) 0.01 
RVH 2 (1) 1 (0.7) N/A 
I 
ST Elevation 19 (13) 29 (20) 0.10 , 
I 
ST Depression 19 (13) 29 (20) 0.10 ! 
T Inversion 30 (20) 25 (17) 0.49 
Qwaves 15 (10) 7 (5) 0.08 
RAD 6 (4) 3 (2) N/A 
LAD 31 (21) 18 (12) 0.05 
Abnormal ECG 117 (79) 92 (63) 0.002 
I 
HR = Heart rate, SR = Sinus rhythm, LBBB = Left bundle branch block, RBBB = Right bundle branch block, 
LVH = Left ventricular hypertrophy, RVH = Right ventricular hypertrophy, RAD = Right axis deviation, LAD = 
Left axis deviation. P value NI A = where the size of the group was too small to accurately perform statistical 
analysis. 
3.02.9 Quality of life 
Quality of life (QoL), as measured by the Cantril Ladder of Life (LOL) questionnaire, was 
reduced in both groups compared to what would be expected in healthy age and sex matched 
individuals. There was no statistically significant difference in QoL between the two groups, 
mean LOL score being 4.6 (2.5) in the group with HF-RSF and 5.0 (2.6) in the patients with 
HF-PSF (p=0.162). 
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3.02.10 Comparison of clinical characteristics of HF -RSF and HF -isolated 
preserved systolic function (HF -IPS F) 
In the HF-PSF group 41% of patients had either valvular heart disease, AF or both, which 
could have accounted for their symptoms and signs of HF. Therefore, I defined a group of 
patients with clinical HF, preserved systolic function who did not have significant valvular 
heart disease or AF. For the purposes of this thesis, this group is referred to as HF with 
isolated preserved systolic function (HF-IPSF), and I have compared their characteristics with 
those of patients with HF-RSF (Table 3.l4 A-D). 
Mean ages in the two groups were similar, but a significantly higher proportion of patients 
with HF-IPSF were female (p<0.0001). With respect to cardiovascular co-morbidities, the 
only significant difference between the two groups was that a higher proportion of patients in 
the isolated PSF group had a history of hypertension (58% vs. 38%, p = 0.002). A 
significantly higher proportion of patients with isolated PSF had COPD, either as a primary or 
additional diagnosis (47% vs. 30% in the group with RSF, p = 0.01). 
Functional limitation, as measured by NYHA class, was significantly worse in patients with 
HF-RSF when compared with those with HF-IPSF. More patients with HF-RSF described 
PND (42% vs. 28%, p < 0.030) or orthopnoea (60% vs. 43%, p = 0.012). The presence of 
reduced exercise tolerance, ankle swelling, general fatigue and leg fatigue was reported in 
similar proportions in both types of heart failure. A similar proportion of patients in each 
group were classified as having moderately severe HF on admission, as determined by Killip 
class of IIA or greater (p = 0.117). With regard to the findings on clinical examination, the 
only significant difference between the two groups was the higher proportion of patients with 
HF-RSF which had an elevated NP (60% vs. 42%, p = 0.005). 
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Patients with HF-RSF were more likely to score positively in all three HF scoring systems, 
however, the majority of patients with isolated PSF did show concordant positive results 
across all three scoring systems. 
There were no significant differences in the clinical findings on admission, with the exception 
of heart rate, which was higher in the group with HF-RSF (p = 0.004). A similar percentage 
of patients were anaemic in both groups. Renal function was significantly worse in the HF-
RSF group, as measured by both serum creatinine concentration (p = 0.002) and eGFR (p = 
0.001). Again, in both groups the mean eGFR equated to moderate renal dysfunction 
according to the National Kidney Foundation criteria for renal function. In both the HF-RSF 
and isolated PSF groups the majority of patients (75% and 60%) had moderate renal 
dysfunction (eGFR < 60ml/minlm2). A significantly smaller proportion of patients with 
isolated PSF had a positive troponin at the time of admission, compared to those with HF-
RSF (p < 0.0001). Patients with HF-RSF were more likely to have an abnormal ECG on 
admission (p = 0.029), though two-thirds of patients in the HF-IPSF group did have an 
abnormal ECG. Admission cardiac medications were similar between the two types groups, 
again with the exception of ACE-I medications which were more commonly prescribed in the 
HF-RSF group (p = 0.026). 
QoL scores were again reduced compared with the general population and there was no 
significant difference in mean (SD) LOL scores between the two groups: HF-RSF 4.6 (2.5) 
and isolated PSF: 5.0 (2.4), p = 0.23. 
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Table 3.14 Summary comparison of clinical characteristics ofHF-RSFIHF-IPSF 
A) Demographics and cardiovascular risk factors 
HF-RSF (n=149) HF-IPSF (n=86) p value 
Age (yrs) mean (SD) 76 (9.5) 73 (10.1) 0.092 
n(%) 
Female 69 (46) 60 (70) <0.0001 
IHD 86 (58) 48 (56) 0.777 
CVD 28 (19) 15 (17) 0.795 
PAD 18 (12) 5 (6) 0.088 
DM 32 (21) 20 (23) 0.753 
HBP 56 (38) 50 (58) 0.002 
Hypercholesterolaemia 45 (30) 25 (29) 0.855 
COPD 44 (30) 40 (47) 0.010 
-- ... _---- ........ - ...... - ... __ .... _._ ...... _-
- ... ---~--
IHD = ischaemic heart disease, CVD = cerebrovascular disease, PAD = peripheral arterial disease, DM = 
diabetes mellitus, HBP = hypertension, COPD = chronic obstructive airways disease 
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Table 3.14 Summary comparison of clinical characteristics ofHF-RSF I HF-IPSF 
B) Clinical Recordings 
Mean (SD) HF-RSF (n=149) HF-IPSF (n=86) p value 
SBP(mmHg) 141 (33) 144 (30) 0.390 
DBP (rrunHg) 78 (19) 77 (17) 0.540 
HR(bpm) 92 (26) 83 (20) 0.004 
RR (breaths pm) 21 (7.8) 21 (9.3) 0.607 
Creatinine (flg/L) 136 (54) 112 (56) 0.002 
EGFR (ml/minlmL) 47 (18) 55 (17) 0.001 
Hb (g/dL) 12.4 (2) 12.5 (2) 0.685 
LOL scores 4.6 (2.5) 5.0 (2.4) 0.233 
n(%) 
Anaemic 59 (40) 31 (36) 0.588 
Troponin +ve 61 (41) 14 (16) <0.0001 
Abnormal ECG 117 (79) 56 (65) 0.029 
Concordant HF scores 135 (91) 61 (71) <0.0001 
~---
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, RR = respiratory rate, eGFR = 
estimated glomerular filtration rate, LOL scores = Ladder of Life scores 
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Table 3.14 Summary comparison of clinical characteristics ofHF-RSFIHF-IPSF 
C) Clinical signs and symptoms 
n(%) HF-RSF (n=149) 
NYHAIII/IV 
Killip ~ IIA 
Elevated JVP 
Lung crepitations 
Peripheral oedema 
Sacral oedema 
Wheeze 
PND 
Orthopnoea 
Reduced ex tolerance 
Reported ankle oedema 
General fatigue 
Leg fatigue 
JVP = Jugular venous pressure, 
PND = paroxysmal nocturnal dyspnoea, 
Ex tolerance = exercise tolerance 
90 (60) 
124 (83) 
90 (60) 
126 (85) 
86 (58) 
12 (8) 
38 (26) 
62 (42) 
89 (60) 
130 (87) 
98 (66) 
115 (77) 
67 (45) 
HF-IPSF p value 
(n=86) 
39 (45) 0.021 
64 (74) 0.117 
36 (42) 0.005 
65 (76) 0.102 
50 (58) 0.950 
2 (2) N/A 
26 (30) 0.439 
24 (28) 0.030 
37 (43) 0.012 
76 (88) 0.799 
60 (70) 0.526 
68 (79) 0.735 
36 (42) 0.643 
p value NI A = where the size of the groups are too small to perform accuracte statistical analysis 
, 
. 
I 
! 
I 
! 
1 
I 
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Table 3.14 Summary comparison of clinical characteristics ofHF-RSF I HF-IPSF 
D) Cardiovascular medications on admission 
n(%) HF-RSF (n=149) HF-IPSF (n=86) p value 
Anti-platelet 90 (60) 45 (52) 0.268 
Diuretics 106 (71) 52 (60) 0.123 
Spironolactone 12 (8) 1 (1) N/A 
ACE-I 67 (45) 26 (30) 0.026 
ARB 12 (8) 4 (5) N/A 
P-Blocker 54 (361) 25 (29) 0.280 
Vasodilator 51 (34) 34 (40) 0.381 
Statin 60 (40) 31 (36) 0.564 
ACE-I = ACE inhibitor, ARB = Angiotensin receptor blocker, B-Blocker = beta blocker 
p value N/A = where the size of the groups are too small to perform accuracte statistical analysis 
3.03 Discussion 
This Chapter describes the detailed clinical characteristics of a cohort of patients hospitalised 
for heart failure. The first and most striking finding is the prevalence of heart failure with 
preserved left ventricular systolic function, which accounted for around half of all heart 
failure admissions studied. This is similar to the recent Euroheart Failure Survey177 where 
over 6000 patients were studied and almost 50% were found to have HF-PSF. Two studies 
published during the time of writing showed that 47% and 31 % of patients with HF had 
preserved systolic function 178;179. Both of these studies defined HF-PSF as having clinical HF 
with an ejection fraction> 50%. Although the current study did not measure ejection fraction 
we did use a single experienced operator to provide a quantitative assessment of LV systolic 
function and previous work has shown that there is a good correlation between this method 
and ejection fraction160. These prevalence figures underline the importance ofHF-PSF, which 
has emerged as a recognised clinical entity over the last decade 13 . 
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One major drawback of prior studies was the lack of systematic data regarding patients with 
HF-PSF. This study has addressed this deficit by gathering detailed clinical information and 
comparing patients with HF-PSF to those with heart failure and reduced systolic function. 
This comparison clearly shows that there are many similarities between patients with heart 
failure and reduced or preserved systolic function. Age was similar between the two groups, 
as were relevant cardiovascular comorbidities such as the presence of ischaemic heart disease 
or atrial fibrillation. Importantly, symptoms and signs of heart failure were broadly 
comparable between the two groups, and there was no difference in the proportion of patients 
presenting in each group with moderate to severe heart failure. This suggests that heart failure 
is a clinical syndrome which exists across a spectrum of normal and impaired L V systolic 
function. 
This study has highlighted a number of important differences, which may improve our 
understanding of HF-PSF. Firstly, a higher proportion of patients with HF-PSF were female. 
Owan et aZ l78 and Bhatia et aZ l79 also found that HF-PSF was more common in females in 
their recent publications. It is not entirely clear why HF-PSF is more common in women. 
Another notable difference between the two groups is the higher prevalence of hypertension 
in the HF-PSF group. This may reflect an important aetiological factor in HF-PSF, which is 
widely thought to be due to left ventricular diastolic dysfunction. Increased afterload in 
systemic hypertension induces compensatory LV hypertrophy, which in tum can cause 
abnOlmalities in diastolic function. The [mdings from this study therefore corroborate 
evidence from previously published studies. Hypertension must now be regarded as a risk 
factor for this type ofHF I8;21 ;33;34;178;179. 
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The incidence of hypeltension increases with age in both sexes however, more so in women. 
In men the incidence of hypertension increases with age from 3.3% per year at ages 30-39 to 
6.2% at ages 70-79 and in women from 1.5% at ages 30-39 to 8.6% at ages 70_79180;181. It is 
therefore possible that as the incidence of hypertension is higher in older women compared 
with older men, that this accounts for some of the increased prevalence ofHF-PSF in women. 
Another possibility is that women are more susceptible to the presence of hypertension and 
the consequential remodelling process that results in the development of HF. More detailed 
imaging techniques such as tissue Doppler echo cardiography and cardiac MRI may provide 
further insight into the diastolic function of this group. 
Renal function was worse in those patients with HF-RSF. However, it is interesting to note 
that a significant proportion of patients with HF-PSF also had significant renal dysfunction. 
This may be due to coincident cardiorenal disease, or it may reflect that there are similar 
levels of renal dysfunction as a consequence of the syndrome of heart failure, regardless of 
the presence of systolic dysfunction. This would again tend to suggest that systolic 
dysfunction is not a pre-requisite for severe or complicated heart failure. 
As would be expected, a higher proportion of patients with HF-RSF had an elevated troponin, 
although this finding was present in a significant minority of the HF-PSF group. Though the 
cause of an elevated troponin was not specifically addressed in this study, potential 
explanations include; myocardial ischaemia, pulmonary embolism, renal impairment, 
sustained tachyarrhythmia, heart failure itself, or a combination of these. It is interesting to 
speculate that myocardial ischaemia or tachyarrhythmias could be causing heart failure 
requiring hospitalisation, without any apparent compromise of LV systolic function. It is also 
possible that either of these may cause transient L V systolic dysfunction which is not present 
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when echocardiography is performed some time after admission. Underlying abnormalities in 
diastolic function may result in these patients being more susceptible to events such as 
myocardial ischaemia or tachyarrhythmias, resulting in clinical heart failure. Therefore it 
would seem that echo cardiography at the time of admission may provide useful insights into 
the roles of systolic and diastolic dysfunction in heart failure. 
Interestingly, less than half of the patients with HF-RSF were taking an ACE-I at the time of 
admission. Just under a half of patients with HF-RSF had a prior diagnosis of HF from the 
medical records. However, it is still not clear whether the low rate of ACE-I use in those 
patients with HF-RSF was because their LV dysfunction was new or previously undiagnosed. 
However poor compliance with medications or lack of adherence to HF guidelines may also 
have been important factors. 
The mean LOL scores for both groups were very similar to those found by Luttik et al in a 
population ofNYHA class III or IV HF patients (4.6 ± 2.6)172. Ormel et al reported higher 
mean LOL scores of 7.9 from a healthy elderly Dutch population182, this underlines that the 
social impact of symptomatic heati failure is not limited to HF-RSF. 
The CHARM-Preserved trial randomised a similar population to that which I have defined 
here as HF_PSFI83. If we use the CHARM-Preserved population as a reference, there are 
many similarities between the population described in this study and the one described in 
CHARM-Preserved. The majority of my patients with HF-PSF were female, and they were 
more likely than those with HF-RSF to have a history of hypertension. The majority (56%) of 
patients with HF-PSF in our study had NYHA class II symptoms, similar to those in 
CHARM-Preserved (61 %)183. The mean age of the patients with HF-PSF in my study is 
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slightly higher than in CHARM-Preserved, at 75 years. 29% of patients in CHARM preserved 
had atrial fibrillation l83 . The same proportion of patients in my study also had atrial 
fibrillation. 
This Chapter illustrates that approximately one-third of all patients admitted with clinical HF 
and preserved systolic function did not have either VHD or AF to account for their signs and 
symptoms. Comparing this group to those with HF-RSF produced a very similar set of 
conclusions to the comparison of HF-PSF and HF-RSF. This is extremely important as it 
supports the view that heart failure with preserved systolic function exists as a clinical entity 
in its own right, and is not merely an expression of other co-morbidity. 
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4.01 Ecbocardiograpby and diastolic dysfunction 
Echocardiography has played a major role in the development of the diagnosis of "diastolic 
heart failure" (DHF). Patients with breathlessness are frequently referred for 
echocardiography, and with the finding of preserved L V systolic function they are often given f 1 
a diagnosis of diastolic heart failure. 
The European Cardiology Society state that a diagnosis of DHF requires: 
1) clinical symptoms of heart failure 
2) demonstration of an ejection fraction ~ 50% 
3) demonstration of diastolic dysfunction 
Diastole encompasses the relaxation and filling phases of the cardiac cycle, between closure 
of the aortic valve, when LV pressure falls below aortic pressure, and closure of the mitral 
valve45 • Diastole has both active and passive components45;46, and can be divided into four 
phases: 
• Isovolumetric relaxation 
• Early rapid LV filling 
• Diastasis 
• Late LV filling due to atrial contraction ( atrial systole) 
Isovolumetric relaxation: the period occurring between the end of LV systolic ejection (aortic 
valve closure) and the opening of the mitral valve, when L V pressure falls and LV volume 
remains constant. This is mainly active L V relaxation 45. 
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Early rapid LV filling: this phase begins when the L V pressure falls below the left atrial 
pressure and the mitral valve opens. During this period the blood has an acceleration which is 
directly related to the aorto-ventricular pressure gradient and therefore reduces as this gradient 
equalises 45. This is an active process involving the use of energy by the myocardium. 
Diastasis: When left atrial and ventricular pressures are almost equal, LV filling is 
maintained by pulmonary venous flow. During diastasis, the left atrium acts as a passive 
conduit45 • 
Atrial systole: LV filling is completed by left atrial contraction. This phase ends with mitral 
valve closure 45. 
There is no single measurement of overall diastolic function. The most clinically relevant 
indices of diastolic function are: 
• Ventricular relaxation 
• Myocardial or chamber compliance 
• Filling pressures 
Left ventricular isovolumetric relaxation occurs during the interval between aortic valve 
closure and mitral valve opening. Abnormal relaxation results in prolongation of the 
isovolumetric relaxation time and a slower rate of decline in the ventricular pressure. There is 
consequently a reduction in the early peak filling, because of the reduced pressure difference 
between the atrium and the ventricle when the atrioventricular valve opens. Measures of left 
ventricular relaxation include: 
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• Isovolumetric relaxation time (IVRT) 
• The maximum rate of pressure decline (-dP/dt) 
• Time constant of relaxation (tau or t) 
There are relatively simple spectral Doppler measurements that can be made during routine 
echo cardiography, that have been advocated as indices of diastolic function 1 84. Spectral 
Doppler measurements of LV diastolic filling velocities correspond closely with ventricular 
filling parameters measured by cardiac catheterisation. Doppler measurements recorded in the 
current study, as described in Chapter 2, were mitral E-wave velocity (m/s), mitral A-wave 
velocity (mls), mitral E/A ratio, mitral inflow deceleration time (ms) and IVRT (ms). These 
measurements are made in the apical four-chamber view which allows alignment of the 
ultrasound beam with mitral inflow. Pulsed-wave Doppler is placed in the mitral inflow at the 
level of the mitral valve tips. The normal mitral inflow Doppler pattern is shown in Figure 
4.1a. 
In the normal mitral inflow Doppler pattern, there is a brief interval between aortic valve 
closure and the onset of ventricular filling, and this is called the isovolumetric relaxation time 
(IVRT). Immediately following mitral valve opening, there is rapid acceleration of blood 
flow from the atrium to the ventricle. In young healthy individuals the early peak filling 
velocity reaches 0.6 to 0.8 mls around 90-11 Oms after the onset of flow 1 64. This early filling 
is shown by the E-wave of the mitral inflow Doppler signal and its maximum velocity reflects 
the maximum pressure gradient between the atrium and ventricle. After this, flow decelerates 
rapidly, in normal individuals the deceleration is 4.3 to 6.7 mls164• Deceleration time (DT) is 
defined as the interval from the peak E-wave to where a line following the initial deceleration 
slope intersects with the baseline. In normal individuals this ranges from 140 to 200ms164• 
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This is followed by a period of minimal flow (diastasis). Then, with atrial contraction, left 
atrial pressure again exceeds ventricular pressure, resulting in a second velocity peak in the 
mitral inflow signal (A-wave). The peak velocity of the A-wave typically ranges from 0.19 to 
0.35 rnls in young nOlmal individuals164 (Figure 4.1a). 
Figure 4.1 
m/s 
(A) Normal pattern and (B) Abnormal pattern of left ventricular diastolic 
filling recorded with pulsed-wave Doppler 
o 
E 
~ 
IVRT 
Adapted from Galderisi et az4s 
114 
r-' 
Diastolic dysfunction has two main components: 
1) Impaired left ventricular relaxation 
2) Impaired left ventricular compliance 
Impaired relaxation is characterised by a classical pattern of reduced early diastolic filling and 
an increased atrial contribution to total LV filling. Impaired relaxation is shown on the mitral 
inflow Doppler by: 
• Reduced E-wave velocity 
• E/A ratio < 1 
• Prolonged IVRT 
• Prolonged DT 
If LV compliance is decreased (a "stiff ventricle"), as the LV fills, the diastolic pressure rises 
rapidly giving a high E-wave velocity, followed by a steep deceleration slope. The atrial 
contribution to filling is relatively small because it occurs on a steep portion of the pressure-
volume curve. In addition, the LV pressure in end-diastole is typically elevated resulting in a 
reduced atrio-ventricular pressure gradient following atrial systole. 
Reduced compliance is associated with: 
• Increased E-wave velocity 
• E/A ratio> 1 
• Reduced IVRT 
• Decreased DT 
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One of the main difficulties with echo cardiographic assessment of diastolic function is that 
there are many different criteria for the diagnosis of diastolic dysfunction. This was 
illustrated by Petrie et aI, who applied the most common criteria for diastolic dysfunction to 
consecutive patients with suspected HF. They found up to a 16-fold difference in the 
prevalence of diastolic dysfunction, depending on which measure was used, indicating very 
poor concordance between the different measures for diagnosing diastolic dysfunctionl84 . 
However, Redfield et aP6 provide a useful explanation of the different patterns of mitral 
inflow and their relationship to diastolic function. Diastolic dysfunction was categorised as 
mild, moderate or severe. Mild diastolic dysfunction was defined as impaired relaxation 
without increased filling pressures. Moderate diastolic dysfunction was defined as impaired 
relaxation associated with moderate elevation in filling pressures or pseudonormal filling. 
Severe diastolic dysfunction was defined as advanced reduction in compliance or restriction 
of the left ventricle (Figure 4.2). 
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Figure 4.2 Doppler criteria for classification of diastolic dysfunction (adapted from Redfield et a136) 
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4.02 Results 
4.02.1 Basic echocardiographic measurements 
! 
I 
Patients were categorised into HF-RSF and HF-IPSF as documented in Chapter 2. As f~ 
described previously, those with HF-IPSF did not have significant valve disease or atrial 
fibrillation. 
Basic echo cardiographic measurements of left atrium and left ventricle were recorded for all 
patients within 48 hours of admission. All patients had qualitative assessment of LV function 
and quantitative assessment of valvular function. In some studies imaging windows were 
limited and it was therefore not possible to make formal measurements of atrial or ventricular 
dimensions. Table 4.1 shows left atrial and ventricular dimensions. 
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Table 4.1 Left atrial and left ventricular dimensions: HF-RSF and HF-PSF 
Echo parameters HF -RSF (n=149) HF-PSF (n=147) 
Mean (SD) 
LA diameterT n=96 
4.5 (0.8) 
LVSDD+ n=83 
1.04 (0.3) 
LVlDDrt n=94 
5.8 (0.9) 
LVIDS++ n=51 
4.9 (1) 
LVPWDrtr n=81 
0.96 (0.2) 
LV mass+++ n=80 
226 (69) 
Left atrial diameter (cm) 
t Interventricular septum diameter in diastole (cm) 
ttLeft ventricular internal diameter in diastole (cm) 
U Left ventricular internal diameter in systole (cm) 
tttLeft ventricular posterior wall diameter in diastole (cm) 
m Left ventricular mass 
n=92 
4.3 (0.9) 
n=90 
1.2 (0.3) 
n=90 
4.6 (0.8) 
n=28 
3.1 (0.7) 
n=89 
1.02 (0.2) 
n=88 
186 (62) 
p value 
0.098 
0.003 
<0.0001 
<0.0001 
0.045 
<0.0001 
Table 4.1 illustrates that the HF-RSF group had increased LV diameter and greater LV mass 
compared with the HF-PSF group. The septum and posterior wall were thicker in the HF-PSF 
group. There was no significant difference in the left atrial size between the two groups. 
Table 4.2 details these parameters when the HF-RSF group is compared to the HF-IPSF 
group. 
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Table 4.2 Left atrial and left ventricular dimensions: HF-RSF and HF-IPSF 
Echo parameters HF-RSF (n=149) HF-IPSF (n=86) 
Mean (SD) 
LA diameter T n=96 
4.5 (0.8) 
IVSDD+ n=83 
1.04 (0.3) 
LVIDDTT n=94 
5.8 (0.9) 
LVIDSn n=51 
4.9 (1) 
LVPWDTTT n=81 
0.96 (0.2) 
LVmass+H n=80 
226 (69) 
Left atrial diameter (cm) 
~ Interventricular septum diameter in diastole (cm) 
ttLeft ventricular internal diameter in diastole (cm) 
U Left ventricular internal diameter in systole (cm) 
tttLeft ventricular posterior wall diameter in diastole (cm) 
m Left ventricular mass 
n=51 
3.9 (0.6) 
n=52 
1.13 (0.2) 
n=53 
4.6 (0.7) 
n=5 
3.2 (0.7) 
n=52 
0.97 (0.2) 
n=52 
175 (57) 
p value 
<0.0001 
0.031 
<0.0001 
0.003 
0.846 
<0.0001 
Table 4.2 illustrates that the HF-RSF group had significantly larger left atrial and ventricular 
dimensions and also had greater left ventricular mass compared with the HF-IPSF group. The 
HF-IPSF group did have significantly thicker left ventricular septum compared with the HF-
RSF group. 
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4.02.2 Echocardiographic measures of diastolic function 
The patients in the HF-IPSF group had a further echocardiogram specifically to assess 
parameters of diastolic function, and these are shown in Table 4.3. As it is not possible to 
achieve satisfactory imaging windows in all patients, not all measurements have been 
recorded for every patient. 
Table 4.3 Parameters of diastolic function in patients with HF-IPSF 
n Mean SD 
LA systole 51 3.9 +/-0.6 
RVEDD 30 2.9 +/-0.4 
IVRT 63 108 +/-25 
DT 57 216 +/-63 
Median IQR 
E velocity 64 0.69 0.6-0.9 
A velocity 63 0.82 0.66-1.0 
EI A velocity 63 0.79 0.69-1.0 
E velocity (Valsalva) 13 0.53 0.4-0.6 
A velocity (Valsalva) 13 0.7 0.54-1.13 
E/A ratio (Val salva) 13 1.0 1.0-1.0 
'-------
RVEDD = right ventricular end-diastolic diameter, IVRT = isovolumetric relaxation time, 
DT = decleration time 
! 
I 
I 
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4.02.3 Criteria for diastolic heart failure 
Using a Medline literature search, seven different sets of criteria for the diagnosis of diastolic 
dysfunction were identified and the HF -IPSF group was categorised according to each one 
separately (Table 4.4). The 7 criteria for diastolic dysfunction used were those of 
Krishnaswamy et al165 , Lubien et al166, Redfield et aP6, Cohen et al167 , European Working 
Group criteria (EWGR)168, Chen et all69 , and Zile et all7o. 
Table 4.4 Comparison of median natriuretic peptide concentrations between 
positive and negative criteria for diastolic dysfunction 
Doppler criteria (n) Median (IQR) p value Median (IQR) NT- P value 
BNP pg/ml proBNP pg/ml 
Krishnaswamy +ve (n=17) 120 (52-250) 1223 (446-3856) 
Krishnaswamy -ve (n=48) 74 (33-223) 0.148 610 (129-1871) 0.068 
Lubien +ve (n= 14) 105 (47-686) 669 (417-7839) 
Lubien -ve (n=49) 77 (33-205) 0.175 660 (134-2078) 0.189 
Redfield +ve (n=24) 85 (39-289) 933 (254-2323) 
Redfield - ve (n=18) 131 (46-250) 0.647 931 (167-3576) 0.949 
Chen +ve (n=34) 115 (48-340) 1180 (405-3576) 
Chen -ve (n=31) 47 (27-152) 0.054 410 (106-878) 0.007 
Cohen +ve (n=18) 63 (43-262) 595 (144-1457) 
Cohen -ve (n=47) 120 (32-232) 0.792 769 (165-2508) 0.895 
EWGR * +ve (n=32) 60 (38-205) 591 (129-1280) 
EWGR * -ve (n=33) 144 (35-256) 0.227 1010 (173-3039) 0.325 
Zile +ve (n=67) 84 (37-256) 748 (144-2496) 
Zile -ve (n=4) 115 (53-138) 0.921 598 (173-2308) 0.718 
*European Working Group 
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There was no significant difference in the natriuretic peptide concentrations between those 
who scored positively or negatively in each individual diastolic dysfunction score (Table 4.4). 
The only exception to this was the Chen criteria where there was a significantly higher 
median BNP and NT -proBNP concentration in those who had diastolic dysfunction as 
classified by this score compared to those who did not (p=O.054, p=O.007 for BNP and NT-
proBNP respectively). 
As discussed in Chapter 2, many of these Doppler criteria differentiate diastolic dysfunction 
into impaired relaxation (mild), pseudonormal (moderate) and restrictive (severe) diastolic 
dysfunction patterns. The following Figures (4.3 - 4.9) illustrate the relationship between 
mild, moderate and severe diastolic dysfunction and BNP for each diastolic dysfunction 
criteria. Three of the criteria (Cohen, EWGR and Zile) reported only the presence or absence 
of diastolic dysfunction. 
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Figure 4.3 Median BNP concentrations using the Krishnaswamy criteria for diastolic 
dysfunction 
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Figure 4.4 Median BNP concentrations using the Lubien criteria for diastolic 
dysfunction 
Lubien criteria 
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Figure 4.5 Median BNP concentrations using the Redfield criteria for diastolic 
dysfunction 
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Figure 4.6 Median BNP concentrations using the Cohen criteria for diastolic 
dysfunction 
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Figure 4.7 
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Figure 4.8 
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Figure 4.9 
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These Figures show that for those criteria that differentiate between mild, moderate and 
severe diastolic dysfunction, BNP concentrations become higher as the diastolic dysfunction 
gets worse. The exception to this was with the Redfield criteria, presumably because no 
patients were classified as having either pseudonormal or restrictive diastolic dysfunction. 
Table 4.5 shows the number of positive diastolic Doppler criteria and corresponding 
natriuretic peptide concentrations. There did not appear to be any correlation between the 
number of Doppler indices of diastolic dysfunction and the median BNP or NT -proBNP 
concentrations (Table 4.5). 
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Table 4.5 Diastolic Doppler criteria and natriuretic peptide concentrations 
No. of DD criteria +ve n Median (IQR) Median (IQR) 
BNP pg/ml NT -proBNP pg/ml 
1 13 120 (27-355) 567 (114-3723) 
2 12 133 (42-455) 792 (123-4946) 
3 22 57 (29-209) 422 (137-1503) 
4 6 60 (16-812) 796 (122-14052) , 
i 
5 2 40 (nJa) 878 (nJa) 
• 
6 0 N/A N/A ! 
-
- .. _-- .... -
- ...... _ ..... _ ... 
L- _ _ _____ .... _ _ 
_ .... _.- _ ........ _ .... __ ....... _ .... _-------' 
Of the HF -IPSF group who had satisfactory Doppler measurements taken, only three subjects 
did not score positively for diastolic dysfunction on any criteria. Table 4.6 shows the 
proportions of patients with diastolic dysfunction as classified by each diastolic Doppler 
criteria. 
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Table 4.6 Proportion of patients with diastolic dysfunction according to different 
criteria 
Diastolic dysfunction criteria n(%) 
Krishnaswamy 17 (26) 
Lubien 14 (22) 
Redfield 24 (57) 
Chen 34 (52) 
Cohen 18 (28) 
European Working Group 32 (49) 
Zile 67 (94) 
For each set of criteria, all the diastolic parameters had to be measured in order for the criteria 
to be applied. This was not always possible, particularly as most of the patients in the study 
were elderly and might therefore be expected to have some difficulty with manoeuvres such 
as Valsalva. Of the 86 patients with HF-IPSF, 74% had all measurements of diastolic 
function recorded. 
Table 4.6 illustrates that there is poor concordance between different criteria for diastolic 
dysfunction in our population. The rates of diastolic dysfunction varied from 22% - 94% 
depending on the criteria used. 
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4.03 Discussion 
The echocardiographic data from this study show that those patients with either HF-PSF or 
HF-IPSF have significantly increased interventricular septum diameter when compared with 
those with HF-RSF. This would be consistent with a higher proportion of these patients 
having a prior history of hypertension and is in tum recognised to be associated with diastolic 
dysfunction 1 69. These patients also differed from those with HF-RSF in that the median LV 
diameters were not increased in those with HF-PSF or HF-IPSF. 
I did not find that the different published echocardiographic criteria were useful in 
determining which patients had diastolic dysfunction. There was a wide variation in the 
estimated prevalence of diastolic dysfunction in this cohort, depending on the set of criteria 
used. There was also no correlation between the presence of the individual echocardiographic 
criteria for diastolic dysfunction and natriuretic peptide concentrations. Of the seven diastolic 
criteria used only the Chen criteria showed higher median natriuretic peptide concentrations 
in those with diastolic dysfunction, compared to those without. There was no obvious reason 
as to why the Chen criteria should show this relationship which was not seen with the other 
criteria. The Chen criteria did show that BNP concentrations were higher when more severe 
diastolic dysfunction was present Therefore I feel that this study suggests that the use of 
standard diastolic Doppler echocardiography with currently available criteria is not sufficient 
to diagnose clinically relevant diastolic dysfunction. There does appear to be an association 
between worsening diastolic dysfunction and rising BNP, which supports the idea that 
elevated BNP broadly represents functional L V compromise. 
However, this does not mean that echo cardiography has no place in the diagnosis of diastolic 
dysfunction. Since this study was started newer techniques, such as tissue Doppler 
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echocardiography have been developed to evaluate LV filling dynamics. The tissue velocity 
measured during early filling (E') can be considered to be a surrogate marker for tau (the time 
constant of relaxation during the active component of diastole), as it is primarily determined 
by the expansion of the left ventricle during relaxation. Therefore, the ratio of peak early 
transmitral flow velocity (E) to the peak early myocardial tissue velocity (EIE') is frequently 
cited as evidence of myocardial diastolic dysfunction. This ratio reflects the LA pressure 
elevation compared with the degree of tau prolongation185 . 
Although newer echo cardiographic techniques such as tissue Doppler will improve our non-
invasive assessment of diastolic function, the problem still remains that these measurements 
do not provide direct pathophysiological insights into the mechanisms responsible for causing 
the volume overload in patients with HF. It is possible that imaging modalities such as 
cardiac MRI may be able to provide more detailed information regarding the true 
pathophysiology of this cohort of HF patients. 
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5.01 Introduction: Natriuretic peptides and HF-PSF 
Plasma concentrations of B-type natriuretic peptide (BNP) and its precursor, NT -proBNP are 
known to be increased in patients with reduced LV systolic function, regardless of the 
presence or absence of symptoms of heart failure92;186. It is also clear that plasma 
concentrations of both peptides are positively correlated with the severity of heart 
failure95;98;103;105;165;187-194 BNP independently predicts morbidity and mortality in 
asymptomatic reduced LV systolic function, and in mild to moderate HF_RSF104;195;196. In 
addition, BNP has been shown to be a strong and independent predictor of sudden death in 
patients with HF107. NT -proBNP has also been shown to be an independent predictor of 
mortalityl06;197 or decompensated HF following myocardial infarction ll8, and in patients with 
chronic HF-RSF ofischaemic aetiology104. 
Data on the predictive value of natriuretic peptides in patients with HF-PSF are more limited. 
Studies have shown that BNP is elevated in patients with HF-PSF in the non-emergency 
setting165;166;198-201. 
Maisel et al were one of the first groups to demonstrate that BNP can reliably rule out the 
presence of abnormal LV systolic or diastolic function on echocardiographlo2. Lubien et al 
confirmed these findings in patients with preserved systolic function but abnormal diastolic 
function 1 66. They demonstrated that BNP concentrations accurately predicted the presence of 
abnormalities in diastolic function on echo cardiography, regardless of the presence of 
symptoms of HF. In that study, diastolic dysfunction was classified as impaired relaxation, 
pseudonormal filling or restrictive filling, as discussed in Chapter 4. The mean BNP 
concentration was highest in those with restrictive filling patterns. The authors concluded 
that, although BNP could not be used to differentiate between systolic and diastolic 
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dysfunction, BNP concentrations within normal limits in the setting of preserved systolic 
function may be able to rule out clinically significant abnormalities in diastolic function. 
BNP concentrations in those with preserved systolic function correlated with the presence of 
diastolic dysfunction. The authors calculated an area under the receiver operator curve (ROC) 
of 0.92 which is comparable to those for currently used screening tools such as prostate-
specific antigen (which has an area under the curve (AUC) of 0.94 for prostatic cancer 
detection) and superior to some others, for example cervical smears (AUC = 0.7) and 
mammography (AUC= 0.85)166;203-205. 
Krishnaswamy et al took this concept a stage further, and hypothesised that as BNP reliably 
predicts the presence of systolic or diastolic LV dysfunction, a normal BNP concentration 
may preclude the requirement for echocardiographyl65. They demonstrated that BNP 
concentrations were higher in those with echo cardiographic abnormalities. The BNP 
concentrations were highest in those with both systolic and diastolic dysfunction. Patients 
with systolic dysfunction had higher BNP concentrations than those with diastolic 
dysfunction. Of those with diastolic dysfunction, a restrictive filling pattern was associated 
with the highest BNP concentrations. The authors concluded that it was not possible to 
differentiate between systolic and diastolic dysfunction using BNP alone, but that an elevated 
BNP concentration in the context of preserved systolic function indicates the presence of 
diastolic dysfunctionl65 . 
Similar findings have been demonstrated in the emergency setting. The Breathing Not 
Properly Multinational study recruited patients presenting with shortness of breath to hospital 
emergency departments and reported that HF-PSF was common in this group. When they 
examined BNP, they found higher concentrations in patients with HF compared to those 
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without HF. Once again, BNP alone could not differentiate between HF-RSF and HF-PSF, 
I: 
however, the authors concluded that a low BNP concentration in the setting of breathlessness 
had a negative predictive value of 96%. They therefore suggested that BNP should not be a 
,-
surrogate for echocardiography but could be used in conjunction with clinical findings to aid 
diagnosis and further managementlOO• , 
More recently, Dahlstrom et al reported that patients with restrictive or pseudonOlmal filling 
patterns had higher BNP concentrations and consequently that BNP could be used as a marker 
for the presence of these abnormalities. However, they found that patients with relaxation 
abnormalities, who accounted for the majority of their cohort, had low BNP concentrations. 
The authors therefore argued that low BNP concentrations in the context ofHF-PSF could not 
be used to rule out the presence of diastolic dysfunction, as mild diastolic dysfunction in the 
form of impaired relaxation was not associated with an elevated BNP in their studlo6. 
Hypertension is a major risk factor for diastolic heart failure, as it can result in left ventricular 
hypertrophy (LVH) which can result in reduced compliance8;19. In vitro studies have shown a 
close relationship between BNP and cardiomyocyte hypertrophlo7;208. Of particular interest, 
was the fmding that adaptive hypertrophy alone did not promote ventricular BNP production 
in Dahl salt-sensitive hypertensive rats, and that BNP was only elevated in the presence of 
maladaptive LV hypertrophy with fibrosis, which caused overt symptomatic DHF. 
Yamaguchi et al demonstrated elevated BNP concentrations may be a hallmark in patients 
with, or at risk of developing, diastolic heart failure among subjects with preserved systolic 
function independent of LV hypertrophlo9. 
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5.02 Results 
5.02.1 Comparison of natriuretic peptide levels in HF-RSF and HF-PSF 
As described in the Chapter 2, both BNP and NT -proBNP plasma concentrations were 
measured in all patients. 
A small number of patients (n=17), were recruited into the study but did not have clinical 
evidence of heart failure when assessed using the heart failure scores. Significantly higher 
median concentrations of both BNP and NT -proBNP were found in those with clinical 
evidence of heart failure. Median BNP was 371 pg/ml (IQR:114-920 pg/ml) and median NT-
proBNP was 3624 pg/ml (IQR: 1047-1059 pg/ml) in patients with clinical evidence of heart 
failure, as compared to a median BNP of 36 pg/ml (IQR: 28-116 pg/ml) [Figure 5.1] and 
median NT-proBNP of 234 pg/ml (IQR: 1047-10593 pg/ml) in those with no evidence of 
heart failure (p<0.0001) [Figure 5.2]. 
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As described in Chapter 2, those patients with clinical evidence of HF were divided into two 
groups according to the initial echocardiogram, either reduced (HF-RSF) or preserved systolic 
function (HF-PSF). The following two figures illustrate the differences in the median BNP 
and NT -proBNP concentrations found between these two groups. 
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Figure 5.3 Median BNP concentrations in patients with HF-RSF and HF-PSF 
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There is a significantly higher median BNP concentration in those with HF-RSF at 621 pg/ml 
(IQR: 287-1228 pg/ml) compared to 158 pg/ml (49-488 pg/ml) in the HF-PSF group 
(p <0.0001) [Figure 5.3]. 
Figure 5.4 Median NT-proBNP concentrations in patients with HF-RSF and HF-PSF 
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Again, the median concentration ofNT-proBNP is significantly higher the HF-RSF group at 
6507 pg/ml (IQR: 2888 - 13,523), compared with the HF-PSF median value of 1541 pg/ml 
(IQR: 410-5223 pg/ml) (p<O.OOOI) [Figure 5.4]. 
As described in Chapter 2, the upper limit of normal for natriuretic peptide concentrations 
were taken as the 95th percentile of a local healthy population. Figures 5.5 - 5.6 illustrate the 
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proportion of patients in each group that have an elevated natriuretic peptide concentration i.e. 
have biochemical evidence of L V compromise. 
Figure 5.5 
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Figure 5.6 Percentage of patients in each group with an elevated NT -proBNP 
concentration 
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It is clear that nearly all patients with HF-RSF have an elevated BNP and NT-proBNP (94% 
and 100% respectively) . In the HF-PSF group, 71 % of patients had an elevated BNP and 
82% of patients had an elevated NT -proBNP. These percentages are significantly less than 
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those in the HF-RSF group (p<0.0001), but still represent well over two-thirds of the patients 
in the HF-PSF group. 
5.02.2 Influence of valve disease or atrial fibrillation on natriuretic peptides in HF-PSF 
In HF-PSF the presence of valve disease or atrial fibrillation (AP) results in higher BNP and 
NT-BNP concentrations. As shown in Figures 5.7 and 5.8 the highest median BNP and NT-
proBNP concentrations were found in those with both valve disease and atrial fibrillation 
(BNP 578 pg/ml [IQR: 284-1070 pg/ml], NT-proBNP 5354 pg/ml [IQR: 3300-16,025 
pg/mID. The presence of valve disease alone had a more profound effect on natriuretic 
peptide concentrations (median BNP 265 pg/ml [IQR: 130-798 pg/ml], median NT-proBNP 
3101 pg/ml [IQR: 1049-10,180 pg/mlD than the presence of atrial fibrillation alone (median 
BNP 193 pg/ml [IQR: 109-450] pg/ml, median NT-proBNP 2176 pg/ml [1187-4127 pg/mID. 
The lowest median BNP and NT-proBNP concentrations were found in those with HF-PSF 
but without valve disease or atrial fibrillation (median BNP 92pg/ml [IQR: 37-259pg/ml], 
median NT-proBNP 649pg/ml [IQR: 174-2596pg/mID. However, in this group, 56% had an 
elevated BNP concentration and 71 % had an elevated NT -proBNP concentration without 
VHD or AF to account for the elevation in natriuretic peptides. 
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Figure 5.7 Effect of valve disease or atrial fibrillation on BNP concentrations in HF-
PSF 
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Figure 5.8 Effect of valve disease or atrial fibrillation on NT-proBNP concentrations 
in HF-PSF 
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HF-PSF = All heart failure with preserved systolic function 
VD + AF= HF-PSF including those with valve disease and atrial fibrillation 
VD = HF-PSF with valve disease but no atrial fibrillation 
AF = HF-PSF with atrial fibrillation but no valve disease 
HF-IPSF = HF-PSF with no valve disease or atrial fibrillation 
For further analysis I have used BNP as the marker of LV compromise because it is my view 
that as the upper limits of normal were obtained locally, they are more reliable for the 
population being studied. 41% of patients with HF-PSF have VHD, AF or both which could 
account for their symptoms and signs of HF and could also contribute to the elevated 
natiuretic peptide concentrations. If we examine only those with HF-IPSF then we can use 
elevated BNP concentrations to highlight which of these patients has biochemical evidence of 
L V compromise. Figure 5.9 illustrates the subsets of patients within the study. 
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Figure 5.9 Subsets of patients recruited 
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I have now isolated a group of patients without VHD or AF who have clinical evidence of 
HF, with preserved LV systolic function by echocardiography, but biochemical evidence of 
LV compromise. This group accounts for 16% of all patients recruited with clinical evidence 
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n==23 
n==21 
n==37 
n==16 
n==25 
n=18 
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of heart failure, and 33% of all those with HF-PSF. Tables 5.1-5.6 compare the clinical 
characteristics of this group of patients to those who have HF-IPSF but a normal BNP. 
Table 5.1 Clinical characteristics of patients with HF -IPSF and elevated or 
normal BNP concentrations 
HF-IPSF and HF-IPSF and p value 
elevated BNP normalBNP 
(n=48) (n=38) 
Age (yrs) mean (SD) 74 (10.7) 72 (9.3) 0.33 
Female n (%) 38 (79) 22 (58) 0.03 
BMI mean (SD) 29.2 (5.9) 29.5 (5.1) 0.87 
SBP (mmHg) mean (SD) 143 (31) 145 (29) 0.75 
DBP (mmHg) mean (SD) 77 (18) 77 (16) 0.90 
RR (breaths pm) mean (SD) 20 (5) 22 (13) 0.56 
HR (bpm) mean (SD) 84 (20) 82 (20) 0.62 
Creatinine (p.tmollL) median (IQR) 103 (82-129) 102 (89-110) 0.69 
eGFR median (IQR) 50 (83-129) 57 (49-67) 0.08 
Hb (g/dL) mean (SD) 12.1 (2.1) 13 (1.5) 0.02 
Troponin positive n(%) 14 (29) 0 <0.001 
Abnormal ECG n (%) 37 (77) 19 (50) 0.01 
! 
I 
I 
! 
I 
I 
I 
I 
I 
: Ladder of life score mean (SD) 4.7 (2.3) 5.3 (2.6) 0.27 
I 
BMI = Body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, RR = respiratory rate, 
HR = heart rate, eGFR = estimated glomerular filtration rate, Hb = haemoglobin 
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Table 5.2 Symptoms and signs of patients with HF-IPSF and elevated or normal 
BNP concentrations 
n(%) HF-IPSF and HF-IPSF and p value 
elevated BNP normalBNP 
(n=48) (n=38) 
Symptoms 
NYHA (IIIIIV) 24 (50) 23 (61) 0.33 
Killip ~IIA 37 (77) 27 (71) 0.52 
Paroxysmal nocturnal dsypnoea 14 (29) 10 (26) 0.77 
Orthopnoea 23 (48) 14 (37) 0.30 
Wheeze 13 (27) 13 (34) 0.48 
Reduced exercise tolerance 42 (88) 34 (89) 0.78 
Ankle swelling 36 (75) 24 (50) 0.24 
Leg fatigue 20 (42) 16 (42) 0.97 
Weight loss 2 (4) 0 N/A 
General fatigue 40 (83) 28 (74) 0.28 
Signs 
Raised JVP 27 (56) 9 (24) 0.001 
3fa HS 0 0 N/A 
Peripheral oedema 31 (65) 23 (61) 0.17 
Sacral oedema 2 (4) 0 N/A 
Ascites 0 0 N/A 
Wheeze 8 (17) 5 (13) 0.65 
Crepitations 38 (79) 27 (71) 0.39 
--_ .. _ ... - .. _- - ._._- ... _- L 
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Table 5.3 Comparison ofNYHA scores in patients with HF-IPSF and elevated or 
normal BNP concentrations 
NYHA Score n (%) HF-IPSF and elevated HF -IPSF and normal BNP 
I 
II 
III 
IV 
Table 5.4 
BNP (n=48) (n=38) 
0 0 
24 (50) 23 (61) 
15 (31) 7 (18) 
9 (19) 8 (21) 
Comparison of Killip scores in patients with HF-IPSF and elevated or 
normal BNP concentrations 
Killip Score n (%) HF-IPSF and elevated HF-IPSF and normal BNP 
BNP (n=48) (n=38) 
I 0 0 
II 11 (23) 11 (29) 
IIa 20 (42) 17 (45) 
lib 6 (13) 6 (16) 
III 11 (23) 0 
IV 0 0 
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Table 5.5 Co-morbidities of patients with HF-IPSF and elevated or normal BNP 
concentrations 
n(%) HF-IPSF and HF-IPSF and 
elevated BNP normalBNP 
(n=48) (n=38) 
IHD 29 (60) 19 (50) 
Hypertension 30 (63) 20 (53) 
Hypercholesterolaemia 15 (31) 10 (26) 
PAD 3 (6) 2 (5) 
DM 13 (27) 7 (18) 
CVD 11 (23) 4 (11) 
COPD 24 (50) 16 (42) 
Anaemic 22 (46) 9 (24) 
IHD = ischaemic heart disease, PAD = peripheral arterial disease, DM = diabetes mellitus, 
CVD = cerebrovascular disease, COPD = chronic obstructive pulmonary disease 
p value 
0.33 
0.36 
0.61 
N/A 
0.34 
N/A I 
0.46 
0.03 I 
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Table 5.6 Comparison of admission cardiovascular medications of patients with HF-
IPSF and elevated or normal BNP concentrations 
Medication n (%) HF-IPSF and HF-IPSF and p value 
elevated BNP normalBNP 
(n=48) (n=38) 
Antiplatelet 28 (58) 17 (45) 0.25 
Diuretic 31 (65) 21 (55) 0.46 
Spironolactone 1 (2) 0 N/A 
ACE I 14 (29) 12 (32) 0.75 
ARB 1 (2) 3 (6) N/A 
Statin 19 (40) 12 (32) 0.49 
Il-Blocker 15 (31) 10 (26) 0.67 
Vasodilator 17 (35) 17 (45) 0.33 
Digoxin 2 (4) 0 N/A 
- ... _- ... -
-
. 
-
________________________ J 
Tables 5.1-5.6 compare the clinical characteristics of those with HF-IPSF and an elevated 
BNP to those with a normal BNP. Mean ages in the two groups were similar (p=0.33). A 
higher proportion of patients with an elevated BNP were female (79% vs 58%, p=0.03). The 
mean haemoglobin was lower (p=0.02) and the proportion of anaemic patients higher 
(p=0.03) in the elevated BNP group. A significantly higher proportion of patients in the 
elevated BNP group had an abnormal ECG (p=0.01). In both groups, the median eGFR 
showed moderate renal dysfunction. There was a trend towards worse renal function in the 
elevated BNP group but this was not statistically significant. A higher proportion of patients 
with an elevated BNP also had a positive troponin (p<0.001). No patients in the group with 
HF-IPSF and a normal BNP had a positive troponin on admission. 
Symptoms and signs were similar in both groups with the exception of an elevated JVP which 
was reported more commonly in the group with an elevated BNP concentration (p=0.001). 
154 
Similar proportions of patients in each group had an NYHA score of III/IV and a Killip score 
of~ IIA. 
Similar cardiovascular co-morbidities were seen in both groups. A similar proportion of 
patients in each group had a prior history of COPD. Cardiovascular medications on 
admission were also similar between both groups. 
5.02.3 Relationship between troponin and natriuretic peptide concentrations 
An elevated troponin I was taken to be one greater than or equal to O.2~g/L (see Chapter 2). 
Figures 5.10 and 5.11 illustrate the similar relationship between elevated troponin and both 
BNP and NT -proBNP concentrations. I have divided the patients with clinical evidence of 
heart failure into four groups: All HF, HF-RSF, HF-PSF (including valve disease and AF) 
and HF-IPSF (no valve disease or AF) and compared the troponin and natriuretic peptide 
levels in each group. In each group the highest median BNP and NT -proBNP concentrations 
are found in those with elevated troponin levels on admission (Table 5.7). This is particularly 
prominent in the HF-IPSF group (median BNP 496pglml [IQR: 138-1,111pg/ml], median 
NT-proBNP 6,776 pglml [IQR:2435-14,653 pglmlD. This is compared to the lower median 
BNP and NT -proBNP seen in those with negative troponin levels on admission (median BNP 
61pglml [IQR: 33-178], median NT-proBNP 480pglml [IQR: 144-1,401pglmID. The 
differences in BNP and NT -proBNP concentrations between those with positive and negative 
troponin levels were significant (p = 0.0001 and p < 0.0001 respectively). Although it would 
seem that a positive troponin is associated with higher natriuretic peptide concentrations, only 
16% of those with HF -IPSF had an elevated troponin at the time of admission, compared with 
41% of the HF-RSF group. 
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Figure 5.10 Influence of positive troponin on BNP concentrations 
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Figure 5.11 Influence of positive troponin on NT -proBNP concentrations 
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Table 5.7 Influence of positive troponin on natriuretic peptide concentrations 
Median (IQR) BNP Median (IQR) NT -proBNP 
Troponin -ve Troponin +ve p value Troponin -ve Troponin +ve p value 
ALLHF n=214 n=93 n=214 n=93 
(n= 307) 233 (72-610) 860 (431-1346) <0.0001 2275 (563-5918) 10594 (5329-19107) <0.0001 
HF-RSF n=88 n=61 n=88 n=61 
(n = 149) 498 (223-1000) 874 (431-1424) <0.006 4177 (2243-10380) 10592 (5873-19206) <0.0001 
HF-PSF n=117 n=30 n=117 n=30 
(n = 147) 124 (47-276) 784 (260-1188) <0.0001 1045 (285-3057) 10028 (3027-15677) <0.0001 
HF-IPSF n=72 n=14 n=72 n=14 
(n =86) 61 (33-178) 496 (138-1111) 0.0001 480 (144-1401) 6776 (2435-14653) <0.0001 
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Of patients with HF-IPSF, the majority had a negative troponin on admission. Of these, 47% 
still have an elevated BNP and 65% an elevated NT-BNP concentration, and do not have 
valve disease, atrial fibrillation or positive troponin to account for the elevated natriuretic 
peptide concentrations. 
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5.02.4 Characteristics of patients with HF -IPSF and a negative troponin with elevated 
and normal BNP concentrations 
Table 5.8 Summary of characteristics of patients with HF-IPSF and a negative 
troponin with elevated BNP or normal BNP concentrations 
Elevated BNP NormalBNP p value 
n=34 n=38 
Age (yrs) mean (SD) 75 (9.6) 72 (9.3) 0.313 
Female n (%) 27 (79) 22 (58) 0.042 
BMI mean (SD) 29.9 (6.6) 29.5 (5.2) 0.814 
SBP (mmHg) mean (SD) 141 (29) 145 (29) 0.540 
DBP (mmHg) mean (SD) 74 (16.3) 77 (15.5) 0.432 
HR (bpm) mean (SD) 79 (17.8) 82 (20.4) 0.540 
RR (breaths pm) mean (SD) 21 (5.5) 22 (12.8) 0.722 
Creatinine (flg/L) mean (SD) 101 (81-134) 102 (89-110) 0.982 
eGFR mean (SD) 54 (42-64) 57 (49-67) 0.209 
Hb (g/dL) mean (SD) 11.8 (2.1) 13.0 (1.5) 0.008 
Ladder of life score mean (SD) 5.1 (2.1) 5.3 (2.6) 0.683 
NYHA (1II1IV) n (%) 17 (50) 15 (39) 0.367 
Killip Score ~ lIa n (%) 25 (74) 27 (71) 0.814 
n(%) 
Anaemic 17 (50) 9 (24) 0.017 
IHD 23 (68) 19 (50) 0.122 
DM 7 (21) 7 (18) 0.817 
CVD 9 (26) 4 (11) N/A 
PAD 1 (3) 2 (5) N/A 
Hypertension 20 (59) 20 (59) 0.597 
Hypercholesterolaemia 11 (32) 10 (26) 0.574 
COPD 18 (53) 16(42) 0.355 
Abnormal ECG 26 (76) 19 (50) 0.015 
I 
I 
I 
I 
1 
I 
I 
I 
I 
I 
I 
I 
I 
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BMI = body mass index, IHD = ischaemic heart disease, HBP = hypertension, PAD = peripheral arterial disease, 
DM = diabetes mellitus, CVD = cerebrovascular disease, COPD = chronic obstructive pulmonary disease, SBP = 
systolic blood pressure, DBP = diastolic blood pressure, RR = respiratory rate, HR = heart rate, eGFR = 
estimated glomerular filtration rate, Hb = haemoglobin. 
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Table 5.8 summarises some of the key characteristics of patients with HF-IPSF and a negative 
troponin on admission and compares those with elevated and normal BNP concentrations. 
The mean ages were similar in both groups, 75 (9.6) years in the elevated BNP group and 72 
(9.3) years in the normal BNP group (p=0.313). A higher proportion of patients (79%) in the 
elevated BNP group were female (p=0.042). The two groups had a similar proportion of 
patients with NYHA class UIIIV HF and with Killip scores ~ UA on admission. Both groups 
had comparable haemodynamic variables on admission. The cardiovascular risk factor 
profiles were also similar between the two groups. Renal function was similar in both groups 
and would be classed as moderate renal dysfunction. A similar proportion of patients in each 
group had COPD. 
Half of the patients in the elevated BNP group were anaemic and the mean Hb was 
significantly lower in this group (Hb g/dL 11.8 +/- 2.1), compared with the normal BNP 
group where only 24% were anaemic (p=0.017). Over two-thirds of the patients with an 
elevated BNP concentration had an abnonnal ECG on admission compared to 50% of those 
with a normal BNP concentration (p=0.015). 
5.02.5 Relationship between natriuretic peptides and aminoterminal propetide of type 
III procollagen (PIIINP) 
Table 5.9 compares the median PUINP concentrations in patients with elevated and normal 
BNP concentrations in all types of HF. The upper limit of normal for PUINP, described in 
Chapter 6, was 4.5~g/L. 
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Table 5.9 Median PIIINP concentrations in HF with elevated or normal BNP 
concentrations 
PIIINP (llgIL) p value 
Median (IQR) 
RSF + elevated BNP 7.0 (5.9-8.6) 
RSF + normal BNP 5.3 (4.4-7.5) 0.845 
PSF + elevated BNP 6.4 (5.3-8) 
PSF + normal BNP 5.2 (4.2) <0.0001 
IPSF + elevated BNP 6.1 (5.1-8.2) 
IPSF + normal BNP 5.2 (4.2-5.9) 0.0001 
_ .. _ .. _ .... - .... -
- - - -
- .... - ... - - ... _- ... - ... - .. _- .... - ... _ ..... - .. _ ... _ .... _ .... _ .... _ .. -
The results from Table 5.9 are illustrated in Figure 5.12, and show that the median PIIINP 
concentrations are higher when BNP concentrations are elevated compared to those with 
normal BNP concentrations across all groups of HF patients. This difference was significant 
with the exception of the RSF group which only showed a trend towards a higher PUINP 
concentration in the elevated BNP group. 
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Figure 5.12 Median PIIINP concentrations according to type of HF and BNP 
concentration 
..I 
...... 
en 
::::I 
u 
C 
o 
U 
Q. 
Z 
.... 
.... 
.... Q. 
14~~-----------------------------------------------' 
12 
10 
8 
4.,.. .... - - - 1-- - 4 ---6 4 
2~L----r---------r---------r---------.---------.---------.---~ 
f>.c:J"'\ ~o,"'\ c:J~"'\ ~~ ~f>.~ h",tb"'\ 
~~ ~ ~~ <:1 <:1 <:1 ~ #- ~ ~~ 5l~ 5l~ ~~ +<lJ ~ ~~ ~~ ~~ ~ 4 ~<lJ !<~ !<~ !<~ ~~ ~ ~4o ~" ~" ~" 
- -- Upper limit ofnOlmal 
EBNP = elevated BNP concentration 
NBNP = normal BNP concentration 
This pattern is replicated when comparing the median PIIINP concentrations in those with 
elevated and normal NT-proBNP concentrations. All patients in the HF-RSF group had an 
elevated NT-proBNP concentration, and the median PIIINP concentration was 7.0Ilg/L. In 
HF-PSF the highest median PIIINP concentrations were seen in those with elevated NT-
proBNP concentrations: 6.2llg/L compared to 5.31lg/L in those with normal NT-proBNP 
concentrations (p=O.0003). This was also true for those with HF-IPSF and an elevated BNP 
(5.9Ilg/L) compared to those with a normal BNP concentration (p=O.006). This is illustrated 
in Figure 5.13. 
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Figure 5.13 Median PIIINP concentrations according to type of HF and NT-
proBNP concentrations 
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5.03 Discussion 
This examination of NP concentrations demonstrates that patients with clinical evidence of 
heart failure have higher NP concentrations than those without. The highest NP 
concentrations are found in those with HF-RSF, and nearly all patients in this group have 
elevated NP concentrations. These values are significantly higher than those found in the HF-
PSF group. However, even in the HF-PSF group, approximately four-fifths of patients have 
NP concentrations above the upper limit of normal. 
Previous studies have shown that the presence of valve disease correlates with higher NP 
concentrations210-216, as may be expected due to the fact that most clinically significant 
valvular heart disease (VHD) will result in pressure or volume overload of the left ventricle. 
These findings have been reproduced in this study, where patients with VHD also had higher 
NP concentrations. The prognostic value of BNP in VHD remains to be established. 
There is less literature on the association between AF and NP concentrations and this has 
largely remained controversial, with some authors reporting higher NP concentrations in the 
presence of AF, even in the absence of structural heart disease217-219. This study suggests that 
the presence of AF is indeed associated with higher NP concentrations. However, the exact 
mechanism by which the presence of AF, in the absence of structural heart disease, may 
influence NP concentrations remains unclear. 
Those patients with HF-IPSF and an elevated BNP concentration were more likely to be 
female. Nearly half of these patients were anaemic and the median eGFR was in the moderate 
renal dysfunction range. These findings are similar to those discussed in Chapter 3, where I 
showed that HF-RSF was associated with significant renal dysfunction and anaemia. This 
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finding, that HF-IPSF is frequently associated with significant renal dysfunction and anaemia 
strongly suggests that HF-IPSF is not merely a benign manifestation of the heart failure 
syndrome, but rather is associated with similar complications to those found in HF-RSF. 
One possible mechanism for the occurrence of heart failure with preserved systolic function, 
is transient LV dysfunction caused by a period of myocardial ischaemia, indicated by an 
elevated troponin. However, in this study, the majority of patients with HF-IPSF had a 
negative troponin but an elevated plasma BNP concentration. We have therefore identified a 
group of patients who have clinical evidence of heart failure, preserved systolic function, 
biochemical evidence of LV compromise, but without VHD, AF or myocyte necrosis to 
account for this. These patients undoubtedly have heart failure, in the presence of preserved 
LV systolic function, without a separate cardiac pathology which may be causing secondary 
heart failure. The cumulative results of this study, from detailed characterisation of heart 
failure patients, indicate that HF-PSF exists as a clinical entity in its own right. 
Interestingly, this study also found that in patients with HF-IPSF, a positive troponin at the 
time of admission was associated with an elevated NP concentrations. No patients with HF-
IPSF and a normal BNP had an elevated troponin. This co-distribution of troponin with BNP 
is relevant in the light of emerging evidence regarding the prognostic value of troponin in 
heart failure22o, and conversely, that BNP predicts outcome in acute coronary syndromes221 • 
The interplay between these two biomarkers suggests that they represent related processes in 
the pathophysiology of heart failure, and this is an area which requires further study. 
Evidence to suggest possible ventricular strain in patients with heart failure is found in the 
relationship between NP and PUINP concentrations. PUINP (examined in detail in Chapter 6) 
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is a recognised marker of increased collagen turnover109;222 and has been shown to be elevated 
in association with cardiac pathologyI29;223;224. In addition, pnINP is associated with a poor 
prognosis 129;225. In this study, in both types of heart failure, the highest pnINP concentrations 
were seen in those with elevated NP concentrations. 
In summary, in this study I have identified a group of patients who have HF-PSF and elevated 
NP concentrations without an adequate alternative explanation for these findings. In the 
presence of preserved LV systolic function these patients have both clinical evidence of heart 
failure on validated scores, and objective biochemical evidence of left ventricular strain. 
Therefore, these patients may truly be said to have heart failure with preserved systolic 
function. Moreover, these patients do not appear to have a benign syndrome, but instead share 
markers of an adverse prognosis, such as elevated BNP, troponin or PIIINP and abnormal 
renal function, with patients with HF-RSF. 
The focus of this study has been to characterise patients with HF -PSF and in this Chapter I 
have described their NP concentrations. However, my findings, that BNP and NT-proBNP are 
elevated in the majority of patients with positive heart failure scores, regardless of systolic 
function, also supports the developing role of BNP in the diagnosis of heart failure. Indeed, 
the diagnostic accuracy of BNP rises when patients with preserved systolic function are 
studied, and from this it has been suggested that, BNP may be superior to ejection fraction as 
a diagnostic and prognostic too1226• However, in routine clinical practice, the role of BNP is 
now clearly established as a diagnostic tool alongside echocardiography, and both should be 
performed in patients presenting with symptoms and signs compatible with heart failure l42 . 
167 
CHAPTER SIX 
AMINO TERMINAL PROPEPTIDE OF TYPE III 
PROCOLLAGEN 
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6.01 Introduction 
6.01.1 Myocardial extracellular matrix 
The myocardial extracellular matrix (ECM) is the connective tissue skeleton of the heart, and 
it plays a key role in cardiac function. It determines the structure of the myocardium and 
provides both the tensile strength and stiffness of the tissue. This is important for ventricular 
function through the transmission of myocyte generated ventricular force to the atria and 
ventricles. It also contributes to myocyte lengthening in diastole, and the ECM is therefore the 
main determinant of diastolic stiffness227-229. 
The myocardial ECM in the normal heart is a fibrillar network organised in a honeycomb 
pattern. It consists of collagen, basement membrane, fibronectin, proteoglycans, laminin, 
matrix metalloproteinases (MMPs) and growth factors. The ECM has three distinct 
components. The endomysium is a sheath of delicate reticular fibrils, which support and 
connect the individual myocytes. The endomysial weave envelops each myofibre, and is 
connected to adjacent myocytes by lateral struts. The perimysium is a connective tissue 
sheath which surrounds groups of myocytes. Collagen struts also connect myocytes to 
interstial microvessels and perimysial collagen fibrils 123 (see Figure 6.1). 
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Figure 6.1 Scanning electron microscopy of normal myocardial ECM 
Adapted from Rossi et aIl23 
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Figure 6.2 Scanning electron microscopy of hypertrophied myocardial ECM 
Adapted from Rossi et all23 
More than simply a scaffold for cells, the extracellular matrix has dynamic properties and 
undergoes functional remodelling in disease states. Examples include: ventricular 
hypertrophy, dilated cardiomyopathy and remodelling following MI. ECM remodelling is an 
important part of L V remodelling, which plays a key role in the development of HF, 
regardless of aetiolog~30 (see Figure 6.2). 
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6.01.2 Components of the ECM 
Collagen types I and III are the most common, both in normal and diseased myocardium23o. 
They are normally found together, but during a fibroproliferative response, the deposition of 
type III collagen precedes that of type 1231;232. These collagen fibres ensure the structural 
integrity of the adjoining myocytes and provide the means by which myocyte shortening is 
translated into the generation of coordinated force. Collagen is also essential on a cellular 
level, as it forms part of the collagen-integrin-cytoskeleton which maintains alignment of the 
myofibrils within the myocyte. Collagen production is stimulated by growth factors such as 
transforming growth factor (TFG), insulin-like growth factor (IGF) and basic fibroblast 
growth factor (BFGF). Angiotensin II (Ang II) has also been shown to stimulate collagen 
gene expression and protein turnover in cultured cardiac fibroblasts233 . Ang II also stimulates 
collagen synthesis and regulates collagen degradation in endothelial cells by attenuating 
interstial MMP-I activity, through activation of its tissue inhibitor234-236. 
Endothelin has been shown to mediate the effects of angiotensin II on cardiac fibroblasts. 
Endothelin is synthesized by both cardiomyocytes and fibroblasts and has been shown to 
stimulate collagen I and III synthesis237. In animal experimental models inhibition of 
endothelin has been shown to decrease left ventricular collagen accumulation238. 
Fibroblasts constitute the majority of non-myocyte cells in the heart. Cardiac fibroblasts 
increase their production of fibronectin and collagen when the heart is exposed to insults such 
as myocardial infarction (MI), pressure overload, or myocarditis230;239;24o. Excess collagen 
deposition and the resultant cardiac fibrosis are implicated in increased tissue stiffness and 
diastolic dysfunction. 
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6.01.3 Myocardial extracellular matrix control mechanism 
Matrix metalloproteinases (MMPs) are a family of functionally related enzymes that cleave 
ECM components resulting in collagen denaturation and degradation, and the synthesis of 
new fibrous tissue241-248. The MMPs are secreted by fibroblasts, smooth muscle cells and 
myocytes249 as proenzymes (proMMPs), and are then activated by proteolytic cleavage to 
their active form. To date, 20 MMPs have been identified and work to identify others is 
continuing. The MMPs are differentiated by their structure and specificity: collagenase 
(MMP-l) which degrades fibrillar collagens; stromelysin (MMP-3) which degrades 
proteoglycans and glycoproteins; and gelatinases (MMP-2 and MMP-9) which degrade 
denatured collagens and basement membrane collagens250. 
The activity of the MMPs is regulated by a number of chemical agents, neurohormones and 
cytokines243;246;248;249;251;252. In most cases, the activation of proMMPs involves the "cysteine-
switch" mechanism253 . The active MMPs are then regulated by levels of TIMPs and a2-
macroglobulin, which inhibit MMP activity. The TIMPs inhibit MMPs directly, but also form 
complexes with proMMPs to modulate MMP activation254. The tight regulation of MMP-
mediated collagen degradation appears to fail during the development of heart failure255-257. 
MMPs are thought to play a role in collagen synthesis, through the formation of 
matrikines247;258 such as glycyl-histidyl-Iysine, and by releasing biologically active growth 
factors which stimulate collagen production259. 
In rodents, heart failure can be induced by over-expression of tumour necrosis factor alpha 
(TNFa), the animals develop progressive ventricular hypertrophy and dilatation. These 
changes have been shown to be accompanied by a significant increase in MMP-2 and MMP-9 
levels, an increase in collagen synthesis, deposition and denaturation, and a decrease in non-
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denatured soluble collagens26o. The changes in the ECM of these rats were associated with 
marked diastolic dysfunction demonstrated by significantly reduced transmitral E/A rati026o• 
6.01.4 Aminoterminal pro peptide of type III pro collagen (PIIINP) 
Type III collagen is a homotrimer of three 0,1 (III) chains, encoded by a single gene found on 
chromosome two (location q24.3-q31 i 61 • Like the other fibrillar collagens, type III collagen 
is synthesised as a large precursor molecule (pro collagen type III) with propeptides at each 
end. These propeptides are cleaved enzymatically during the extracellular processing of type 
III collagen. One of these propeptides, PIIINP, is cleaved by a specific N-proteinase during 
the formation of collagen type III. 
PIIINP has a molecular weight of approximately 42,000 and consists of a cysteine rich 
globular domain (see Figure 6.3 coli), a non-collagenous domain (see Figure 6.3 col 2) 
ending in the N-telopeptide and the 29 amino-acid triple-helical region (see Figure 6.3 col 3) 
which lies between col 1 and col 2. The cystiene-rich globular domain consists of five inter-
chain disulfide bridges along with 79 amino acids. The non-collagenous domain is an area of 
12 amino acids and is located in the carboxy-terminal region of the propeptide, and contains 
three interchain disulfide bonds. The PIIINP molecule is stabilised by these three interchain 
disulfide bridges. The melting temperature of the collagenous domain is 53°C and the 
refolding of the helix from the denatured peptides takes place extremely fast, mainly due to 
the disulfide bonds that already keep the three chains together262• Figure 6.3 is a 
diagrammatic illustration of the PIIINP molecule. 
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Figure 6.3 Diagramatic illustration of PIIINP molecule (modified from Risteli et at263) 
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Circulating PIIINP is cleared by scavenger receptors located on hepatic endothelial cells. It 
has been postulated that tyrosine sulfation plays a role in the recognition of PIIINP by the 
scavenger receptors263 . The amino-terminal component is renally cleared264. 
6.01.5 PIIINP as a marker of collagen synthesis 
PIIINP is believed to reflect enhanced collagen turnover. In the rat heart, following induction 
of MI, degradation of collagen occurs at the infarct site at day one and two. Collagenolysis at 
the infarct site peaks at day seven, and then declines over the next 14 days. Over days three to 
five, accumulation of fibrillar collagen is seen. The synthesis of type III pro collagen peaks 
after three weeks and appears to normalize after a period of months. This increased collagen 
turnover is reflected by an increase in semm PIIINP in the sub-acute phase of MI. In 
summary, this represents an initial increase in collagenolysis with an overlapping but 
prolonged increase in collagen synthesis 109. 
Elevated PIIINP concentrations are associated with a poor prognosis in patients following 
Me23. Poulsen et at studied 47 consecutive patients admitted with their first acute MI. Using 
the same radioimmunossay (PIIINP-RIA Kit, Orion Diagnostics) as the CUlTent study, peak 
PIIINP concentrations measured on day four post MI were significantly higher compared to 
controls. PIIINP concentrations remained elevated during the first three months post MI129. 
The persistent elevation of PIIINP indicates a consistent increase in collagen synthesis during 
this time265 . Patients with acute MI and an elevated PIIINP demonstrated significant LV 
dilatation and persistently depressed L VEF compared with patients with normal pnINP 
following MI during the one year follow-up. In addition, Doppler analyses of transmitral and 
pulmonary venous flow indicated restrictive LV diastolic filling in those with higher pnINP 
concentrations. A restrictive L V filling pattern is associated with increased L VEDP, which 
176 
can be due to increased myocardial stiffness or increased LV volumes266 . As discussed 
above, these patients did develop LV dilatation. However, increased collagen deposition 
might also contribute to the development of restrictive filling. It has been shown that 
increased collagen deposition occurs not only at the infarct site, but also at remote sites in the 
ventricle, and this may be expected to increase myocardial stiffness 128. Poulsen et al 
identified PUINP > 5.0 Il/L and deceleration time :S 140ms (an indicator of restrictive LV 
filling, discussed in Chapter 4) as predictors of adverse clinical outcome129. A further study in 
patients following MI, demonstrated a positive correlation between PUINP concentrations and 
infarct size, LVSD and the presence of coronary artery occlusion132• 
In left ventricular hypertrophy (L VH), collagen accumulation results in increased chamber 
stiffness and diastolic dysfunction267 . Lombardi et al studied indices of collagen turnover in 
36 patients with hypertrophic cardiomyopathy (HCM), which is characterised by: 
asymmetrical L VH: myocyte disarray; interstitial fibrosis; and increased arteriolar wall 
thickness. When compared with age and sex-matched controls, those with HCM had 
increased PIIINP levels. However, the authors did not find any correlation between PUINP 
levels and the severity of L VH. An inverse relationship was found between PUINP and 
LVEDD, thus serum PIIINP concentrations were higher in those with small ventricles, who 
would be expected to have restrictive defects in diastolic function224 . 
6.01.6 Prognostic significance of PIIINP 
Zannad et al reported on a sub-study of the Randomized Aldactone Evaluation Study 
(RALES) which examined the value of serological markers for cardiac ECM turnover as 
predictors of death and hospitalisation. They also assessed the effects of treatment with 
spironolactone on these markers and the interaction between spironolactone induced changes 
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in ECM turnover on mortality and morbidity230. All the patients in the RALES trial had 
severe HF. This was defined as NYHA class IV symptoms within the six months prior to 
randomisation and class III or IV symptoms at the time of randomisation, along with a 
depressed L VEF «35%). Patients were randomised to receive conventional therapy with 
either placebo or spironolactone268. The baseline mean PIIINP concentration was 5.0 +/- 2.5 
llg/L, which is well above the normal range (1.7-4.211g/L/64. The baseline PIIINP 
concentration in this group was similar to those found in other studies of post-MI patients 
(5.08 +/- 0.36 Ilg/L)132 and those with dilated cardiomyopathy (DCM) (6.1 +/- 0.4 Ilg/L)225. 
There was no difference in baseline median PIIINP concentration between the placebo and 
spironolactone arms. After six months, median PIIINP concentration was significantly lower 
in the spironolactone treated group. In this subgroup analysis, morbidity and mortality benefit 
was greatest in those with the highest PUINP concentration. 
Rossi et al studied patients with stable heart failure for at least six months and a diagnosis of 
DCM, in the presence of a depressed L VEF « 45%)131. Those patients who also had severe 
diastolic dysfunction, as characterised by restrictive ventricular filling, had the highest PUINP 
concentrations and the worst prognosis. 
A recent study examined both natriuretic peptides and collagen markers after acute MI. 
Natriuretic peptides are anti-fibrotic and have been shown to be elevated following 
MI50;93;95;269-271. In this study natriuretic peptide elevation correlated positively with PUINP 
concentration. The authors postulated that natriuretic peptides may be involved with PIIINP 
in the regulation of collagen formation during remodelling following MI272. 
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6.02 Results 
6.02.1 PIIINP concentrations in HF-RSF and HF-PSF 
The median PIIINP concentrations are significantly higher in the HF-RSF group when 
compared with the HF-PSF group (7.0Jlg/L vs 5.9 Jlg/L, p=O.0001). This is shown in Figure 
6.4. 
Figure 6.4 Median PIIINP concentrations in HF-RSF and HF-PSF 
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Figure 6.5 Proportion of patients with elevated PIIINP concentrations in HF-RSF 
and HF-PSF 
Proportion with elevated PIIINP concentration 
Proportion with nonnal PIIINP concentration 
Figure 6.5 illustrates that the majority or patients in each group have an elevated PIIINP 
concentration. A significantly higher proportion of patients in the HF-RSF group have an 
elevated PIIINP concentration (96% vs 88%, p=0.009). 
As described in Chapter 5, higher natriuretic peptide concentrations were associated with the 
presence of VHD and AF. Figure 6.6 illustrates that a similar relationship existed with 
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PUINP concentration. There was a trend towards higher PUINP concentrations in patients 
with VDH, AF or both compared to those with HF-IPSF (p=O.06). 
Figure 6.6: Median PIIINP concentration and VHD or AF in HF-PSF 
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6.02.2 Comparison of PIIINP levels in established cardiac pathology 
Figure 6.7 compares the mean PUINP concentration in the current study to those from 
previous studies using the same radioimmunoassay (Orion Diagnostics, Espoo, Finland). 
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Figure 6.7 Comparison of mean PIIINP concentrations 
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As discussed previously in this Chapter, these studies all required LVSD and included 
patients with severe HF (study 1 in Figure 6.7i64, post-MI patients (study 2 in Figure 6.7)132, 
and those with DCM (study 3 in Figure 6.7)225. In all groups, the mean PIIINP concentrations 
were above the upper limit of normal, including the patients in our study in both the HF-RSF 
and HF-PSF groups. Therefore, the mean PIIINP concentrations in the current study are in 
line with elevated PIIINP concentrations from previous studies with documented cardiac 
pathology. 
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6.03 Discussion 
These results show that median PUINP concentrations are elevated in both types of HF, and 
are significantly higher in HF-RSF. As would be expected, nearly all patients (96%) in the 
HF-RSF group had an elevated PUINP concentration. This is in keeping with previous studies 
that describe a higher PUINP concentration in patients with L VSD. In this study, the mean 
PUINP concentrations are in fact slightly higher than those observed in other studies of HF 
with L VSD across a variety of aetiologies. This is possibly due to the fact that patients in this 
study were admitted with acute heart failure. 
As well as reproducing the observation that PIIINP is elevated in the context of L VSD, we 
have demonstrated that the majority of patients with HF-PSF also have elevated PUINP. This 
suggests that enhanced collagen formation is a feature both types of HF. 
In conjunction with the results described in Chapter 5, I have found that there was an 
association between BNP and PUINP in both groups of HF patients. The pathophysiological 
mechanism underlying this relationship has yet to be elucidated. It is possible that BNP 
acting as an anti-fibrotic agent is involved in the regulation of cardiac fibrosis for which 
PUINP is a marker. Or it may be that both BNP and PUINP are simply markers of this 
process. Investigation of this is beyond the scope of the current investigation, but is an 
important avenue for future research especially as recent studies have shown that PUINP is a 
predictor of mortality in patients with HF_RSF l31 ;273. Recently it has been suggested that 
traditional imaging techniques do not assess LV longitudinal systolic function274. Poulsen et 
af demonstrated that in patients with hypertension the longitudinal systolic L V function was 
in fact depressed when compared to controls. They also demonstrated that these patients had 
elevated PUINP concentrations suggestive of myocardial fibrosis274• It is therefore possible 
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that the combination of more advanced imaging techniques with BNP and PIIINP 
concentrations may provide a more detailed understanding of the extent and effect of 
myocardial fibrosis in this cohort ofHF patients. 
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7.01 Introduction 
Aldosterone is the principal mineralocorticoid hormone in humans, and is produced in the 
zona glomerulosa of the adrenal gland. The hormone is the product of a series of biosynthetic 
reactions, which are summarised in Figure 7.1 275 • Aldosterone is released from the adrenal 
cortex in response to an increase in the concentrations of angiotensin II, corticotrophin, 
catecholamines, endothelins and potassium276;277. 
Figure 7.1 Steroid biosynthetic pathwa~75 
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Angiotensin II and potassium are the principal regulators of aldosterone production. 
Angiotensin II stimulates aldosterone secretion in response to both sodium depletion and 
reduced extracellular fluid volume278. Even small increments in plasma potassium act as a 
powerful stimulus for aldosterone production279. 
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The principal target organ for aldosterone is the kidney. However, mineralocorticoid 
receptors, which bind aldosterone, are also found in secretory epithelial sites in colon, sweat 
and salivary ducts, heart, brain, vascular smooth muscle, liver and peripheral blood 
leukocytes275 . 
The best characterised physiological effect of aldosterone is to increase the reabsorption of 
sodium at the expense of potassium and hydrogen ions278. Aldosterone therefore affects 
blood pressure (BP) by plasma volume expansion and the associated increase in cardiac 
output. It is likely however, that aldosterone also regulates BP by mechanisms other than its 
action on sodium homeostasis. Evidence suggests that aldosterone binding to 
mineralocorticoid receptors in cardiac tissue regulates collagen formatio~8o. It is possible 
that it may have a similar action on peripheral blood vessels, resulting in remodelling and an 
elevated BP. This is supported by evidence that aldosterone levels are inversely related to 
arterial compliance in essential hypertension281 . 
Over the past two decades, a greater understanding of the importance of the remn-
angiotensin-aldosterone system (RAAS) in cardiovascular disease has been achieved. 
Activation of the RAAS is associated with poor outcomes, especially in patients with 
hypertension and heart failure276;277;282-286. Aldosterone contributes to hypertension, and to the 
progression of both cardiovascular and renal disease. This occurs through sodium retention, 
an increase in magnesium and potassium loss, impairment of endothelial and baroreceptor 
function, reduction in vascular compliance, and promotion of cardiac and vascular 
fibrosis276;282;286-29o (Figure 7.2). 
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Figure 7.2 Renin-angiotensin-aldosterone system291 
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In HF, aldosterone release results in over-activation of the RAAS and further elevation of 
aldosterone levels. This leads to sodium retention, with resultant expansion of the 
extracellular volume, which leads to impaired haemodynamic responsiveness and a fall in 
cardiac output. Decreased renal blood flow stimulates the RAAS further, producing a vicious 
cycle, which results in secondary hyperaldosteronism and excessive sodium retention. Also, 
the electrolyte imbalances produced, in particular hypokalaemia and hypomagnesemia, 
increase the risk of sustained ventricular arrhythmias, which are a major cause of sudden 
cardiac death in heart failure292;293. 
More recent research has identified new pathophysiological mechanisms by which 
aldosterone could be expected to contribute to the progression of HF and increase the risk of 
sudden cardiac deat~94 (Figure 7.3). 
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Figure 7.3 Mechanisms of promotion of sudden cardiac death by aldosterone294 
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A growing body of research suggests that aldosterone contributes to endothelial 
dysfunction295-30o. The endothelium plays a critical role in the regulation of vascular tone, 
platelet aggregation, adhesion of leukocytes and the thrombotic cascade. Endothelial 
dysfunction is predictive of subsequent cardiovascular events301 . 
Aldosterone also contributes to the progression of HF by promoting perivascular and 
interstitial myocardial fibrosis, by its action on cardiac mineralocorticoid receptors. In vitro 
experiments have reported that the administration of aldosterone to cardiac fibroblasts 
significantly enhances collagen synthesis28o;302;303. This fibrosis reduces the flexibility of the 
myocardium, such that higher filling pressures are required, and therefore increases the 
likelihood of diastolic dysfunction. Structural remodelling of the interstitial collagen matrix, 
producing patchy myocardial fibrosis would also be expected to result in electrical 
inhomogeneity and therefore promote arrhythmia. 
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The first proof that the relationship between aldosterone and myocardial fibrosis was 
clinically important, came when it was shown that spironolactone reduced plasma levels of 
PIIINP in heart failure304. A comparison of patients with essential hypertension revealed that 
those with hyperaldosteronism had a higher L V mass index and alterations in myocardial 
texture which suggested increased collagen deposition, compared to those with normal 
aldosterone concentrations305. A further study, undertaken in patients with essential 
hypertension treated with an ACE-I, has reported that the LV mass index fell significantly 
only in patients in whom the aldosterone level was controlled, but remained unchanged in 
those with aldosterone escape306. 
Another potentially harmful effect of aldosterone is its ability to blunt the baroreflex 
response307;308. The normal baroreflex adjusts heart rate to normalise changes in BP. 
Aldosterone inhibits baroreflex sensitivity in healthy volunteers, independent of the 
attenuation of the baroreflex associated with angiotensin II294. 
Inhibition of the angiotensin-converting enzyme and antagonism of the angiotensin II receptor 
protect against vascular injury and end-organ damage. ACE-I mediated blockade of 
angiotensin II synthesis or angiotensin II receptor blockade lead to decreased synthesis of 
aldosterone. These decreases in angiotensin II and aldosterone are thought to be responsible 
for some of the cardioprotective effects of ACE-lor angiotensin II receptor blocker (ARB) 
treatmene76;277;286. 
The data indicating a pathogenic role of aldosterone in HF have now been validated by two 
major prospective clinical trials. In the RALES study, 1663 patients with NYHA class III-IV 
HF were randomised to receive spironolactone (an aldosterone antagonist) or placeb0268. The 
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trial was stopped early (mean follow up 24 months) after demonstrating a 30% reduction in 
mortality in the spironolactone group. This result was driven by a significant reduction in 
death due to progressive HF and sudden cardiac death. The spironolactone treated group also 
showed a significant improvement in HF symptoms, indicated by a reduction in NYHA class. 
The dose of spironolactone used in RALES (25-50mg/day) had no diuretic effect, as 
established by a sub-study where the sodium retention score was measured. The authors 
concluded that a cardio-protective effect of aldosterone blockade contributed to the reduction 
in mortality. 
There are several potential explanations for the benefits of aldosterone blockade: aldosterone 
worsens endothelial function and so increases coronary events, and as discussed above it has 
arrhythmogenic effects309. Serological markers of cardiac collagen turnover (PICP, PINP, 
PUINP) were analysed in a subgroup of the RALES study, to monitor the extent of tissue 
repair and fibrosis 157. The levels of these markers decreased in the spironolactone group, but 
remained unchanged in the placebo cohort. This suggests that the benefit of aldosterone 
blockade is linked to the reduction in cardiac fibrosis. Interestingly, serum levels of all three 
procollagen markers were independently associated with risk of death, and the beneficial 
effects of spironolactone were predominantly seen among patients with the highest levels of 
procollagen markers. It is not yet clear whether aldosterone blockade is more effective in HF 
patients with higher plasma aldosterone levels294. 
The recent EPHESUS trial evaluated the use of the selective aldosterone blocker eplerenone 
in 6632 patients with acute MI complicated by L VSD and HF31O. After a mean follow-up of 
16 months, there was a 15% reduction in mortality compared to placebo and a 15% reduction 
in risk of hospitalisation for HF. The reduction in the primary endpoint was driven by a 21% 
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reduction in sudden cardiac death. The EPHESUS trial illustrated that the cardio-protective 
effect of aldosterone blockade is maintained even when patients are established on optimal 
therapy and close to the acute phase of Mr294. 
7.02 Results 
7.02.1 Renin and aldosterone concentrations 
One of the major problems in measuring renin and aldosterone plasma concentrations is that 
many common cardiac medications influence the RAAS. In this study, the median plasma 
aldosterone concentrations were affected by the use of ACE-I, ARB and spironolactone. 
Table 7.1 and 7.2 show the median aldosterone concentrations in HF-RSF and HF-PSF 
dichotomised according to prescription of ACE-I, ARB or spironolactone. A higher median 
aldosterone concentration was found in HF-RSF (not taking ACE-I, ARB or spironolactone) 
compared to those with HF-PSF (not taking ACE-I, ARB or spironolactone) [p=0.026]. A 
higher proportion of patients in the HF-RSF (31%) had an elevated aldosterone concentration 
compared to those with HF -PSF. However nearly a one-fifth of the HF -PSF group also had 
an elevated aldosterone concentration and were not taking medications that influence the 
RAAS. 
Table 7.1 Plasma aldosterone concentrations in patients with HF-RSF and HF-PSF 
HF-RSF (n=149) HF-PSF (n=147) 
Taking ACE-I I Not taking Taking ACE-I I Not taking , 
ARB ACE-II ARB I ARB ACE-II ARB I 
No spiro spiro No spiro spiro 
(n=67) (n=71) (n=52) (n=93) 
Median (IQR) 6(3-11) 11 (7-24) 7 (3-l3) 10 (4-16) 
Aldo ng/dl 
Elevated Aldo 5 (7) 22 (31) 4 (8) 16 (17) 
n(%) 
Aldo = Aldosterone, spiro = spironolactone 
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Table 7.2 Plasma renin concentrations in patients with HF-RSF and HF-PSF 
HF -RSF not taking HF-PSF not taking p value 
ACE-I I ARBI Spiro ACE -I I ARB I spiro 
(n=71) (n=93) f: 
Median (IQR) renin ,.UfL 30 (17-109) 31 (13-59) 0.190 
Elevated renin n (%) 28 (39%) 28 (30%) 0.224 
, 
-
Spiro = spironolactone 
Median renin concentrations were analysed in the same way as shown in Table 7.2. There 
was no significant difference in the median renin concentration in HF-RSF and HF-PSF (not 
taking ACE-I, ARB or spironolactone) and a similar proportion of patients had elevated renin 
concentrations in each group. Only a few patients in both the HF-RSF (n=5) and HF-PSF 
(n=9) with elevated renin concentrations (not on ACE-I, ARB and spironolactone) were on a 
~-blocker. 
7.02.2 Relationship between aldosterone and PIIINP 
As already described in Chapter six and earlier in this Chapter, aldosterone can promote 
fibrosis and PIIINP is a marker of collagen fOlmation, which occurs during fibrosis. 
Table 7.3 shows the median PIIINP concentrations in HF-RSF and HF-PSF. In patients not 
taking medications that influence the RAAS, it is clear that higher PIIINP concentrations are 
seen in HF-RSF compared to those with HF-PSF. 
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Table 7.3 Median PIIINP concentrations in patients with HF-RSF and HF-PSF 
HF-RSF HF-PSF p 
Median PIIINP Median PIIINP 
Jtg/L Jtg/L 
Taking ACE-I I ARB I spironolactone 6.9 (4.9-11.6) 5.0 (N/A) 0.28 
Taking ACE-I I ARB 6.6 (5.6-8.1) 6.2 (5.1-7.3) 0.07 
Not takin2 spironolactone 
Not taking ACE-I I ARB I 7.2 (6.0-8.8) 5.8 (4.9-7.6) 0.0009 
spironolactone 
NI A = sample size too small for statistical analysis 
Table 7.4 shows the median PUINP concentrations in those patients with elevated aldosterone 
concentrations in both HF-RSF and HF-PSF not taking ACE-I, ARB or spironolactone. 
Table 7.4 Median PIIINP concentrations in patients with HF-RSFIHF-PSF and 
elevated or normal aldosterone concentrations 
HF-RSF + elevated HF-RSF + normal p value 
aldosterone aldosterone 
Median (IQR) 6.6 (5.3-9.3) 7.4 (6.4-8.6) 0.565 
PIIINP (Jtg/L) 
HF-PSF + elevated HF-PSF + normal 
aldosterone aldosterone 
Median (IQR) 5.9 (5.2-7.5) 5.8 (4.9-7.8) 0.909 
PIIINP (Jtg/L) I 
In this study, patients with elevated plasma aldosterone concentrations did not have higher 
PUINP concentrations. This finding was the same for both types of HF and there was also no 
significant difference in the PUINP concentrations in those with elevated aldosterone 
concentrations in either HF-RSF or HF-PSF (p=0.237). This finding is in contrast to the 
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association, described in Chapter five, between elevated natriuretic peptide levels and 
elevated PUINP. 
7.03 Discussion 
In patients not taking medications known to influence the RAAS (such as ACE-I, ARB and 
spironolactone), significantly higher median aldosterone and PIIINP concentrations were 
found in HF -RSF compared with HF -PSF. A higher proportion of patients with HF -RSF had 
elevated aldosterone concentrations. Renin concentrations were similar in both types of HF. 
As has been discussed, the renin and aldosterone concentrations are difficult to interpret in 
isolation because of the influence of many common cardiovascular medications on the RAAS. 
I have tried to take this into account by further separating the two groups, into those who were 
taking ACE-I1ARB or spironolactone and those who were not. 
It is important to appreciate, however, that other cardiac medications, such as diuretics and ~­
blockers also influence the RAAS. As less than one-fifth of the patients with clinical HF in 
this study were not on any medications which affect the RAAS, it is very difficult to interpret 
the significance of isolated renin and aldosterone measurements. Therefore, in future studies 
it would be beneficial to adopt measurements used in specialist hypertension practice for 
assessing aldosterone and renin, such as the plasma aldosterone to renin ratio (ARR). As a 
ratio, this provides an index of RAAS activation which is less influenced by the effects of 
medications on absolute renin or aldosterone concentrations. 
Recently there has been increasing interest in aldosterone as a key cardiovascular hormone. 
Aldosterone excess results in hypertension and promotes collagen deposition in blood vessels, 
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thus enhancing vascular remodelling at the expense of vessel compliance. It has been shown 
that aldosterone excess in the presence of sodium chloride will stimulate perivascular and 
interstitial cardiac fibrosis and hypertrophy, independently of blood pressure. Treatment of 
severe heart failure with mineralocorticoid receptor antagonists such as spironolactone and 
eplerenone, significantly reduce mortality and morbidity, and this effect is also independent of 
any effect on blood pressure. Recently, animal models have shown that eplerenone can 
prevent and reverse mineralocorticoid induced fibrosis3)). Given that fibrosis and 
hypertrophy are important pathological factors in the development of diastolic dysfunction, it 
may well be that RAAS over-activation is contributing to the development of HF-PSF. 
Results from this study would certainly seem to suggest that a proportion of patients with HF-
PSF have RAAS over-activation. RAAS inhibition may therefore prove to be beneficial in 
HF-PSF. It may be that, in the future, measures of RAAS activation, such as ARR could 
identify those patients with HF-PSF who may benefit most from the early use of aldosterone 
antagonists. 
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CHAPTER EIGHT 
HEART FAILURE AND CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
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8.01 Introduction 
The concern that patients thought to have heart failure in the context of preserved systolic 
function may have been misdiagnosed has been raised by a number of authors. One obvious 
cause of breathlessness that could be confused with heart failure is that arising as a 
consequence of chronic lung disease. Of course, it is also possible that both conditions might 
co-exist, especially given the role of smoking in causing both cardiac and pulmonary disease. 
No previous study has investigated the prevalence of chronic lung disease in patients with 
suspected heart failure and preserved systolic function. 
8.02 Methods 
A clinical diagnosis of chronic obstructive pulmonary disease (COPD) was defined as either: 
a past medical history of COPD or the prescription of bronchodilators, nebulisers or long term 
oxygen therapy (L TOT). 
In order to further investigate the possibility of misdiagnosis, pulmonary function tests (PFTs) 
were requested in all patients with HF and preserved LV systolic function. The definition of 
COPD on spirometry was an FEV1:FVC ratio less than 70312. 
PFTs were not requested, routinely, in patients with HF-RSF. For this reason, a comparison 
between HF-RSF and HF-PSF was only made using the "clinical" definition of COPD. 
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8.03 Results 
8.03.1 Clinical COPD in HF-RSF and HF-PSF 
Using the "clinical" definition of COPD, a significantly higher proportion of patients with 
HF-PSF had COPD (42%) than patients with HF-RSF (30%) [p=0.02]. 
8.03.2 Pulmonary function tests in HF -PSF 
Nearly half (48%) of patients with HF-PSF had PFTs performed. Table 8.1 compares the key 
baseline characteristics of patients with HF-PSF; comparing those with and without PFTs. 
Most of the baseline characteristics were similar between those who had PFTs completed, 
compared with those who did not. The only exceptions were a greater mean age and higher 
median BNP and NT -proBNP concentrations in those patients for whom PFT data was not 
available. 
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Table 8.1 Clinical characteristics of patients with HF-PSF: PFTs recorded or not 
recorded 
HF-PSF+ HF-PSF + No 
PFTs recorded PFTs recorded 
(n=77) (n=70) 
Female n (%) 50 (65) 47 (67) 
Age (yrs) mean (SD) 73 (9.3) 78 (10.9) 
BNP (pg/ml) median (lQR) 113 (41-274) 259 (95-601) 
NT -proBNP (pg/ml) median (IQR) 2552 (814-7890) 649 (183-2232) 
Creatinine (f.tg/L) median (lQR) 104 (88-119) 104 (89-124) 
eGFR (mllmin) (SD) 55 (16) 53 (18) 
Hb (g/dL) mean (SD) 12.6 (2) 12.4 (2) 
Anaemic n (%) 24 (31) 29 (41) 
Positive troponin n (%) 14 (18) 16 (23) 
SBP (mmHg) mean (SD) 146 (29) 144 (30) 
DBP (mmHg) mean (SD) 77 (18) 80 (17) 
Smokern (%) 20 (26) 14 (20) 
Ex-smoker n (%) 28 (36) 24 (34) 
NYHA class IIIIIV n (%) 35 (45) 29 (41) 
Killip class 2:IIA n (%) 22 (29) 25 (36) 
eGFR = estimate glomerular filtration rate, Hb= haemoglobin gldL, SBP=systolic blood pressure, 
DBP=diastolic blood pressure 
p value 
0.78 
0.01 
0.01 
0.001 
0.76 
0.52 
0.48 
0.19 
0.48 
0.61 
0.23 
0.39 
0.79 
0.62 
0.35 
I also calculated the proportions of patients with normal and abnormal pulmonary function 
tests and whether these patients had a clinical diagnosis of COPD (Table 8.2). 
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Table 8.2 Proportion of patients with HF -PSF and a diagnosis of COPD 
n(%) Abnormal PFTs Normal PFTs 
(n = 27) (n = 50) 
Clinical COPD (n=34) 18 (53) 16 (47) 
No clinical COPD (n=43) 9 (21) 34 (79) 
21% of patients with HF-PSF and no clinical diagnosis ofCOPD had spirometric evidence of 
aitways obstruction. Of these 9 patients, 7 had an elevated BNP concentration. As an 
elevated BNP concentration is known to be a biochemical marker of L V stress, and a sensitive 
marker for the presence of HF, it is unlikely that these patients were misdiagnosed with HF, 
rather that HF and COPD may have co-existed. In the remammg two patients BNP 
concentration was normal. Therefore it is possible that these two patients were incorrectly 
diagnosed with heart failure. 
Table 8.3 Proportion of patients with an elevated BNP 
Elevated BNP concentration n (%) 
Clinical COPD + normal PFTs (n=16) 13 (81) 
Clinical COPD + abnormal PFTs(n=18) 8 (44) 
Any clinical COPD (n=34) 21 (62) 
No clinical COPD + abnormal PFTs (n=9) 7 (78) 
No clinical COPD + normal PFTs(n=34) 20 (59) 
Any abnormal PFTs (n=27) 15 (56) 
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8.03.3 COPD in HF-IPSF 
The HF-IPSF group consisted of patients with a clinical diagnosis of HF (n=86), preserved 
LV systolic function and the absence of either valvular heart disease or atrial fibrillation. Of 
these, 55 had PFTs performed. Of these 55, a clinical diagnosis of COPD was present in 27 
patients. Table 8.4 shows the proportion of patients in each group. 
Table 8.4 Proportion of patients with HF -IPSF and a diagnosis of COPD 
n(%) Abnormal PFTs Normal PFTs 
(n = 18) (n = 37) 
Clinical COPD (n = 27) 15 (56) 12 (44) 
No clinical COPD (n = 28) 3 (11) 25 (89) 
Of the 55 patients with HF-IPSF and PFTs recorded, 29 had an elevated BNP. The proportion 
of patients in each group with an elevated BNP concentration is shown in Table 8.4 
Table 8.5 HF -IPSF: Proportion of patients with an elevated BNP 
Elevated BNP concentration n (%) 
Clinical COPD + normal PFTs (n=12) 9 (75) 
Clinical COPD + abnormal PFTs (n=15) 7 (47) 
Any clinical COPD (n=27) 16 (59) 
No clinical COPD + abnormal PFTs (n=3) 2 (67) 
No clinical COPD + normal PFTs (n=25) 11 (44) ! I 
I 
Any abnormal PFTs (n=18) 9 (50) I 
I 
I 
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8.04 Discussion 
It was intended that all patients with HF-PSF would have PFTs recorded. However, these 
could only be performed in just under half of the patients. The remainder of the patients 
either did not attend for PFTs as an out-patient or were not able to perform the test. A 
comparison of these two groups revealed that those who did not have PFTs performed were 
older and had higher median BNP and NT-proBNP concentrations. This highlights a major 
difficulty in studying this cohort of HF patients, who are very often extremely elderly. 
However, the higher median natriuretic peptides suggests that these patients were perhaps 
more unwell. Clearly, these differences suggest that the group who did have PFTs performed 
were not entirely representative of the HF-PSF group as a whole, However, one could argue 
that the group with the lowest BNP levels is the one where a misdiagnosis of HF is most 
likely, and by examining PFTs in this group I may in fact over- rather than underestimate the 
prevalence of COPD being misdiagnosed as HF. 
It is now well established that COPD does not result in elevated natriuretic peptide 
concentrations99;313-315 and that in clinical situations where they may be a significant overlap 
of symptoms and signs, natriuretic peptide levels are extremely useful for differentiating 
between cardiac and respiratory causes of breathlessness99 . I have therefore examined BNP 
concentrations in those patients with HF-PSF and data from pulmonary function tests, in order 
to examine the interplay between COPD and HF and to determine whether COPD has been 
misdiagnosed in this cohort of patients. 
The first conclusion is that the combined pathology of HF and COPD is common, this 
supports the recent findings of Rutten et ae 16, who reviewed the literature and found that 
although data on the prevalence of HF in COPD and vice versa were scarce, the available data 
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indicated that the two conditions frequently coexisted .. In my study, approximately one-third 
of patients with HF-PSF or HF-IPSF had PFTs revealing COPD and half of these (in each HF 
group) also had an elevated BNP concentration, indicating that COPD and HF coexisted in 
these patients. Of these patients with spirometric evidence of COPD, one-third had no 
clinical diagnosis of COPD. It is therefore likely that COPD is under-diagnosed as a comorbid 
condition in patients with HF. Only 15% of patients with with HF-PSF had PFTs showing 
obstructive airways disease and a normal BNP. In the IPSF group this figure was similar 
(16%). This would suggest that a low proportion of patients had been incorrectly diagnosed 
with HF when in fact COPD was the relevant pathology. 
Conversely the results highlight that HF may well be under-diagnosed in patients thought to 
have COPD. In both the HF-PSF and HF-IPSF groups, the majority of patients with a clinical 
diagnosis of COPD but normal PFTs, had an elevated BNP concentration (81 % and 75% 
respectively). It is therefore likely that these patients have been incorrectly diagnosed with 
COPD, and possible that some will have been prescribed bronchodilators for breathlessness 
when in fact they have HF. 
These results therefore highlight that as clinicians we should be more aware of the possible 
presence of combined pathology, or incorrect diagnosis of COPD in the HF patient. Basic 
spirometry should be a routine investigation for the assessment of the breathless patient, 
regardless of LV function. 
These results also indicate that the use of BNP could appropriately direct the investigation and 
management of the breathless patient. A patient with signs and symptoms of heati failure and 
a normal BNP should have more extensive respiratory investigations. Those patients with 
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HF-PSF and an elevated BNP should have more cardiovascular investigations. However, 
spirometry should be routine, in order to exclude dual pathology, as it is likely that those 
patients in whom HF and COPD coexist may present complex management issues, and may 
perhaps benefit from joint care from both cardiology and respiratory physicians. 
In summary, the goal of this analysis was to address one of the main controversies 
surrounding HF-PSF, namely that patients may be misdiagnosed with HF, when in fact they 
have other pathologies, such as COPD. In fact, these data would suggest the reverse. A low 
proportion of patients with either HF-PSF or HF-IPSF had both abnormal PFTs and a normal 
BNP, indicating misdiagnosis. On the contrary, a significant majority of patients who had 
been diagnosed with (and in some cases treated for) COPD, had normal PFTs but elevated 
BNP levels, indicating that their HF had been misdiagnosed as COPD. This finding has 
enormous relevance to clinical practice, and it is clear that the interplay between COPD and 
HF is one which requires further investigation, to ensure accurate diagnosis and treatment for 
these two common and important conditions. 
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9.01 Introduction 
Clinical trials have shown that the case fatality related to HF is high, but has been 
significantly improved by the use of angiotensin-converting-enzyme (ACE) inhibitors and 
more recently ~_blockers317;318. However, such studies have tended to preferentially enrol 
middle-aged men. Many patients with HF are elderly, and many with HF-PSF are female. 
The prognosis in these patients has been less well studied. This study therefore had looked at 
mortality in this cohort of patients. 
9.02 RESULTS 
9.02.01 Unadjusted case fatality from life tables 
Table 9.1 shows 30 day and one, two and three-year unadjusted case fatality rates. For all 
individuals with HF these were 6.8%, 39.7% and 46.5%. When all HF was dichotomised to 
HF-RSF and HF-PSF the 30 day, one, two and three-year unadjusted case fatality was 8.7%, 
32.2%, 47.2% and 57.7% respectively for HF-RSF, and 4.78%, 21.1%, 32.9% and 37% 
respectively for HF-PSF. The differences in the case fatality rate were statistically significant. 
Prognosis was poor following an admission for HF-RSF. The case fatality was almost 50% at 
2 years. In the HF-PSF group, rates were lower but remained substantial at nearly 40% 
mortality after three years. 
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Table 9.1 Case fatality for HF-RSF and HF-PSF 
HF-RSF HF-PSF All Heart Failure 
Case 95%CI Case 95%CI Case 95%CI 
fatality fatality fatality % 
% % 
30 Day 8.7 8.68 8.77 4.73 4.7 4.8 6.76 6.73 6.79 
1 year 32.2 32.14 32.3 21.02 21.02 21.2 27.03 26.98 27.08 
2 year 47.9 47.78 47.9 32.84 32.8 32.9 39.71 39.66 39.77 
3 year 57.7 57.61 57.8 37.02 37.02 37.2 46.49 46.43 46.55 
9.02.02 Median survival 
Survival time was calculated from recruitment date to date of death or censoring, which took 
place on 1st March 2006. Maximum follow-up was 39 months. Kaplan-Meier analysis was 
used to determine the median survival, which was calculated only if 50% of individuals had 
died at the censor date. 
The median survival for all individuals with HF was greater than 1228 days (50% had not 
died by the censor date). The median survival for HF-RSF was 824 days (95% CI 547.27 -
1100.73) and for HF-PSF the median survival was greater than 1228 days (again, 50% had not 
died by the censor date). 
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8.02.03 Kaplan-Meier survival curves for HF-RSF and HF-PSF 
A detailed description of the statistical analysis is given in Chapter 2. Unadjusted Kaplan-
Meier curves for all-cause mortality demonstrated a significant difference in survival between 
the HF-RSF and HF-PSF groups (log rank test p = 0.001) (see Figure 9.1). 
Figure 9.1 
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9.02.04 Multivariate analysis 
Multivariate analysis was carried out using a Cox proportional hazards regression model. 
Variables were entered into the regression model based on the CHARM model for predictors 
of mortality. Not all variables from the CHARM model were available in this study174. 
The following variables were entered: smoking, age, gender (male vs. female), estimated 
glomerular filtration rate (eGFR), haemoglobin (Hb), heart rate (HR), atrial fibrillation (AP), 
diabetes mellitus (DM), hypercholesterolemia, peripheral arterial disease (PAD), 
cerebrovascular disease (CVD), ischaemic heart disease (IHD), chronic obstructive 
pulmonary disease (COPD), NYHA class, presence of bundle branch block (BBB), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), BNP and HF group (RSF or PSF). 
Table 9.2 summarises the results. 
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Figure 9.2 Final multivariate model for all-cause mor tality based on a Cox regression 
analysis 
Variable Hazard Ratio 95%CI P value 
Smoker 1.221 0.770 - 1.935 0.397 
Age (yrs)* 1.032 1.008 - 1.057 0.009 
eGFR (mllmin/m2) * 0.985 0.972 - 0.998 0.022 
Hb (gldl)* 1.010 0.917-1.112 0.847 
HR (beats per min)* 1.001 0.993 - 1.010 0.761 
AF 1.405 0.907 - 2.177 0.128 
DM 1.263 0.808 - 1.974 0.305 
Hypercholesterolaemia 0.953 0.619 - 1.466 0.826 
PAD 0.985 0.505 - 1.918 0.965 
COPD 1.619 1.099 - 2.386 0.015 
IHD 1.048 0.714 - 1.539 0.811 
CVD 0.787 0.494 - 1.256 0.316 
HF Group (PSF v RSF) 0.899 0.592 - 1.366 0.619 
NYHA class III t 1.131 0.732 - 1.747 0.579 
NYHA class IV t 2.134 1.356 - 3.359 0.001 
Bundle branch block 1.874 1.247 - 2.818 0.003 
SBP (mmHg)* 0.990 0.982 - 0.998 0.018 
DBP(mmHg)* 1.002 0.986 - 1.017 0.846 
BNP (lOOpglml)* 1.045 1.017 - 1.075 0.002 
Sex (male v Female) 1.153 0.793 - 1.676 0.457 
* fitted as continuous variables 
t compared to class I and class II combined 
After adjusting for the variables in the Cox regression model; age, eGFR, presence of COPD, 
NYHA class IV HF, presence of bundle branch block, SBP and BNP were found to be 
independent predictors of mortality. The presence of a higher eGFR and systolic blood 
pressure at the time of admission was associated with a better outcome in this population. 
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Increasing age, the presence of COPD, any bundle branch block, or higher BNP 
concentrations on admission were associated with a poor prognosis. In this study, for every 
100 unit increase in BNP there was a 4% increase in risk of death. The presence of NHY A 
class IV HF was also an independent predictor of mortality in this group. 
No other variables within the model independently predicted mortality after multivariate 
analysis. This included the distinction between reduced and preserved systolic function. 
Although the Kaplan-Meier plots separate and show a significant mortality difference 
between the two groups, this is a univariate analysis, which does not take into account the 
distributions of other variables within the two groups. When these different distributions 
were adjusted for, by entering them into a Cox proportional hazard regression model, there 
was no significant difference in mortality between the two groups. 
9.3 Discussion 
It is now established that HF-RSF is a significant escalating public health problem in terms of 
mortality, morbidity and consequent economic cost. Studies such as the Euroheart Failure 
Survey177 revealed that almost 50% of the 6000 patients studied had HF-PSF and 
consequently the medical community is beginning to appreciate that HF-PSF has similar 
implications in terms of mortality, morbidity and economic cost. 
The 3-year unadjusted case fatality in this study confirmed findings from several recent 
studies (published after this study was started) that mortality in HF-RSF (58%) was worse 
than HF-PSF (37%). However, mortality in both groups was poor. The Helsinki Ageing 
Study reported four year mortality rates, 54% for HF-RSF and 43% for HF_PSF40. 
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These figures are similar to the overall five-year mortality rate of 65% in the Olmsted County 
incidence study19. In this study, the age and gender-adjusted mortality rates in those with HF 
were higher than those without HF. However, there was no significant difference in mortality 
between patients with PSF and those with RSF. Data published recently after the completion 
of this study reported mortality rates of 65% and 68% for HF-PSF and HF-RSF respectively 
at five years178. 
Patients with HF-RSF in the Framingham study had an annual mortality rate of 18.9% 
compared with 4.1 % in age and gender-matched controls over 6.2 years. Framingham 
patients with HF-PSF had an annual mortality rate of 8.7% compared with 3% in their 
controls. Hospital cohort studies show that patients with HF-PSF have better survival at all 
time points from admission compared with HF-RSF. However, patients with HF-PSF still 
have a high mortality following admission to hospital, with rates of 40-50% after four to five 
years of follow-up8. In that study median survival for all HF was greater than 3.4 years and 
for HF-RSF was 2.3 years. This is better than the median survival reported by McIntyre et al 
in a Scottish cohort of HF patients from 1896-1995. The median survival in this cohort was 
1.5 years319. This indicates a small improvement in the prognosis for HF patients which may 
be due to the use of evidence-based medical therapy ACE-I, ARBs, aldosterone antagonists 
and ~-blockers 
Kaplan-Meier curves for HF-RSF and HF-PSF show a significant difference in mortality 
between the two groups. However, after multivariate analysis using a Cox proportional 
hazards model, classification of HF as HF-RSF or HF-PSF was not an independent predictor 
of survival. The difference in survival suggested by Kaplan-Meier analysis must therefore be 
explained by the differing distributions of variables between the two groups. 
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In this cohort of HF patients, independent predictors of death were: increasing age; eGFR, 
presence of chronic obstructive airways disease, NYHA IV HF, the presence of any bundle 
branch block, lower systolic blood pressure, and higher BNP concentrations. Better renal 
function and higher systolic blood pressure at the time of admission was correlated with 
improved survival. Increasing age, the presence of chronic obstructive airways disease, 
NYHA class IV HF, any bundle branch block and higher BNP concentrations were correlated 
with increased mortality. It should be noted that, this assessment of predictors of mortality is 
limited in that we could not adjust for ejection fraction in the multivariate analysis. 
In this cohort of HF patients, after adjustment for potentially confounding variables, there was 
no significant difference in mortality between HF-RSF and HF-PSF. This reflects a Canadian 
study published recently. Bhatia et at reported that patients with HF-PSF had high 30-day 
and I-year mortality rates that were not significantly lower than those of patients with HF-
RSF with or without adjustment for clinical differences between the two groupS179. This 
study showed that every 100 unit increase in BNP was associated with a 5% increase in risk 
of death. Kirk et at published data after the completion of this study demonstrating that a 
significantly higher NT -proBNP concentration was found in those patients who did not 
survive 12 months from the time of testing. In that study, NT-proBNP was found to be a 
strong prognostic predictor of mortality regardless of systolic function197. Importantly, recent 
data suggest that mortality may be reduced in patients in whom NT -proBNP or BNP levels 
fall during medical treatment for HF320. Previous studies have shown that BNP independently 
predicts morbidity and mortality in asymptomatic reduced LV systolic function and in mild to 
moderate HF_RSF104;195;196. In addition, BNP has been shown to be a strong and independent 
predictor of sudden cardiac death in patients with HF107. 
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This study has shown that despite advances in the treatment of HF the prognosis is still poor. 
In addition it has provided evidence that like patients with HF-RSF, patients with HF-PSF 
have a similarly poor prognosis. 
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HF is recognised as a major public health problem1;2 particularly in view of the fact that the 
population is ageing. In the UK the prevalence of HF is more than 100 cases per 1,000 
population, in those aged 65 years and older. HF is also a significant economic burden, 
accounting for 2% of the UK NHS budget3. There has been growing interest in HF-PSF over 
the past decade, and epidemiological studies have suggested that 13-74% of patients with 
clinical HF have preserved LV systolic function 12. There has been growing interest in HF-
PSF over the past decade, and epidemiological studies have suggested that 13-74% of patients 
with clinical HF have preserved LV systolic function24;26;31 ;32. If approximately 40% of 
patients hospitalised with HF have PSF then approximately 40% of the overall cost of treating 
HF is due to HF-PSF. As well as representing a significant economic burden, this patient 
group has a poor prognosis. Reported mortality rates vary widely. The consensus from 
several studies however, is that mortality in patients with HF-PSF is better than those with 
HF -RSF but is poor compared to patients without heart failure8;41. As outlined in Chapter 1, 
there has been little evidence collected regarding clinical characteristics of patients with HF-
PSF, particularly with regard to variables which may yield insights into the pathophysiology 
ofHF-PSF. Also, outcome data for patients hospitalised with HF-PSF was scarce. 
This study has examined in detail the clinical, echo cardiographic and biochemical 
characteristics of patients admitted with heart failure on an emergency basis. The 
characteristics of patients with HF-PSF have been compared to those of patients with HF-
RSF, with the aim of identifying important characteristics shared between the two groups and 
those characteristics which may be particularly common in HF-PSF. The subsequent clinical 
outcomes of these patients have also been documented, and the variables independently 
associated with an increased risk of death in this cohort have been determined through 
statistical analysis. 
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I. 
Of the total number of patients with clinical HF who agreed to enter the study, approximately 
half had preserved systolic function. As described in Chapter 1, prior to commencement of 
this study there was a wide variation in the estimated prevalence of HF-PSF, partly due to 
heterogeneity in sample size and patient selection. Since then, a large retrospective study has 
examined patients with a diagnosis of HF and an objective assessment of L VEF over a 15 
year period178 and found the prevalence of HF-PSF to be 47%, comparable to the proportion 
found in my study. 
However, the main drawback in examining the literature as regards prevalence ofHF-PSF is 
the lack of a single agreed definition for preserved, as distinct from reduced ejection fraction. 
The practice of many studies, including the recent analysis by Owan et aZ l78 has been to use a 
numerical ejection fraction obtained by anyone of a number of methods (echocardiography, 
radionuclide imaging, cardiac catheterisation). Normal ranges for ejection fraction differ 
according to the method of measurement, meaning that it may not be valid to compare 
percentage ejection fractions obtained by different methods. 
In my study, systolic function was determined to be either reduced or preserved from 
echocardiographic images by a single experienced operator, an approach which is qualitative 
and therefore has inherent disadvantages. However, these are minimised by use of a single 
technique and single operator. Given that there is no gold standard method for determination 
of ejection fraction in this context, or agreed cut-off for preserved ejection fraction, I think it 
is reasonable to compare my findings with those from the other studies cited, and conclude 
that HF-PSF does indeed account for around half of all cases of clinical HF. 
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With regard to clinical characteristics, there were some notable differences between HF-RSF 
and HF-PSF. The main demographic difference was that a higher proportion of patients in the 
HF-PSF group were female, a fmding similar to those in previous studies, described in 
Chapter 1. This finding has also been borne out by the long-term prevalence studied 
published recently by Owan et al178 and a more recent report of contemporary patients 179. 
Indeed, this fmding is becoming well established in the literature as a characteristic of HF-
PSF13. This may, in part reflect the increased prevalence of coronary artery disease in men, 
which may well be expected to predispose them to reduced, rather than preserved systolic 
function heart failure. It may also be related, as discussed in Chapter 3, to an interaction 
between age, sex and the incidence of hypertension. 
Hypertension is now recognised to be an important risk factor for the deVelopment of HF-
PSF, and this is supported by the findings of my study, in which a higher proportion of 
patients with HF-PSF had a history of hypertension. Patterns of other important co-morbid 
diseases were similar to those in recent studies I78;179, with the notable exception of atrial 
fibrillation (AF), the prevalence of which was not significantly different between the two 
groups in my study, but has been found to be greater in the HF-PSF groups of both Owan et 
al and Bhatia et al. The reasons for this discrepancy are not clear. The proportions of patients 
with AF in the groups with reduced systolic function are comparable across all three studies 
(29%178,25%179 and 30% in my study). Indeed, an increased incidence of AF in HF-PSF may 
be expected as AF can be both a cause and consequence ofHF-PSF. 
In telms of their symptoms and signs, patients in the HF-RSF group were more likely to 
report moderate to severe symptoms of HF (i.e. NYHA IIVIV). However, severity of HF on 
admission, as assessed by the Killip score was at least moderate (Killip 2:IIa) in the majority 
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of patients in both groups. This is another area where the results from this study have 
improved our understanding of HF-PSF. Prior to starting this study, when there was 
controversy surrounding HF-PSF, it was generally perceived to be a condition which 
produced mild symptoms and signs. Recent evidence agrees with my own findings that this is 
not the case l79 . 
The debate surrounding HF-PSF also focused on whether symptoms and signs of heart failure 
in the absence of impairment of L V systolic function were merely a consequence of other 
comorbid pathologies. There are clearly other cardiac pathologies which can produce 
symptoms and signs of heart failure, for example, valvular heart disease or atrial fibrillation. 
Of my patients with HF-PSF, 41% had VD, AF or both. I have referred to the group without 
VD or AF as HF-IPSF. HF-IPSF accounted for approximately one-third of admissions with 
clinical HF. This definition is not one which is commonly found in the heart failure literature. 
However, I felt it was extremely important to make this distinction, in order to clearly define a 
group of patients with HF-PSF for whom there was no other clear explanation for their 
symptoms and signs. 
Clearly the clUcial question is: did all the patients in the HF-IPSF group in this study really 
have heart failure? They all had symptoms and signs compatible with a diagnosis of heart 
failure, and therefore scored positively on objective heart failure scoring systems. In addition, 
just over half had elevated natriuretic peptide levels, strongly indicating that heart failure was 
present, and certainly meeting modern definitions for the diagnosis heart failure. 
Examining the findings of this study helps to clarify the roles of diagnostic tools in HF. 
Natriuretic peptides accurately predicted both systolic function and prognosis, but simple 
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echocardiographic measures failed to reliably detect diastolic dysfunction. Although 
echo cardiography is essential for the identification of reduced systolic function and other 
cardiac pathology, at the current time routine echocardiography alone cannot exclude the 
diagnosis of HF. I would therefore propose that in a patient with suspected HF, 
echo cardiography and natriuretic peptide testing should be employed to determine 
independently whether there is LV systolic dysfunction or biochemical evidence of LV 
compromise. These diagnostic tests should be regarded as complementary to one another, and 
both should be required for accurate diagnosis and classification of heart failure. 
It has been suggested that, in many cases, the syndrome of HF-PSF has resulted from 
misdiagnosis of heart failure, when the primary pathology is quite separate. Chronic 
obstructive pulmonary disease (COPD) is a common condition which can produce symptoms 
and signs similar to or indistinguishable from those produced by heart failure. The findings 
from this study suggest that only a small proportion of patients with a clinical diagnosis of 
HF-PSF have COPD but not heart failure (on the basis of a normal BNP and PFTs diagnostic 
of COPD). Interestingly, in the HF-PSF group a significant proportion of patients who had a 
clinical diagnosis of COPD prior to admission actually had normal PFTs but an elevated 
BNP, indicative of the fact that their heart failure may have been previously misdiagnosed as 
COPD. 
Clearly, COPD also exists as a comorbid condition in patients with HF, and despite the fact 
both are extremely common there are no studies to date that have specifically assessed the 
incidence of COPD in HF316. This study has shown, perhaps not surprisingly that the 
presence of COPD is an independent predictor of death in patients with HF. Not only is 
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COPD a serious comorbidity, but it can also limit scope for treatment with P-blockers, both of 
which could account for the increased mortality seen in this group of HF patients. 
The relationship between HF and COPD is likely to be complex, and it is clear that COPD 
presents both a diagnostic and therapeutic challenge in HF management. It is possible that the 
use of combinations of echocardiography, BNP, pulmonary function testing and cardiac 
magnetic resonance imaging may provide more detailed information regarding the importance 
ofCOPD in HF and in particular, in HF-PSF. 
Considering the above discussion, I would regard the first major finding ofthis study to be the 
fact that a significant proportion of acute heart failure admissions, as defined by HF scores 
and BNP levels, occur in the context of preserved left ventricular ejection fraction. 
Having established that HF-PSF indeed exists, and accounts for a number of HF admissions, 
the next major finding of my study is that the prognosis associated with this condition is poor. 
The unadjusted Kaplan-Meier curves for HF-RSF and HF-PSF showed a significant 
difference in mortality between the two groups. However, after adjustment using a 
multivariate Cox regression analysis, there was no significant difference in survival between 
the two types of heart failure. 
Therefore, both types of HF have a poor prognosis. If we consider case fatality, almost 50% 
of those with HF-RSF were dead at two years, and almost 40% of the HF-PSF group were 
dead after three years. Patients with HF-RSF and HF-PSF therefore have similar mortality 
but, unlike the former, no evidence-based treatment is available for the latter. 
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The only large randomised controlled trial to examine the effects of drug treatment on the 
prognosis of patients with HF-PSF published to date is the Candesartan in Heart failure 
Assessment of Reduction in Morbidity and mortality (CHARM) Programme. The CHARM-
Preserved component study enrolled 3023 patients with NYHA II-IV HF and L VEF > 40% 
and randomised them to candesartan or placebo. After a median follow-up of 36.6 months the 
authors observed no difference in the primary endpoint (cardiovascular death or admission to 
hospital for HF) but showed a reduction in hospital admissions for HF in the group treated 
with candesartan 183 • 
Although there was no mortality benefit demonstrated in CHARM-Preserved, the result does 
suggest that blockade of the RAAS is of some clinical benefit in patients with HF -PSF. This 
study looked at renin and aldosterone measurements, in an attempt to explore possible 
aetiological factors in HF-PSF. Difficulties due, primarily, to the confounding effect of 
medications have precluded significant conclusions being drawn regarding the role of RAAS 
activation in this group of patients. However, the argument remains a convincing one: RAAS 
over-activation promotes fibrosis and hypertrophy which can lead to a reduction in ventricular 
compliance and abnormalities in diastolic function, producing the clinical syndrome ofHF, in 
the absence of abnormalities in systolic function. There is therefore a plausible potential 
explanation for the effect of candesartan in CHARM-Preserved, and this area is one which 
should be a focus for future research, both in terms of focused large-scale clinical trials and of 
mechanistic work. 
This study has detailed the clinical, echocardiographic and biochemical characteristics of 
patients with HF-PSF. I have shown that approximately half of the patients admitted on an 
emergency basis with HF had preserved systolic function. Many of these patients may have 
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had other causes for their symptoms and signs of HF. I have therefore characterised a group 
of patients who did not have VHD or AF as a possible cause for their symptoms. I propose 
that in this group (HF-IPSF), it is those with biochemical evidence of LV compromise that 
may be said to have heart failure with preserved systolic function. 
Further investigation of this patient group is required in order to advance our understanding of 
the pathophysiology of the disease process, and to establish how best to treat these patients. 
For future studies, the definition ofHF-PSF needs to be carefully considered. It is my feeling 
that a contemporary diagnosis of heart failure should include clinical signs and symptoms of 
heart failure, echo cardiographic evidence of preserved LV systolic function and an elevated 
BNP or NT -proBNP concentration as biochemical evidence of LV compromise. 
Newer imaging techniques such as tissue Doppler echo cardiography and cardiac MRI are less 
influenced by the haemodynamic loading conditions, and may therefore become useful in the 
future as diagnostic tools. However, decisions will still need to be made regarding the 
appropriate criteria for establishing diastolic dysfunction. 
One of the many questions that remains unanswered is that regarding the significance of 
underlying ischaemia. Coronary angiography is the gold standard for assessment of coronary 
arteries however, it is an invasive investigation with potential risks to the patient, particularly 
in the elderly. Cardiac MRI with gadolinium enhancement would allow for the assessment of 
ischaemia in a non-invasive manner. Similarly, CT coronary angiography may become a 
more widely utilised diagnostic tool for the assessment of coronary arterial stenosis, 
particularly in patients where the risk: benefit ratio of coronary angiography is unfavourable. 
Increased use of these non-invasive tools may therefore be a means of progressing our 
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knowledge regarding the underlying pathophysiology of heart failure with preserved systolic 
function. 
Importantly, this HF cohort needs to be included in more large-scale prospective clinical 
trials, in order to establish a successful treatment strategy. In addition to CHARM-
PRESERVED and Perindopril for Elderly People with Chronic Heart Failure (PEP-CHF), 
further studies ofRAAS inhibition such as Irbesartan in Heart Failure with Preserved Systolic 
Function (I-PRESERVE), and the Trial of Aldosterone Antagonist Therapy in Adults with 
Preserved Ejection Fraction Congestive Heart Failure (TOP CAT) may begin to answer this 
question. 
Further investigation of the pathophysiology and determination of the optimal treatment 
strategy are imperative, because, as demonstrated by this study, HF with preserved systolic 
function is common and carries a significant burden in terms of mortality and socio-economic 
cost. 
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Appendix 1- Patient information sheet and consent form 
THIS SHEET HAS BEEN APPROVED BY THE WEST ETHICS COMMITTEE 
INFORMATION SHEET FOR PATIENTSNOLUNTEERS IN CLINICAL RESEARCH 
PROJECT 
Brief Title of Project 
Characterisation of patients with heart failure despite preserved left ventricular systolic 
function: A prospective, descriptive, cohort study. 
Patient's Summary (Purpose of study, nature of procedure, discomfort and possible risks in terms 
which the patient or volunteer can understand). 
You are invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you wish. 
Ask if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
This study is about a condition called "heart failure". Heart failure causes 
breathlessness, fatigue and swollen ankles and occurs when the heart does not pump 
normally. There are two main kinds of heart failure, one where the main muscular 
pump of the heart is weakened and the other where it is not. The aim of this study is to 
describe the nature of the second type of heart failure and its outcome. This will be 
done by assessing patients who present as an emergency to hospital with possible heart 
failure. This study may eventually allow us to develop treatments to improve outcome. 
We will be recruiting patients into this study for eighteen months and each patient will 
be followed up in the study for at least one year. 
You have been chosen for this study because you presented to hospital with symptoms 
which could be due to heart failure. However, we know that many patients will turn 
out to have another explanation for their symptoms ego a lung problem. We are 
hoping to recruit 700 patients over an eighteen month period into this study. It is up to 
you to decide whether or not to take part. If you do decide to take part you will be 
given the information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free at any time to withdraw without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care that you receive. 
If you decide to take part in this study we will seek your permission to do 5 things: 
1 To ask you a series of questions about your health and the symptoms that led to your 
hospital admission. 
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2 To examine you (focusing mainly on your heart and lungs). 
3 To take an extra blood sample. We need about 20 millilitres (or about 4 teaspoonfuls). 
Taking this amount of blood should not be harmful. We wish to measure a number of 
substances that are increased in the blood if the heart is damaged or not pumping 
properly. Having blood taken may be uncomfortable and can leave minor bruising. 
All of 1-3 should not take more than one hour 
4 To collect the results of all the other routine tests you will have carried out during and 
after your hospital admission. Usually, these will include an ECG tracing, a chest x-
ray, a heart ultrasound scan (echo cardiogram), breathing tests, a treadmill exercise test 
and so on. We wish to collect all this information so as to have a complete picture of 
what might have caused your symptoms and hospital admission. 
5 To follow your progress over the next year after discharge from hospital. We would 
like to do this in person (by telephoning you), through your hospital records and 
through national records (eg. the NHS system that identifies all hospital admissions). 
This is in order to see what happens to patients like yourself with this type of medical 
problem. 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then 
you may have grounds for a legal action but you may have to pay for it. Regardless of 
this, if you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms are available to you. 
All infOlmation which is collected about you during the course of the research will be 
kept strictly confidential. Any medical information from the study about you which 
leaves the hospital will have your name and address removed so that you cannot be 
recognised from it. The results from this study will be kept on a hospital computer 
data base and may be used in the future. The results are also likely to be published in 
national cardiology journals. 
It should be noted that your participation in this study may not be of direct benefit to 
you, but could help in the development of treatment for the benefit of future patients. 
If you do not wish to participate in this study, or wish to withdraw at any time after 
commencing the trial, your care will in no way be affected. 
If you wish to take part in this study, your General Practitioner will be advised of your 
participation and the clinical management that you will undergo. 
This proposal has been reviewed by the West Glasgow's Research and Ethics 
Committee. Should you require any further information then you can contact Dr 
Karen Hogg (page 4244) through the Western Infirmary switchboard (0141-211-
2000). 
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WEST ETHICS COMMITTEE 
FORM OF CONSENT FOR PATIENTSNOLUNTEERS IN CLINICAL RESEARCH 
PROJECT 
Title of Project: 
Characterisation of patients with heart failure despite preserved left ventricular systolic 
function: A prospective, descriptive, cohort study 
By signing this form you give consent to your participation in the project whose title is at the 
top of this page. You should have been given a complete explanation of the project to your 
satisfaction and have been given the opportunity to ask questions. You should have been 
given a copy of the patient information sheet approved by the West Ethics Committee to 
read and to keep. Even though you have agreed to take part in the research procedures you 
may withdraw this consent at any time without the need to explain why and without any 
prejudice to your care. 
Consent: 
I, ...................................................................................................................... (PRINT) 
of ..................................................................................................................... . 
give my consent to the research procedures above, the nature, purpose and possible 
consequences 
of which have been described to me 
by ..................................................................................................................... . 
Patient's signature ............................................................. Date ...................... . 
Doctor's signature ............................................................................................ . 
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Appendix 2: Heart Failure Scores 
BOSTON CRITERIA FOR HEART FAILURE 
mSTORY: 
SOB* AT REST D 4 
ORTHOPNOEA D 4 
PND D 3 
SOB* ON EXERTION (Level) D 2 
SOB* ON CLIMBING D 1 
PHYSICAL EXAMINATION: 
Heart rate (91-110 bpm) D 1 
Heart rate (> 11 0 bpm) D 2 
ELEV ATED JVPt > 6CMS D 2 
JVPt > 6CMS + HEPATOMEGAL Y / OEDEMA D 3 
BASAL CREPS D 1 
> BASAL CREPS D 2 
WHEEZE D 3 
S3 GALLOP D 3 
CXR: 
ALVEOLAR PULMONARY OEDEMA D 4 
INTERSTIAL PULMONARY OEDEMA D 3 
BILATERAL PLEURAL EFFUSION D 3 
CARDIOTHORACIC RATIO> 0.5 D 3 
UPPER ZONE FLOW REDISTRIBUTION D 2 
* shortness of breath 
t jugular venous pressure 
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Boston Heart Failure Score: 
Maximum of 4 points from each section 
0-4 = No heart failure 
5-7 = possible heart failure 
8-12 = Definite heart failure 
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NHANESSCORE 
HISTORY: 
SOB* when hurrying on the level or up slight hill I- 1 '-II 
SOB* when walking at ordinary pace on the level I- 1 '-II 
Do you stop for breath when walking at own pace .. 2 '-II 
Do you stop for breath after 100 yards on the level I- 2 '-II 
PHYSICAL EXAMINATION: 
Heart rate 91-110 .. 1 '-II 
Heart rate> 110 .. 2 '-II 
Basal crepitations I- 1 '-II 
> Basal crepitations I- 2 '-II 
Raised NPt l- I '-II 
Raised JVPt & oedema / hepatomegaly I- 2 '-II 
CXR: 
Upper lobe diversion l- I ~ 
Interstitial oedema I- 2 ~ 
Alveolar fluid & pleural fluid I- 3 ~ 
Interstitial oedema & pleural fluid I- 3 '-II 
HF PRESENT IF SCORE > 3 
* shortness of breath 
t jugular venous pressure 
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FRAMINGHAM CRITERIA 
Framingham Criteria for Heart Failure 
2 major criteria, or 1 major criteria and 2 minor criteria 
Major Criteria 
Paroxysmal nocturnal dyspnoea 
Neck vein distention 
Rales 
Radiographic cardiomegaly 
Acute pulmonary oedema 
Third heart sound 
Increased central venous pressure 
Circulation time >24secs 
Hepatojugular reflex 
Pulmonary oedema, visceral congestion, or cardiomegaly at autosy 
Weight loss>4.5kg in response to treatment of CHF 
Minor Criteria 
Bilateral ankle oedema 
Nocturnal cough 
Dyspnea on ordinary exertion 
Hepatomegaly 
Pleural effusion 
Decrease in vital capacity by 33% from maximal value recorded 
tachycardia (rate .120beats per minute) 
HF = 2 major criteria or 1 major + 2 minor criteria 
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Appendix 3 : Case record forms 
ADMISSION DATE: ADMITTING CONSULTANT: 
NAME: MAIDEN NAME: 
D.OB: HOSPNo: 
AGE: CHINO: 
SEX: GPDETAILS: 
I 
MARITAL STATUS: ETHNIC ORIGIN: 
I 
: 
ADDRESS: TELEPHONE NO: ! 
NEXT OF KIN: MOBILE NO: I 
I 
OTHER CONTACT NO: 
OCCUPATION: FORMER OCCUPATION: 
HT: TRANSFERRED TO WARD: 
WT: DISCHARGE DATE: 
ALCOHOL UNITS / WK: DATE OF DEATH: 
c--
SMOKING HISTORY: NO EX+ YES NO/ YEARS 
DATE DAY 
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PATIENT HISTORY - Cardiac symptoms 
NO YES 
SOB I II IIA lIB III IV 
(post Admission) 
Killip Classifcation 
SOB NYHAI NYHAII NYHA NYHAIV 
(Normally) III 
PND 
--
ORTHOPNOEA 
NOCTURAL 
COUGH 
COUGH 
SPUTUM AMOUNT COLOUR WORSE 
TIME 
HAEMOPTYSIS AMOUNT TIMES/DAY ADMISSTI 
ONS 
WHEEZE 
tEXERCISE 
TOLERANCE 
ANKLE 
SWELLING 
CHEST PAIN 
PALPITATIONS 
GENFATIGUE 
LEG FATIGUE 
WTLOSS 
INTERMITTENT <200YRDS >200YARDS 
CLAUDICATION 
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KlLLIP CLASSIFICATION: I No Symps with normal activities, clear lungs 
II Normal activities initiate symps, but subside with rest 
IIA crackles < 1/3 lIB crackles> 113 
III Symps on minimal activity or rest / pulmonary oedema 
IV Cardiogenic Shock 
NYHA CLASSIFICATION: I Normal daily activity does not initiate symps 
II Normal activity initiates symps but subside with rest 
III Minimal activity initiates symps ; patient usually symp free at rest 
IV Any type of activity initiates symps and symps are present at rest 
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PAST MEDICAL HISTORY- Cardiovascular (1) 
PASTMED DK NO YES 
: HX 
Known valve AS AI MR MS 
disease 
T M M S T M M S T M M S T M M S 
0 0 0 0 
d d d d , 
Previous AORTIC DATE MITRAL DATE 
valve replacement 
I 
I 
I 
I 
I 
Myocardial VERIFIED NON-VERIFIED I 
infarction I 
Angina VERIFIED NON-VERIFIED 
ANGIOIETT 
Previous CABG DATE: 
Previous DATE: 
angioplasty 
Prior heart failure HOSPITALDX GPDX 
Hypertension On Admission Previous Treated 
I High cholesterol On Admission Previous Treated 
, 
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PAST MEDICAL HISTORY- Cardiovascular (2) 
PMHX DK NO YES 
Previous stroke 
Previous TIA 
I 
Previous carotid RESULT: 
doppler 
Previous 
endarterectomy I I 
PVD Clinic Angio Other Ix AngiopJasty Surgery I 
Proven previous AF ATRIAL FLUTTER SVT OTHER 
arrhythmia 
I 
I 
! 
Cardiomyopathy DILATED HYPERTROPHIC RESTRICTIVE 
Diabetes INSULIN NON-INSULIN DIET 
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PAST MEDICAL HISTORY- General (1) 
PMHX DK NO YES 
COPD RESP Consultant NO 
CLINIC 
Asthma RESP Consultant NO 
CLINIC 
Bronchiectasis RESP Consultaut NO 
CLINIC 
Post TB respiratory RESP Consultant NO 
disease CLINIC 
Asbestosis RESP Consultant NO 
CLINIC 
Pleural plaques RESP 
CLINIC 
Consultant NO 
Pulmonary fibrosis RESP Consultant NO 
CLINIC 
Other respiratory RESP Consultant NO 
disease CLINIC 
Amyloidosis 
Sarcoidosis 
Haemochromatosis 
Rheumatoid 
Arthritis 
SLE 
Sjogrens 
Raynauds 
Systemic Sclerosis 
Other CT Disease 
_ .. _-_ .. _ .. - -----
---_ .. - -- --- - -- - --- -- - .. -
- -
. 
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PAST MEDICAL HISTORY-General (2) 
PMHX DK NO YES 
Anaemia Investigations Known Cause Treated 
Renal failure Clinic Dialysis Transplant 
Renal artery 
stenosis 
Thyroid disease Hyper Hypo Treated 
Prostatic disease Benign Malignant Treated 
Parkinsonism 
Multiple Sclerosis 
Motor Neurone 
Disease 
Muscular 
Dystrophy 
Osteoporosis 
Obesity Clinic Medication Surgery 
Anxiety 
Other 
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DRUG HISTORY - Cardiovascular (1) 
DRUG CLASS DRUG NAME NO YES DOSE 
ANTI- Aspirin 
PLATELET 
Clopidogrel 
CARDIAC Digoxin 
GLYCOSIDE 
DIURETIC Frusemide 
Other loop diuretic 
Spironolactone 
Amiloride 
Bendrofluazide 
Bumetanide 
Metolazone 
Indapamide 
Co-amilofruse 
Acetazolamide 
Other Diuretic 
P-BLOCKER Atenolol 
Bisoprolol 
Carvedilolol 
Metoprolol 
Propranolol I 
Labetalol I 
Sotalol 
Other 
ACE Ramipril 
IINHffiITOR 
Lisinopril 
Captopril 
Enalapril 
Trandolopril 
Fosinopril 
Perindopril 
Quinapril 
267 
DRUG HISTORY - Cardiovascular (2) 
NO YES DOSE 
VASODILATORS Nitrates 
Hydralazine 
Minoxidil 
GTNSpray 
Other 
ALPHA- Prostate Hyptertension 
BLOCKERS 
ARB Losartan 
Candesartan 
ANTI-
ARRHYTHMICS 
Class I Flecainide 
Propafenone 
Quinidine 
Disopyramide 
Class II B-Blockers 
Class III Amiodarone 
Sotalol 
Class IV Ca Channel Blockers -
Verapamil 
Diltiazem 
STATIN Pravastatin 
Simvastatin 
Atorvastatin 
Fluvastatin 
ANION-
EXCHANGE 
RESINS 
, 
I 
: FmRATES : 
. CENTRAL Methyldopa 
i 
ANTI-jBP I 
Moxonidine 
Clonidine 
Other 
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DRUG HISTORY - Respiratory 
DRUG CLASS DRUG NAME NO YES DOSE 
INHALEDB- Salbutamol 
AGONIST 
Salmeterol 
Terbutaline 
Bambuterol 
Fenoterol 
Tulobuterol 
ORAL p-AGONISTS Salmeterol 
INHALED ANTI- Ipratropium Bromide 
MUSCARINIC 
Oxitropjum Bromide 
Other 
THEOPHYLLINE 
INHALED STEROID Pulmicort 
Beclomethasone 
Becotide 
Budesonide 
Fluticasone 
Serotide 
Inhaled combination 
Steroid/p-Agonist 
ORAL STEROIDS Prednisolone 
Budesonide 
LEUKOTRIENE REC Montelukast 
. ANTAGONISTS 
Zafirlukast 
NEBULISERS 
HOME O2 I 
ANTI-TB ! I 
- - -
, 
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DRUG HISTORY- General (1) 
DRUG CLASS DRUG NAME NO YES DOSE 
INSULIN 
SULPHONYLUREAS 
METFORMIN 
PIOGLITAZONES 
ACARBOSE 
NSAIDS 
PPI 
H2 RECEPTOR 
BLOCKERS 
WARFARIN 
ANTffiIOTIC 
ANALGESIA 
ANTI-EPILEPTICS 
IRON SULPHATE 
B12 INJECTIONS 
FOLIC ACID 
ANTI-HISTAMINE 
K+ SUPPLEMENTS 
LAXATIVES J 
_ ... _ ... __ ... _ .. _ .. __ ... ______ ... _ ... ______ .. _____________ .. _____________ .. _ .. _________ ... ____ .. _ .. _ .. _._._. __ . __ . __ .... _._ .. _. __ ..... ___ ... _ .. ___ ... _ ... _ .. _____ -.l 
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DRUG HISTORY- General (2) 
DRUG CLASS DRUG NAME NO YES DOSE 
HRT PREPARATIONS 
HORMONE ANTAGONISTS 
ANTI-GOUT 
PANCREATIN 
ANTI-PARKINSONIAN L-dopa 
Madopar 
Sinemet 
Amantadine 
Apomorpbine 
Bromocriptine 
Cabergoline 
Entacapone 
Lisuride 
Pergolide 
Pramipexole 
Ropinirole 
Sele2iline 
Benzatropine 
Anti-muscarinics 
NEURO-MUSCULAR Haloperidol 
Riluzole 
Tetrabenazine 
ANTI-DEPRESSANTS 
BENZODIAZEPINES 
ANTI-PSYCHOTIC 
LITIDUM 
CYTOTOXICS 
IMMUNOMODULATING I 
QUININE I , 
NASAL PREPARATIONS I I 
ALENDRONATE I I 
CALCICHEW D3 FORTE i 
ANTI-EMETIC : 
OTHER 
I 
- - -
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NEW MEDICATION STARTED ON ADMISSION 
DRUG DOSE TIME HRSAFTER REASON 
NAME ADMISSION 
MEDICATIONS STOPPED ON ADMISSION 
DRUG DOSE TIME HRSAFTER REASON 
NAME ADMISSION 
_ ... _ .. _ ... _ .... _ .... _ ... - _ ... _ .. _ ... _ .. _ .. _ .. __ .. _ ... _ ... _ .. _ ... _ .... - --
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CLINICAL SIGNS (1) 
CLINICAL SIGNS ON ADMISSION DAY 1 POST 
ADMISSION 
RR 
HR 
BP Systolic 
Diastolic 
Mean pulse pressure 
i 
, 
Weight i I 
I 
i 
BMI 
I 
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CLINICAL SIGNS (2) 
CLINICAL SIGNS ON ADMISSION DAY 1 POST 
ADMISSION 
DK N Y DK N Y 
Raised JVP 
Hepatojugular reflex 
Parasternal heave 
3r <l HS 
4th HS 
Crepitations Basal 
Mid-Zone 
Upper-Zone 
Leg oedema Ankle 
Shin 
Knee 
Thigh 
Sacral oedema 
Ascites 
Hepatomegaly 
Pulsatile liver 
----------------------- -------- --
-------------------
- - .. - - ._. __ ._._' 
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CLINICAL SIGNS (3) 
CLINICAL SIGNS ON ADMISS DAY 1 POST 
ADMISS 
DK N Y DK N Y 
Pleural effusion R sided 
clinical 
Rsided 
Radiological 
L sided 
Clinical 
L sided 
Radioligical 
Bilateral 
Murmur AS 
AI 
MR 
MS 
TR 
Displaced apex 
Wheeze Inspiratory 
Expiratory 
General 
_ ..... _ .... _ .. - _ ... - ~- -
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INVESTIGATIONS 
lli SATS: 
DATE 
TIME 
O2 
REPACEMENT 
O2 SATS 
ABGS: 
DATE 
TIME 
O2 
REPLACEMENT 
P02 
PC02 
H+ 
HC03-
, 
I 
, 
I 
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INVESTIGATIONS - ROUTINE BLOODS: 
DATE 
Hb 
. 
MCV 
WCC 
Lymph. 
Neut 
. 
Mono 
Eosino , 
Plat 
Na 
Ie" I I 
cr 
HC03-
Ur 
Creat 
CK 
Trop 
Chol 
Glu 
HBAIC 
TSH 
T4 
T3 
Bil 
AlkP 
AST 
ALT 
GGT 
Urate 
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INVESTIGATIONS 
CXR: 
CXR FEATURES YES NO 
HEART FAILURE FEATURES 
Pleural Effusion Right 
Left 
Bilateral 
Cardiomegaly 
Upper lobe diversion 
Interstitial oedema . 
Alveloar oedema 
, 
NON-HEART FAILURE FEATURES 
1 
Hyperinflated lung fields 1 
1 
Mediastinal enlargement 1 1 
Intra-thoracic mass I 
Radiological old TB 
Previous pneumonectomy 
Pneumothorax 
Other 
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ECG CRITERIA 
* 
** 
*** 
Sokolow + Lyon criteria: 
Cornell criteria: 
S VI + R V5 or V6 > 35mm 
SV3 + R avl > 28mm (men) 
SV3 + R avl > 20mm (female) 
ST depression and T inversion in V5,V6 
RAD (>90) 
Tall R waves in RV leads 
Deep S waves in LV leads 
R VI + S V5 (V6) 10 mm 
**** ST depression and T inversion in VI-V3 (+/- aVF) 
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DAY 1 POST ADMISSION ECG: 
POST RATE 
I ADMISSION 
ECG I 
ECGCHANGES NO YES DESCRffiE 
FROM OLD 
1 
ECG I 
ECGCHANGES NO YES DESCRffiE i FROM I 
ADMISSION I 
1 
ECGCHANGES NO YES 1 
I 
Cardiac Rhythm SR AF FLUTTER VT OTHER 
J 
AVBLOCK 1 2 3 1 
1 
i 
LBBB 
J 
RBBB I 
1 
LVH SL CRITERIA* CORNELL CRITERIA * I 
1 
I 
I 
LVH + Strain ** 
RVH*** 
RVH+ I 
Strain**** 
ST Elevation INFERIOR ANTERIOR LATERAL 
ST Depression INFERIOR ANTERIOR LATERAL 
T wave Inversion INFERIOR ANTERIOR LATERAL 
Biphasic T INFERIOR ANTERIOR LATERAL 
Waves 
Pathological Q INFERIOR ANTERIOR LATERAL 
waves 
Prolonged QT 
interval 
RAD 
LAD 
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INVESTIGATIONS 
PFT's: 
VALUE RESULT 0/0 Predicted 
FEVl 
FVC 
FEVl:FVC 
VC 
TLCO 
REVERSmILITY , , 
COMMENT 
I 
_ ... _.- .-
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Appendix 4: Electrocardiographic data collection form 
POST RATE 
ADMISSION 
ECG 
ECGCHANGES NO YES DESCRmE 
FROM OLD 
ECG 
ECGCHANGES NO YES DESCRmE 
FROM 
ADMISSION 
ECGCHANGES NO YES 
Rhythm SR AF FLUTTER VT OTHER 
AVBLOCK 1 2 3 
LBBB 
RBBB 
LVH SLCRITERIA CORNELL CRITERIA 
LVH+ Strain 
RVH 
RVH+ Strain 
ST Elevation INFERIOR ANTERIOR LATERAL 
ST Depression INFERIOR ANTERIOR LATERAL 
T wave Inversion INFERIOR ANTERIOR LATERAL 
Biphasic T INFERIOR ANTERIOR LATERAL 
Waves 
Pathological Q INFERIOR ANTERIOR LATERAL 
waves 
Prolonged QT 
interval 
RAD 
LAD 
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